Methods for synthesizing peptides containing n-substituted amino acids

By using weaker acids and tailored protecting groups, the synthesis of peptides with N-alkylated amino acids achieves high purity and efficiency, addressing the challenges of acid hydrolysis and low reactivity in conventional methods.

JP2024163219AActive Publication Date: 2024-11-21CHUGAI PHARMA CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024151276
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-06-09
Filing Date
2024-09-03
Publication Date
2024-11-21
Estimated Expiration
2038-06-08

AI Technical Summary

Technical Problem

Conventional methods for synthesizing peptides containing N-alkylated amino acids face challenges such as acid hydrolysis, N→O acyl shift reactions, and low reactivity during elongation steps, leading to low purity and yield, which hinder the industrialization and commercialization of these peptides.

Method used

The method employs weaker acids like 2,2,2-trifluoroethanol (TFE) or hexafluoro-2-propanol (HFIP) instead of trifluoroacetic acid (TFA) for cleavage and uses specific protecting groups that are not deprotected during the cleavage step, along with appropriate solvents to minimize side reactions and enhance solubility, ensuring high purity and efficiency.

Benefits of technology

This approach allows for the synthesis of peptides with high purity and efficiency, reducing side reactions and improving solubility, making it suitable for both parallel and industrial-scale peptide synthesis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163219000124
    Figure 2024163219000124
  • Figure 2024163219000125
    Figure 2024163219000125
  • Figure 2024163219000126
    Figure 2024163219000126
Patent Text Reader

Abstract

To provide novel methods for producing a peptide containing an N-substituted amino acid or an N-substituted amino acid analogue with high purity and high efficiency.SOLUTION: Provided is a method for producing a peptide containing an N-substituted amino acid or an N-substituted amino acid analog according to the present invention comprising: providing an Fmoc-protected amino acid, an Fmoc-protected amino acid analogue, or an Fmoc-protected peptide; deprotecting a protective group having an Fmoc skeleton such as an Fmoc-protected amino acid with a base; and adding a novel Fmoc-protected amino acid or the like to form an amide bond, and characterized by that when the peptide is produced by a solid phase method, the resulting peptide is cleaved from the solid phase under acid conditions weaker than TFA, and additionally by that at least one side chain of the resulting peptide has a protecting group that is not deprotected under basic conditions and is deprotected under acid conditions weaker than TFA.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel method for synthesizing peptides containing N-substituted amino acids, which enables the synthesis of peptides with high purity and high synthesis efficiency. [Background technology]

[0002] Peptides are valuable chemical species, with more than 40 types of peptides being marketed as pharmaceuticals (Non-Patent Document 1). Among them, cyclic peptides and N-methylated (or N-alkylated) non-natural peptides are expected to improve membrane permeability by improving lipid solubility and metabolic stability by acquiring resistance to hydrolases (Non-Patent Document 2). Recently, studies on drug-like (drug-like: preferably exhibiting both membrane permeability and metabolic stability) cyclic peptides, which are key for intracellular transfer and oral administration, have been progressing (Non-Patent Documents 3 and 4). In addition, a patent document clarifying the conditions required for drug-like cyclic peptides has been published (Patent Document 1), and their importance in drug discovery and their recognition are increasing.

[0003] On the other hand, the progress in the development of methods for synthesizing peptides containing many non-natural amino acids, such as N-alkylamino acids, is comparatively limited. Most of the methods established for natural peptides are directly applied to non-natural peptides.

[0004] The Fmoc and Boc methods are widely known as methods for synthesizing peptides, and much of the knowledge about these methods was gained from the development of synthetic methods for natural peptides. Since the Fmoc group is stable to acids, when the amino group at the N-terminus is protected with the Fmoc group, the deprotection reaction is carried out with a base such as DBU or piperidine. Therefore, for example, a protecting group that can be deprotected with an acid is used as a protecting group for the peptide side chain functional group, and the N-terminus amino group is selectively deprotected to elongate the peptide chain. In the Fmoc method, commonly used protecting groups for the amino acid side chains include t-butyl (tBu) and trityl (Trt) groups that can be deprotected with an acid such as trifluoroacetic acid (TFA), and the peptide cleavage process from the resin and the deprotection of the protecting group of the side chain functional group can be carried out under milder conditions than in the Boc method.

[0005] However, even in the solid-phase synthesis method using the Fmoc method, which allows the step of cleavage from the resin and the step of deprotection of the protecting group of the side chain functional group to be performed under relatively mild conditions, it has become clear that the synthesis of N-alkylated peptides has the following problems in the step of cleavage from the resin using TFA or the step of deprotection of the protecting group of the side chain functional group.

[0006] Usually, when peptide synthesis is performed by the Fmoc method, TFA is generally used for the cleavage step from the resin and the deprotection of the protective group of the side chain functional group. In many cases, the cleavage reaction from the resin and the deprotection reaction of the side chain functional group are performed simultaneously using a 90% TFA aqueous solution. However, in the case of N-methylated peptides, particularly in the case of sequences in which N-methyl amino acids are consecutive, it is known that a side reaction in which acid hydrolysis proceeds via oxazolonium and the peptide chain is cleaved (Non-Patent Documents 5 and 6). In addition, in the case of peptides in which amino acids having a β-hydroxy group such as serine and threonine are included in the sequence, it is known that in these steps using TFA, not only acid hydrolysis but also N→O acyl shift reaction may proceed as a side reaction, resulting in depsipeptide formation (Non-Patent Documents 7 and 8).

[0007] Attempts have been made to avoid the problem of hydrolysis in the cleavage step and deprotection step using this acid by using a low-concentration TFA solution and controlling the reaction time to be short. For example, according to a report by Albericio et al., in the solid-phase synthesis of a peptide named NMe-IB-01212, when the deprotection of the Boc group on the amino group contained in an N-methylated cyclic hexapeptide was performed with a TFA-DCM (1:1) solution, decomposition of the peptide at the N-Me site was observed. In order to avoid the decomposition, attempts have been made to improve the situation by using a lower concentration of TFA and minimizing the reaction time, but sufficient improvement has not been achieved (Non-Patent Document 9). In the first place, with the protecting groups commonly used in peptide synthesis up to now, in the deprotection step with a low-concentration TFA solution, the cleavage reaction from the resin proceeds at a satisfactory speed, while the deprotection reaction of the side chain may not proceed or may proceed extremely slowly.

[0008] In addition, to prevent the cleavage of Ac-MePhe at the N-terminus, which proceeds via the same reaction mechanism as the hydrolysis of highly N-methylated peptides, Fang et al. have used TFA to lower the reaction temperature to 4°C and deprotect the Pbf group, which is a protecting group for the Arg side chain (Non-Patent Document 10). However, even with this method of lowering the temperature, it is difficult to completely prevent the cleavage of Ac-MePhe, and the reaction is merely stopped at the time when the target product reaches its maximum.

[0009] In addition to the problems during deprotection, there is also a known problem of low reactivity during the elongation step. When the N-terminus of the newly formed amide bond is an N-methylamino acid, the bulkiness of the secondary amine may prevent the amide formation reaction (elongation reaction) with the subsequent amino acid from proceeding sufficiently (Non-Patent Documents 2 and 5).

[0010] To address the problems in this elongation step, efforts have been made to reduce unreacted sites by repeating exactly the same reaction conditions twice or more (the method of repeating twice is called double coupling). In addition, efforts have been made to improve the efficiency of condensation by, for example, changing the activation of the amino acid to be condensed to a more active acid halide (Non-Patent Document 11). However, when the same reaction conditions are repeated as in double coupling, the time and reagent costs are doubled or more, and when condensation is performed with an acid halide, fresh preparation is required, and there are concerns about whether the generated acid halide can be stable during the peptide synthesis process. In addition, HCl and HF are generated by the reaction, which may cause a problem of concern that the deprotection reaction may proceed.

[0011] Other measures to improve the low reactivity in the elongation step include lowering the loading amount of resin to reduce the density of peptide chains on the solid phase and increase the efficiency of condensation, and increasing the concentration of the reaction solution (Non-Patent Document 9). Recently, efforts have been made to improve the efficiency of condensation by increasing the reaction temperature through microwave irradiation (Non-Patent Documents 12 and 13).

[0012] However, no fundamental solution has been reported to the concerns regarding the reduction in purity and yield of the synthesized peptide, and in some cases, the inability to obtain the desired product at all, in the synthesis of N-methylated peptides. [Prior art documents] [Patent documents]

[0013] [Patent Document 1] International Publication No. WO 2013 / 100132 A1 [Non-patent literature]

[0014] [Non-Patent Document 1] SR Gracia, et al. Synthesis of chemically modified bioactive peptides: recent advances, challenges and developments for medicinal chemistry. Future Med. Chem., 2009, 1,1289. [Non-Patent Document 2] J. Chatterjee, et al. N-Methylation of peptides: A new perspective inmedicinal chemistry. Acc. Chem. Res., 2008,41, 1331. [Non-Patent Document 3] JE Bock, et al. Getting inShape: Controlling Peptide Bioactivityand Bioavailability Using ConformationalConstraints. ACS Chem. Biol., 2013, 8,488. [Non-Patent Document 4] K. Jpsephson, et al. mRNA display:from basic principles tomacrocycle drug discovery. Drug Discovery Today,DOI:10.1016 / j.drudis.2013.10.011 [Non-Patent Document 5] M. Teixido, et al. Solid-phase synthesis and characterization ofN-methyl-rich peptides. J. Peptide Res.,2005, 65, 153. [Non-Patent Document 6] J. Urban, et al. Lability ofN-alkylated peptides towards TFAcleavage. Int. J. Pept. Prot. Res., 1996, 47,182. [Non-Patent Document 7] LA Carpino, et al. Dramaticallyenhanced N→O acyl migration during the trifluoroacetic acid-baseddeprotectionstep in solid phase peptide synthesis. Tetrahedron Lett., 2005, 46.1361.

Outdoor Track 8

Outdoor Tools9

Outdoor Tools 10

Outdoor Content11

Outdoor Tools 12

[0015] The present inventors have focused on cyclic peptides containing N-alkylated amino acids that can be drug-like peptides, and have investigated a method for parallel synthesis of peptide compounds having such characteristics. As a result, it has been found that in the case of cyclic peptides containing N-alkylated amino acids that can be drug-like peptides, the problems found in the compounds described in the above known documents become prominent in the conventional synthesis method using TFA, which causes the cyclic peptides to be unable to be isolated. Specifically, in the case of peptides containing N-alkylated amino acids, the main reaction in the reaction under acidic conditions using TFA (the step of cutting out from the solid phase or the deprotection of the protective group of the side chain functional group) is a side reaction in which the peptide chain is cleaved, making it difficult to obtain the desired peptide. In addition, it has been found that when an amino acid having a β-hydroxy group is contained in a peptide, an N→O acyl shift reaction proceeds in the reaction under acidic conditions using TFA, making it difficult to obtain the desired peptide. Although these problems were problems found in the compounds in the above known documents, the present inventors have further found that they are problems that are similarly observed in many other peptides. In addition to these problems, we also found that when a peptide containing an amino acid having a hydroxy group in its skeleton, not limited to the β-position, is reacted under acidic conditions using TFA, the hydroxy group is esterified with TFA.

[0016] In addition, the present inventors have found that, when considering the industrialization of peptide synthesis containing N-alkylated amino acids that can become drug-like peptides, it is extremely difficult to realize industrialization with the conventional deprotection method using TFA, not only in terms of the deprotection reaction and elongation reaction themselves, but also in terms of the subsequent treatment process and large-scale synthesis. For example, when the solvent is removed by concentrating a TFA / DCM solution, the TFA concentration increases as the concentration proceeds, and problems such as hydrolysis and N→O-acyl shift occur at the same time as the concentration, resulting in the failure to obtain the target compound or a significant decrease in yield. In addition, it becomes necessary to carry out the concentration process at a low temperature. Even if the TFA concentration is low, TFA is contained in a large excess relative to the target product, so if an attempt is made to neutralize these to stop the reaction, the amount of base added will also be large and excessive, and a large excess of salt will remain together with the target peptide, making the purification process more complicated. Furthermore, although TFA itself is a solvent that effectively dissolves peptides, reducing the concentration of the TFA solution will lead to a decrease in the solubility of the peptide. Regarding solubility, it is necessary to select a solvent that has high solubility for a group of peptides not only when industrialization is taken into consideration, but also in parallel synthesis in which many different peptide compounds are handled at once.

[0017] In addition, the present inventors have focused on improving reactivity by reducing the steric bulk of the protecting group of Fmoc-amino acids having functional groups with protecting groups on the side chains, which has not been actively addressed so far. For example, threonine (Thr) has a hydroxyl group, so a protecting group for the hydroxyl group is required to selectively proceed with the reaction at the amino group during subsequent acylation. However, because Thr has a secondary alcohol branched at the β-position as a side chain functional group, the condensation efficiency of the protected Thr is relatively low due to its bulkiness. The acetyl (Ac), tBu, Trt, benzyl (Bn), and t-butyldimethylsilyl (TBS) groups are commonly used as Thr protecting groups in peptide synthesis (Albert Isidro-Llobet, et al. Amino Acid-Protecting Groups.Chem.Rev., 2009, 109, 2455., Watanabe Chemical Reagent Catalog Amino acids & chiral building blocks to new medicine 2012-14), but the bulkiness of the Trt and TBS groups reduces the condensation efficiency. Even the tBu group, which can be deprotected with acid, requires high-concentration TFA conditions for deprotection, which brings about the problems of deprotection mentioned above. Other protecting groups cannot be easily removed with acid. In other words, it is necessary to find a protecting group that is sterically small enough not to reduce the condensation efficiency, and can be easily deprotected with an acid that can avoid the above-mentioned problems of acid hydrolysis and N → O-acyl shift. The same holds true for N-methylserine (MeSer), which does not have a branching site at the β-position but is bulky due to N-substitution, and other amino acids that have a hydroxyl group as a functional group.

[0018] That is, the present invention aims to find a novel reaction process that can reduce problems of side reactions such as acid hydrolysis of peptides, N→O-acyl shift, and TFA esterification of hydroxyl groups in the deprotection step using TFA, which have been found to become prominent during parallel synthesis of peptides containing N-substituted amino acids, while ensuring the solubility of peptides. Another objective of the present invention is to provide a method for obtaining a peptide containing an N-substituted amino acid with high purity and high synthesis efficiency by using an appropriate protecting group for a side chain functional group (a protecting group that is appropriate from the viewpoint of reducing the bulkiness of the protecting group in order to improve low reactivity during elongation and from the viewpoint of being deprotectable under the deprotection conditions of the present invention).

[0019] In other words, in parallel synthesis of peptide compounds containing various sequences of N-substituted amino acids, (1) To find the reaction conditions necessary to suppress hydrolysis during the addition of acid (during the separation reaction from the solid phase and the side chain deprotection reaction), particularly hydrolysis originating from N-substituted amino groups; (2) Finding reaction conditions that allow practical post-treatment when adding acid; (3) Finding reaction conditions, including solvents, that take into account the unique solubility of non-natural peptide compounds; (4) When a non-natural peptide compound contains a functional group such as a hydroxyl group, side reactions after deprotection (such as N→O acyl shift and side reactions between the hydroxyl group and a reaction reagent (e.g., TFA acylation reaction when TFA is used as a reagent)) can be suppressed. The objective is to: In addition, the objective is to find a protecting group that satisfies the above four conditions for each functional group in the amino acid side chain. Furthermore, taking into consideration the industrial production of peptide compounds containing N-substituted amino acids, it is also an objective of the present invention to find a production method that can be applied to optimization for specific sequences. [Means for solving the problem]

[0020] In order to realize efficient synthesis of cyclic peptides containing N-substituted amino acids, the present inventors have discovered a novel method that can solve many problems that could not be fully solved by commonly used improvement methods such as reducing the TFA concentration or reducing the reaction temperature, in addition to the problems seen when conventional peptide synthesis methods using TFA were used for the synthesis of compounds described in known literature, such as suppression of hydrolysis and the progression of N→O-acyl shift, establishment of a practical post-treatment method, suppression of TFA ester formation in the presence of a hydroxyl group, and selection of a solvent that can ensure the solubility of peptides. In this novel method, TFA used in conventional peptide synthesis is not used at all, and the target product is successfully obtained with high selectivity.

[0021] In one embodiment of the present invention, TFA is not used in the cleavage step from the solid phase, but a weaker acid, such as 2,2,2-trifluoroethanol (TFE) or hexafluoro-2-propanol (HFIP), is used. In addition, in another embodiment of the present invention, a protecting group for a side chain functional group that is not deprotected in the cleavage step is used. In the cleavage step using an acid weaker than TFA, such as TFE or HFIP, the rate of side reactions such as hydrolysis of amide bonds is sufficiently small even by concentration after the reaction, unlike the case where TFA is used. In particular, when an acid weaker than TFA, such as TFE or HFIP, is used, the side reaction rate is small even for peptides containing highly N-substituted amino acids and cyclized peptides that are more susceptible to side reactions. Therefore, the target compound can be obtained as the main product. In another embodiment of the present invention, the excision step uses a reagent that satisfies the following conditions: (1) the peptide side reaction (hydrolysis, etc.) is suppressed while the excision reaction from the solid phase proceeds smoothly, (2) the rate of the side reaction is sufficiently slow even when post-treatment such as concentration is performed, (3) it exhibits high solubility even for non-natural peptides with high lipid solubility, and (4) it enables excision while retaining the protecting groups of the side chain functional groups. By using a reagent that satisfies these conditions, it becomes possible to synthesize peptides containing many N-substituted amino acids, in particular, to synthesize drug-like peptides containing many N-alkyl groups. A reagent that satisfies these conditions can be used not only in parallel synthesis but also in industrial synthesis of a specific peptide.

[0022] In one embodiment of the present invention, a method for synthesizing a peptide is provided that can suppress hydrolysis and N→O-acyl shift and deprotect side chain protecting groups so as to promote the main target deprotection reaction. There is a possibility that only the strength of the acid (proton concentration) is important for the progress of hydrolysis and N→O-acyl shift. It has been found that the progress of hydrolysis and N→O-acyl shift can be suppressed by using a weak acid with a weaker acidity instead of a strong acid such as TFA. In addition, in order to progress the target deprotection, in addition to the strength of the acid (proton concentration), the stage in which the protecting group is removed as a cationic species (carbocation or oxonium cation) from the protected functional group may also be important. It has been found that the deprotection with the above-mentioned weak acid is promoted by using a solvent having ionization ability as a solvent that promotes the process in which the protecting group is removed as a cationic species.

[0023] In addition, in order to establish a highly efficient synthesis method for the drug-like peptides described in Patent Document 1, we have discovered protecting groups that are not deprotected under the weak acid conditions used for cleavage from the resin but can be deprotected under the above-mentioned weak acid conditions as protecting groups for side chain functional groups of amino acids having a side chain that is less ionized under neutral conditions, such as a hydroxyl group which is a side chain functional group of amino acids such as Ser and Thr, other alkyl alcohol groups having a hydroxyl group in the side chain, a phenol group which is a side chain functional group of amino acids such as Tyr, an imidazole group which is a side chain functional group of amino acids such as His, a side chain carboxylic acid which is a side chain functional group of amino acids such as Asp and Glu, and a carboxylic acid in the main chain of a peptide or amino acid.

[0024] In addition, when amino acids such as β-hydroxy-α-amino acids (e.g., Thr, Ser, and their derivatives) that are of concern for their low reactivity during the extension reaction have a protecting group, the protecting group can be deprotected under the above-mentioned weak acid conditions and can improve the low reactivity during the extension reaction.

[0025] That is, the present invention is as follows. [1] The following steps: 1) preparing an amino acid having at least one functional group each of the following i) and ii) (Fmoc-protected amino acid), an amino acid analog having at least one functional group each of the following i) and ii) (Fmoc-protected amino acid analog), or a peptide containing both or either one of the Fmoc-protected amino acid and the Fmoc-protected amino acid analog (Fmoc-protected peptide); i) a main chain amino group protected by at least one protecting group having an Fmoc skeleton; ii) at least one carboxylic acid group, either free or in an active ester form; 2) supporting the Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide prepared in step 1) on a solid phase; 3) deprotecting a protecting group having an Fmoc skeleton of the Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide supported on a solid phase with a base to expose an amino group; 4) adding a new Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide to form an amide bond; and 5) cleaving the peptide obtained in step 4) from the solid phase under conditions that are weaker acid than TFA; A method for producing a peptide containing at least one N-substituted amino acid or N-substituted amino acid analog, comprising: [2] At least one side chain of the amino acid or amino acid analog constituting the peptide obtained in the step 4) is protected with a protecting group that is not deprotected under basic conditions and is deprotected with a first acid, and the method further comprises a step of deprotecting the protecting group with the first acid before or after the step 5); The method according to [1], wherein in the step 5), the peptide is excised using a second acid, The method of preparation, wherein the first acid and the second acid are both weaker acids than TFA, and the acidity of the first acid is greater than the acidity of the second acid. [3] The following steps: 1) preparing an amino acid having at least one functional group each of the following i) and ii) (Fmoc-protected amino acid), an amino acid analog having at least one functional group each of the following i) and ii) (Fmoc-protected amino acid analog), or a peptide containing both or either one of the Fmoc-protected amino acid and the Fmoc-protected amino acid analog (Fmoc-protected peptide); i) a main chain amino group protected by at least one protecting group having an Fmoc skeleton; ii) at least one carboxylic acid group, either free or in an active ester form; 2) deprotecting a protecting group having an Fmoc skeleton of the Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide with a base to expose an amino group; 3) adding a new Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide to form an amide bond, wherein at least one side chain of the amino acid or amino acid analog constituting the peptide obtained in this step has a protecting group that is not deprotected under basic conditions but is deprotected under conditions that are weaker acid than TFA; and 4) removing the protecting group of the side chain under conditions that are weaker acids than TFA; A method for producing a peptide containing at least one N-substituted amino acid or N-substituted amino acid analog, comprising: [4] The method according to [3], wherein the peptide is produced by a solid phase method. [5] The method according to [4], further comprising a step of cleaving the peptide obtained in step 3) from the solid phase before or after step 4) under weaker acid conditions than those used in step 4). [6] The method according to [3], wherein the peptide is produced by a liquid phase method. [7] Step 4) of [1] or step 3) of [3] a step of deprotecting a protecting group having an Fmoc skeleton of the newly added Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide with a base to expose an amino group; and The method further comprises the step of adding a new Fmoc-protected amino acid, an Fmoc-protected amino acid analog, or an Fmoc-protected peptide to form an amide bond, The method for producing a product according to any one of [1] to [6], wherein these steps are repeated one or more times. [8] The method according to any one of [1] to [7], wherein the produced peptide contains an amino acid residue or amino acid analog residue having one reactive site on the C-terminus and an amino acid residue, amino acid analog residue, or carboxylic acid analog having another reactive site on the N-terminus. [9] The method according to [8], further comprising the step of binding the one reactive site to the other reactive site to cyclize the peptide.

[10] The method according to [9], wherein the amino acid residue, amino acid analog residue, or carboxylic acid analog having another reactive site is at the N-terminus, and the bond is an amide bond.

[11] The method according to [9], wherein the amino acid residue, amino acid analog residue, or carboxylic acid analog having another reactive site is at the N-terminus, and the bond is a carbon-carbon bond.

[12] The process is carried out under conditions that make the acid weaker than TFA by treating a weak acid having a pKa value of 0 to 9 in water with an ionization ability Y OTs The method according to any one of [1] to

[11] , wherein the method is carried out using a weak acid solution in a solvent having a positive pKa value and a pKa in water of 5 to 14.

[13] The method according to

[12] , wherein the solvent is a fluoroalcohol.

[14] The production method according to

[13] , wherein the fluoroalcohol is TFE or HFIP.

[15] The method according to any one of [2] to

[14] , wherein the protecting group of the side chain is a protecting group that is deprotected in the range of pH 1 to pH 7, or a protecting group that is deprotected in 10% or less TFA.

[16] The method according to any one of [2] to

[15] , wherein the protecting group of the side chain is selected from the following a) to d): a) When the protecting group of the side chain is a protecting group for the hydroxyl group of the side chains of Ser, Thr, Hyp, and their derivatives, any protecting group selected from the MOM skeleton group, Bn skeleton, Dpm skeleton, Trt skeleton, silyl skeleton, and Boc skeleton represented by the following general formula; b) When the protecting group of the side chain is a protecting group for the hydroxyl group of the side chains of Tyr and its derivatives, any protecting group selected from the MOM skeleton, Bn skeleton, Dpm skeleton, Trt skeleton, silyl skeleton, Boc skeleton, and tBu skeleton represented by the following general formula; c) When the protecting group of the side chain is a protecting group for the imidazole ring of the side chains of His and its derivatives, any protecting group selected from the MOM skeleton, Bn skeleton, and Trt skeleton represented by the following general formula; d) When the protecting group of the side chain is a protecting group for the carboxylic acid group of the side chains of Asp, Glu, and their derivatives, any protecting group selected from the MOM skeleton, Bn skeleton, Dpm skeleton, Trt skeleton, tBu skeleton, phenyl-EDOTn skeleton, and orthoester skeleton obtained by converting the carbon atom of the carboxylic acid group to be protected into a skeleton substituted with three alkoxy groups; <Protecting group having MOM skeleton> [Chemical formula] (In the formula, R1 is H, R2 is H, and X is methyl, benzyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl, 3,4-dimethoxybenzyl, or 2-trimethylsilylethyl, or R1 is methyl, R2 is H, and X is ethyl, or R1, R2, and R3 are all methyl, or R1 and X together form -CH2-CH2-CH2- or -CH2-CH2-CH2-CH2-, and R2 is H Here, when any of R1, R2, and X is methyl or ethyl, these groups may be further substituted with alkyl, benzyl, or aryl.) <Protecting group having a Bn skeleton>

Chem.

Chem.

Chem.

[0026] According to the present invention, a peptide containing an N-substituted amino acid can be obtained with high synthesis efficiency and high purity.

[0027] For example, in the case of a peptide sequence containing amino acids having protecting groups in their side chains, (1) The combination of an acid that is weaker than TFA and a solvent exhibiting ionization ability, as discovered by the present invention, enables deprotection while minimizing acid hydrolysis of peptide chains and N→O-acyl shift and TFA esterification that may occur in sequences containing β-hydroxy-α-amino acids (e.g., Ser, Thr, and derivatives thereof); and (2) When the amino acid is elongated by an amide bond formation reaction, the reaction rate and reaction efficiency can be improved compared to when the amino acid has a protecting group used in general peptide synthesis. [Brief description of the drawings]

[0028] [Figure 1] FIG. 1 shows a basic synthesis route for a cyclic peptide containing an N-methyl amino acid in the sequence. [Diagram 2] FIG. 2 shows the results of LCMS analysis showing the detection of the target peptide (compound 131), its hydrolysate (TM+HO), and its solvolyzed product by HFIP (TM+HFIP) under deprotection conditions using 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS). [Diagram 3] FIG. 3 shows the results of LCMS analysis showing the detection of the target peptide (compound 131), its hydrolysate (TM+HO), and its solvolyzed product by HFIP (TM+HFIP) under deprotection conditions using 0.05 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS). [Figure 4] FIG. 4 shows the results of LCMS analysis showing the detection of the target peptide (compound 133) and the N→O-acyl shift product of the target peptide under deprotection conditions using 0.05 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS). [Diagram 5]FIG. 5 shows the results of LCMS analysis showing the detection of the target peptide (compound 131), its hydrolysate (TM+HO), and its solvolyzed product by HFIP (TM+HFIP) under deprotection conditions using 0.05 M oxalic acid / HFIP solution (2% TIPS). [Figure 6] FIG. 6 shows the results of LCMS analysis showing the detection of the target peptide (compound 131), its hydrolysate (TM+HO), and its solvolyzed product by HFIP (TM+HFIP) under deprotection conditions using 0.05 M maleic acid / HFIP solution (2% TIPS). [Figure 7] FIG. 7 shows the results of LCMS analysis showing the detection of the target peptide (compound 133) and the N→O-acyl shift product of the target peptide under deprotection conditions in 0.05 M oxalic acid / HFIP solution (2% TIPS). [Figure 8] FIG. 8 shows the results of LCMS analysis showing the detection of the target peptide (compound 133) and the target N→O-acyl shift product under deprotection conditions in 0.05 M maleic acid / HFIP solution (2% TIPS). [Figure 9] FIG. 9 shows the results of LCMS analysis showing the detection of the target peptide (compound 137) and its HFIP-induced solvolyzed product (one of the amide bonds has been solvolyzed by HFIP) under deprotection conditions of 0.05 M tetramethylammonium hydrogen sulfate / HFIP (2% TIPS). [Figure 10] FIG. 10 shows the results of LCMS analysis showing the detection of the target peptide (compound 137) and its TFE solvolyzed product (one of the amide bonds has been solvolyzed by TFE) under deprotection conditions of 0.05 M tetramethylammonium hydrogen sulfate / TFE (2% TIPS). [Figure 11]FIG. 11 shows the results of LCMS analysis showing the detection of the target peptide (compound 135) when the deprotection conditions were 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) and the reaction was stopped by adding a base (DIPEA) to the solution. [Figure 12] FIG. 12 shows the results of LCMS analysis showing the detection of the target peptide (compound 133) when the deprotection conditions were 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) and the reaction was stopped by adding a base (DIPEA) to the solution. [Figure 13] FIG. 13 shows the results of LCMS analysis showing the detection of the target peptide (compound 112) and the target peptide from which Thr has been removed (compound 113) when Fmoc-Thr(Trt)-OH was added. [Figure 14] 14 is a diagram showing the results of LCMS analysis showing the detection of the target peptide (compound 114) when Fmoc-Thr(THP)-OH was added, while the target peptide (compound 114) from which Thr had been removed (compound 113) was not detected. [Figure 15] FIG. 15 shows the results of LCMS analysis showing the detection of the target peptide (compound 115) and the target peptide from which MeSer was removed (compound 116) when synthesis was performed using Fmoc-MeSer(DMT)-OH·0.75DIPEA. [Figure 16] FIG. 16 shows the results of LCMS analysis showing the detection of the target peptide (compound 115) and the target peptide from which MeSer has been removed (compound 116) when synthesis was performed using Fmoc-MeSer(THP)-OH (compound 6). [Figure 17] FIG. 17 shows the results of LCMS analysis showing the detection of the target peptide (compound 131) and the target hydrolysate (TM+HO) under deprotection conditions of 5% TFA / DCE (5% TIPS). [Figure 18]FIG. 18 shows the results of LCMS analysis showing the detection of the target peptide (compound 133), the N→O-acyl shift product of the target, a compound in which one hydroxyl group of the target is TFA-esterified, and a compound in which two hydroxyl groups of the target are TFA-esterified under deprotection conditions of 5% TFA / DCE (5% TIPS). [Figure 19] FIG. 19 shows the results of LCMS analysis showing the detection of the target peptide (compound 133), the N→O-acyl shift product of the target, a compound in which one hydroxyl group of the target is TFA-esterified, and a compound in which two hydroxyl groups of the target are TFA-esterified under deprotection conditions of 5% TFA / DCE (5% TIPS) (0°C). [Figure 20] FIG. 20 shows the results of LCMS analysis showing the detection of the target peptide (compound 133), the N→O-acyl shift product of the target, a compound in which one hydroxyl group of the target is TFA-esterified, and a compound in which two hydroxyl groups of the target are TFA-esterified under deprotection conditions of 5% TFA / DCE (5% TIPS) (25°C). [Figure 21] FIG. 21 is a diagram showing a synthesis method including an extension reaction in a liquid phase. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] In one aspect, the present invention relates to a method for producing a peptide comprising at least one N-substituted amino acid or N-substituted amino acid analog, comprising the steps of: 1) preparing an amino acid having at least one functional group each of the following i) and ii) (Fmoc-protected amino acid), an amino acid analog having at least one functional group each of the following i) and ii) (Fmoc-protected amino acid analog), or a peptide containing both or either one of the Fmoc-protected amino acid and the Fmoc-protected amino acid analog (Fmoc-protected peptide); i) a main chain amino group protected by at least one protecting group having an Fmoc skeleton; ii) at least one carboxylic acid group, either free or in an active ester form; 2) supporting the Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide prepared in step 1) on a solid phase; 3) deprotecting a protecting group having an Fmoc skeleton of the Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide supported on a solid phase with a base to expose an amino group; 4) adding a new Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide to form an amide bond; and 5) A step of cleaving the peptide obtained in step 4) from the solid phase under conditions that are weaker acids than TFA.

[0030] In another aspect, the present invention relates to a method for producing a peptide comprising at least one N-substituted amino acid or N-substituted amino acid analog, comprising the steps of: 1) preparing an amino acid having at least one functional group each of the following i) and ii) (Fmoc-protected amino acid), an amino acid analog having at least one functional group each of the following i) and ii) (Fmoc-protected amino acid analog), or a peptide containing both or either one of the Fmoc-protected amino acid and the Fmoc-protected amino acid analog (Fmoc-protected peptide); i) a main chain amino group protected by at least one protecting group having an Fmoc skeleton; ii) at least one carboxylic acid group, either free or in an active ester form; 2) deprotecting a protecting group having an Fmoc skeleton of the Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide with a base to expose an amino group; 3) adding a new Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide to form an amide bond, wherein at least one side chain of the amino acid or amino acid analog constituting the peptide obtained in this step has a protecting group that is not deprotected under basic conditions but is deprotected under conditions that are weaker acid than TFA; and 4) Deprotecting the protecting group of the side chain under conditions that are weaker acids than TFA. The peptide may be produced by a solid phase method or a liquid phase method.

[0031] The "peptide" in the present invention is not particularly limited as long as it is a peptide formed by amide bonds or ester bonds between amino acids and / or amino acid analogs, but is preferably a peptide of 5 to 30 residues, more preferably 7 to 15 residues, and even more preferably 9 to 13 residues. The peptide synthesized in the present invention contains at least one N-substituted amino acid or amino acid analog (also called N-substituted amino acid) in one peptide, and preferably contains two or more, more preferably three or more, and even more preferably five or more N-substituted amino acids. These N-substituted amino acids may be present consecutively or discontinuously in the peptide. The peptide in the present invention may be a linear peptide or a cyclic peptide, and is preferably a cyclic peptide.

[0032] The "cyclic peptide" of the present invention can be obtained by synthesizing a linear peptide according to the method of the present invention and then cyclizing it. The cyclization may be in any form, such as cyclization via a carbon-nitrogen bond such as an amide bond, cyclization via a carbon-oxygen bond such as an ester bond or an ether bond, cyclization via a carbon-sulfur bond such as a thioether bond, cyclization via a carbon-carbon bond, or cyclization via a heterocyclic ring structure. Although not particularly limited, cyclization via a covalent bond such as an amide bond or a carbon-carbon bond is preferred, and cyclization via an amide bond between a carboxylic acid group in a side chain and an amino group in the main chain at the N-terminus is particularly preferred. The position of the carboxylic acid group or amino group used for cyclization may be on the main chain or on the side chain, and is not particularly limited as long as it is in a position that allows cyclization.

[0033] In the present invention, the term "N-substituted amino acid" refers to an amino acid or amino acid analogue in which the main chain amino group is N-substituted among the "amino acids" or "amino acid analogues" described below, and preferably an amino acid or amino acid analogue that is N-alkylated, such as N-methylated. Specific examples of N-substituted amino acids include amino acids or amino acid analogues in which the main chain amino group is an NHR group, where R is an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, aralkyl group, or cycloalkyl group, or proline in which the carbon atom bonded to the N atom and the carbon atom from the α-position form a ring. The substituent of each group that may be substituted is not particularly limited, and examples thereof include a halogen group, an ether group, and a hydroxyl group. Specifically, alkyl groups, aralkyl groups, cycloalkyl groups, etc. are preferably used as such N-substituted amino acids.

[0034] The term "amino acid" in the present invention refers to α, β and γ amino acids, and is not limited to natural amino acids (in the present application, natural amino acids refer to the 20 types of amino acids contained in proteins. Specifically, they refer to Gly, Ala, Ser, Thr, Val, Leu, Ile, Phe, Tyr, Trp, His, Glu, Asp, Gln, Asn, Cys, Met, Lys, Arg, and Pro), and may be non-natural amino acids. In the case of α-amino acids, they may be L-amino acids or D-amino acids, or α,α-dialkylamino acids. The selection of the amino acid side chain is not particularly limited, and examples thereof include a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, and a cycloalkyl group. The amino acid side chain may each have a substituent, which is freely selected from any functional group including, for example, an N atom, an O atom, an S atom, a B atom, a Si atom, and a P atom. The number of substituents is not particularly limited, and may be one or more than two.

[0035] In the present invention, the term "amino acid analog" preferably refers to an α-hydroxycarboxylic acid. The side chain of the α-hydroxycarboxylic acid is not particularly limited as in the case of amino acids, and examples thereof include a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, and a cycloalkyl group. The three-dimensional structure of the α-hydroxycarboxylic acid may correspond to the L-type or D-type of an amino acid. The side chain is not particularly limited, and may be freely selected from any functional group including, for example, an N atom, an O atom, an S atom, a B atom, an Si atom, and a P atom. The number of substituents is not particularly limited, and may be one or more than two. For example, the amino acid may have an S atom and may further have a functional group such as an amino group or a halogen group. In the case of β- or γ-amino acids, any three-dimensional configuration is allowed as in the case of α-amino acids, and the selection of the side chain is not particularly limited as in the case of α-amino acids.

[0036] The "amino acids" and "amino acid analogs" constituting the peptides synthesized in the present invention include all of the corresponding isotopes. An isotope of an "amino acid" or "amino acid analog" is one in which at least one atom has been replaced with an atom having the same atomic number (number of protons) but a different mass number (sum of the number of protons and neutrons). Examples of isotopes contained in the "amino acids" and "amino acid analogs" constituting the peptide compounds of the present invention include, for example, hydrogen atoms, carbon atoms, nitrogen atoms, oxygen atoms, phosphorus atoms, sulfur atoms, fluorine atoms, and chlorine atoms. Specific examples include, 2 H, 3 H, 13 C. 14 C. 15 N, 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 Examples include Cl.

[0037] The amino acid or amino acid analog may have one or more substituents, such as those derived from an O atom, a N atom, a S atom, a B atom, a P atom, a Si atom, or a halogen atom.

[0038] Halogen-derived substituents include fluoro (-F), chloro (-Cl), bromo (-Br), iodo (-I), and the like.

[0039] Substituents derived from O atoms include hydroxyl (-OH), oxy (-OR), carbonyl (-C=OR), carboxyl (-COH), oxycarbonyl (-C=O-OR), carbonyloxy (-OC=OR), thiocarbonyl (-C=O-SR), carbonylthio group (-SC=OR), aminocarbonyl (-C=O-NHR), carbonylamino (-NH-C=OR), oxycarbonylamino (-NH-C=O-OR), sulfonylamino (-NH-SO2-R), aminosulfonyl (-SO2-NHR), sulfamoylamino (-NH-SO2-NHR), thiocarboxyl (-C(=O)-SH), and carboxylcarbonyl (-C(=O)-COH).

[0040] Examples of oxy (-OR) include alkoxy, cycloalkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, aralkyloxy, and the like.

[0041] Examples of carbonyl (-C=OR) include formyl (-C=OH), alkylcarbonyl, cycloalkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aralkylcarbonyl, and the like.

[0042] Examples of oxycarbonyl (-C=O-OR) include alkyloxycarbonyl, cycloalkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl, and the like. (-C=O-OR)

[0043] Examples of carbonyloxy (-OC=OR) include alkylcarbonyloxy, cycloalkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, aralkylcarbonyloxy, and the like.

[0044] Examples of thiocarbonyl (-C=O-SR) include alkylthiocarbonyl, cycloalkylthiocarbonyl, alkenylthiocarbonyl, alkynylthiocarbonyl, arylthiocarbonyl, heteroarylthiocarbonyl, aralkylthiocarbonyl, and the like.

[0045] Examples of carbonylthio (-SC=OR) include alkylcarbonylthio, cycloalkylcarbonylthio, alkenylcarbonylthio, alkynylcarbonylthio, arylcarbonylthio, heteroarylcarbonylthio, aralkylcarbonylthio, and the like.

[0046] Examples of aminocarbonyl (-C=O-NHR) include alkylaminocarbonyl, cycloalkylaminocarbonyl, alkenylaminocarbonyl, alkynylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, etc. In addition, compounds in which the H atom bonded to the N atom in -C=O-NHR is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl are also included.

[0047] Examples of carbonylamino (-NH-C=OR) include alkylcarbonylamino, cycloalkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, aralkylcarbonylamino, etc. In addition to these, compounds in which the H atom bonded to the N atom in -NH-C=OR is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl are also included.

[0048] Examples of oxycarbonylamino (-NH-C=O-OR) include alkoxycarbonylamino, cycloalkoxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, aralkyloxycarbonylamino, etc. In addition to these, compounds in which the H atom bonded to the N atom in -NH-C=O-OR is further substituted with an alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl are also included.

[0049] Examples of sulfonylamino (-NH-SO2-R) include alkylsulfonylamino, cycloalkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, aralkylsulfonylamino, etc. In addition to these, compounds in which the H atom bonded to the N atom in -NH-SO2-R is further substituted with an alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl are also included.

[0050] Examples of aminosulfonyl (-SO2-NHR) include alkylaminosulfonyl, cycloalkylaminosulfonyl, alkenylaminosulfonyl, alkynylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aralkylaminosulfonyl, etc. In addition to these, compounds in which the H atom bonded to the N atom in -SO2-NHR is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl are also included.

[0051] Examples of sulfamoylamino (-NH-SO2-NHR) include alkylsulfamoylamino, cycloalkylsulfamoylamino, alkenylsulfamoylamino, alkynylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino, aralkylsulfamoylamino, etc. Furthermore, the two H atoms bonded to the N atom in -NH-SO2-NHR may be substituted with substituents independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl, and these two substituents may form a ring.

[0052] Substituents derived from S atoms include thiol (-SH), thio (-SR), sulfinyl (-S=OR), sulfonyl (-S(O)2-R), and sulfo (-SO3H).

[0053] Examples of thio (-SR) are selected from among alkylthio, cycloalkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, aralkylthio, and the like.

[0054] Examples of sulfinyl (-S=OR) include alkylsulfinyl, cycloalkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heteroarylsulfinyl, aralkylsulfinyl, and the like.

[0055] Examples of sulfonyl (-S(O)2-R) include alkylsulfonyl, cycloalkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, and the like.

[0056] Substituents derived from the N atom include azido (-N3, also known as an "azido group"), cyano (-CN), primary amino (-NH2), secondary amino (-NH-R), tertiary amino (-NR(R')), amidino (-C(=NH)-NH2), substituted amidino (-C(=NR)-NR'R''), guanidino (-NH-C(=NH)-NH2), substituted guanidino (-NR-C(=NR''')-NR'R''), and aminocarbonylamino (-NR-CO-NR'R'').

[0057] Examples of secondary amino (-NH-R) include alkylamino, cycloalkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, aralkylamino, and the like.

[0058] Examples of tertiary amino (-NR(R')) include amino groups having any two substituents independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, etc., such as alkyl(aralkyl)amino, and these two substituents may form a ring.

[0059] Examples of substituted amidino (-C(=NR)-NR'R'') include groups in which the three substituents R, R', and R'' on the N atom are each independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl, such as alkyl(aralkyl)(aryl)amidino.

[0060] Examples of substituted guanidino (-NR-C(=NR''')-NR'R'') include groups in which R, R', R'', and R''' are each independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and aralkyl, or groups in which these form a ring.

[0061] Examples of aminocarbonylamino (-NR-CO-NR'R'') include groups in which R, R', and R'' are each independently selected from a hydrogen atom, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl, or groups in which these form a ring.

[0062] Substituents derived from the B atom include boryl (-BR(R')) and dioxyboryl (-B(OR)(OR')). These two substituents R and R' are independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, etc., or may form a ring.

[0063] Thus, the amino acids or amino acid analogs of the present invention may have one or more of various substituents, including O, N, S, B, P, Si and halogen atoms, which are usually used in low molecular weight compounds. These substituents may be further substituted with other substituents.

[0064] In this specification, the "amino acids" and "amino acid analogs" constituting the peptides synthesized in the present invention may also be referred to as "amino acid residues" and "amino acid analog residues", respectively.

[0065] In the present invention, an "Fmoc-protected amino acid" and an "Fmoc-protected amino acid analog" refer to an amino acid and an amino acid analog each having at least one of the following functional groups i) and ii): i) a main chain amino group protected by at least one protecting group having an Fmoc skeleton; ii) at least one carboxylic acid group, either free or activated esterified;

[0066] In the present invention, the term "protecting group having an Fmoc skeleton" refers to an Fmoc group or a group in which an arbitrary substituent has been introduced at an arbitrary position of the structural skeleton of the Fmoc group. Specific examples of the protecting group having an Fmoc skeleton include a 9-fluorenylmethyloxycarbonyl (Fmoc) group, a 2,7-di-tert-butyl-Fmoc (Fmoc*) group, a 2-fluoro-Fmoc (Fmoc(2F)) group, a 2-monoisooctyl-Fmoc (mio-Fmoc) group, and a 2,7-diisooctyl-Fmoc (dio-Fmoc) group. In the present invention, instead of a protecting group having an Fmoc skeleton, a protecting group that can be deprotected under basic conditions or with a nucleophilic species exhibiting basicity (e.g., piperidine or hydrazine) can also be used. Specific examples of such protecting groups include 2-(4-nitrophenylsulfonyl)ethoxycarbonyl (Nsc) group, (1,1-dioxobenzo[b]thiophen-2-yl)methyloxycarbonyl (Bsmoc) group, (1,1-dioxonaphtho[1,2-b]thiophen-2-yl)methyloxycarbonyl (α-Nsmoc) group, 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde) ​​group, tetrachlorophthaloyl (TCP) group, 2-[phenyl(methyl)sulfonio]ethyloxycarbonyl tetrafluoroborate (Pms) group, ethanesulfonylethoxycarbonyl (Esc) group, 2-(4-sulfophenylsulfonyl)ethoxycarbonyl (Sps) group, etc. Protective groups that can be deprotected with a method other than acids or bases can also be used.Specific examples of such protecting groups include a benzyloxycarbonyl (Z) group that can be deprotected by hydrogenation in the presence of a transition metal catalyst such as palladium, an allyloxycarbonyl (Alloc) group that can be deprotected by a combination of a palladium catalyst and a scavenger (e.g., a combination of tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) and phenylsilane), an o-nitrobenzenesulfonyl (oNBS, Ns) group, a 2,4-dinitrobenzenesulfonyl (dNBS) group, and a dithiasuccinoyl (Dts) group that can be deprotected by a combination of an alkylthiol or an arylthiol and a base, and a p-nitrobenzyloxycarbonyl (pNZ) group that can be deprotected by hydrogenation in the presence of a transition metal catalyst or reductively with a reducing agent such as sodium dithionite (Na2S2O4) (Reference: Amino Acid-Protecting Groups, Chem. Rev. 2009, 109, 2455-2504).

[0067] In the present invention using the Fmoc method, for example, an Fmoc-protected amino acid or an Fmoc-protected amino acid analogue can be preferably used in which the amino group in the main chain is protected with an Fmoc group, the functional group in the side chain is protected with a protecting group that is not cleaved by a base such as piperidine or DBU as necessary, and the carboxylic acid group in the main chain is not protected. An Fmoc-protected amino acid or an Fmoc-protected amino acid analogue having an amino group protected with a protecting group having an Fmoc skeleton and a carboxylic acid group without a protecting group can also be preferably used.

[0068] In the present invention, when the Fmoc-protected amino acid, the Fmoc-protected amino acid analog, or the Fmoc-protected peptide has a functional group in the side chain, the functional group is preferably protected by a protecting group. When the functional group in the side chain is protected by a protecting group, a well-known protecting group that can be deprotected under any condition can be used. As such a protecting group, a protecting group that is not cleaved under basic conditions and is deprotected under conditions that are weaker acid than TFA is preferable. As a protecting group that can be deprotected under acidic conditions, for example, a protecting group that can be deprotected in the range of pH 1 to pH 7, preferably in the range of pH 2 to pH 6, can be mentioned. Alternatively, a protecting group that can be deprotected in 10% or less TFA, or a protecting group having the structure described below can be used. In the present invention, a well-known protecting group can be used as the protecting group of the side chain. For example, a protecting group that satisfies the above conditions from among the protecting groups described in the following documents i) and ii) can be adopted as the protecting group of the side chain. Non-patent literature i) Greene's Protective Groups inOrganicSynthesis, Fourth Edition, Non-patent literature ii)Chemical Reviews, 2009, 109(6),2455-2504.

[0069] The method of the present invention can be used for peptide synthesis by parallel synthesis. In this case, a protecting group is not necessarily required for the side chain of the amino acid, but when a protecting group is required for the side chain, it is preferable that the protecting group used is quickly deprotected under the deprotection conditions of the present invention. It is preferable that 50% of the protecting group of the side chain is deprotected within 24 hours, and it is particularly preferable that 90% is deprotected within 4 hours. As a protecting group that satisfies such conditions, a protecting group having a Trt skeleton, a THP skeleton, a THF skeleton, or a TBS skeleton described below is preferable. In addition, in order to be easily deprotected by acid and to have high reactivity during elongation, a protecting group in which at least one hydrogen atom is substituted for an atom on the protecting group side directly bonded to a functional group (a protecting group having a steric bulkiness less than that of a protecting group of a Trt skeleton) is preferable. Among them, a protecting group in which a substituent other than hydrogen forms a ring is more preferable, and THP and THF are particularly preferable.

[0070] The method of the present invention can also be used for industrial peptide synthesis. In this case, as in the parallel synthesis, it is not necessary to have a protecting group on the side chain of the amino acid, but if the side chain has a protecting group, it is preferable to have the same protecting group as in the parallel synthesis. If the sequence of the peptide to be synthesized does not have problems with hydrolysis and N→O-acyl shift during deprotection, but there is a problem with the elongation reaction due to the bulkiness of the protecting group, a strong acid such as TFA that is generally used during deprotection may be used. Also, if there is no problem with the elongation reaction of the peptide to be synthesized, a bulky protecting group may be used.

[0071] In the present invention, the condition of "a weaker acid than TFA" is preferably a condition in which a weak acid having a pKa value in water of 0 to 9 is used with an ionization ability Y OTs Examples of conditions include the use of a weak acid solution in a solvent whose pKa in water is 5 to 14 and whose value is positive.

[0072] More preferably, the "weak acid having a pKa value of 0 to 9 in water" is a weak acid having a pKa value of 1 to 5 in water. Specific examples of such weak acids include tetramethylammonium hydrogen sulfate (pKa=2.0 in water), oxalic acid (pKa=1.23 in water), and maleic acid (pKa=1.92 in water). The concentration of the weak acid dissolved in the solvent may be any concentration as long as it satisfies the condition of being a weaker acid than TFA.

[0073] "Ionization ability Y OTs As the "solvent having a positive pKa value and a pKa in water of 5 to 14," fluoroalcohols are preferred. Fluoroalcohols are a general term for alcohols in which a fluorine atom is bonded to a carbon atom other than the carbon atom to which a hydroxyl group is bonded. In the present invention, fluoroalcohols include those in which a hydroxyl group is bonded to an aromatic ring, such as 2,3,4,5,6-pentafluorophenol. As fluoroalcohols, 2,2,2-trifluoroethanol (TFE) and hexafluoro-2-propanol (HFIP) are preferred.

[0074] In the present invention, other organic solvents (e.g., dichloromethane, 1,2-dichloroethane, etc.) and cation scavengers (e.g., triisopropylsilane, etc.) can be further added to the weak acid solution as long as the condition for making the weak acid weaker than TFA is satisfied.

[0075] In the present invention, when the Fmoc-protected amino acid or Fmoc-protected amino acid analog has a protecting group in its side chain, preferred examples of the protecting group in the side chain include the following.

[0076] When the side chain protecting group is a protecting group for the hydroxyl group of Ser, Thr, Hyp, or derivatives thereof, a protecting group having a MOM skeleton, a Bn skeleton, a Dpm skeleton, a Trt skeleton, a silyl skeleton, or a Boc skeleton represented by the following general formula is preferred.

[0077] [ka] Representative examples of protecting groups having a MOM skeleton include MOM (R1=H, R2=H, X=Me), EE (R1=Me, R2=H, X=Et), MIP (R1=Me, R2=Me, X=Me), THP (R2=H, with a ring structure of four carbon atoms between R1 and X), THF (R2=H, with a ring structure of three carbon atoms between R1 and X), and SEM (R1=H, R2=H, X=2-trimethylsilylethyl). The Me and Et substituents on the skeleton can also be replaced with other alkyl groups, benzyl groups, aryl groups, etc.

[0078] [ka] Representative examples of protecting groups having a Bn skeleton include Pis (R6=Me, R7=Me, other R=H), PMB (R3=OMe, other R=H), and DMB (R1=OMe, R3=OMe, other R=H). Other alkyl groups may be used in place of the Me substituent. In addition, the benzene ring may be substituted with an alkyl group, an aryl group, a halogen group, or the like.

[0079] [ka] A representative example of a protecting group having a Dpm skeleton is Dpm (all R=H). The aromatic ring may be substituted with an alkyl group, an aryl group, an alkoxy group, a halogen group, or the like. Also, a bridge may be used between R5 and R6, such as an Xan group bridged via an oxygen atom or a dibenzosuberyl group bridged via two carbon atoms.

[0080] [ka] Representative examples of protecting groups having a Trt skeleton include Trt (all R=H), Mmt (R3=Me, other R=H), Mtt (R3=OMe, other R=H), Dmt (R3=OMe, R8=OMe, other R=H), Clt (R1=Cl, other R=H), etc. The aromatic ring may be substituted with an alkyl group, an aryl group, an alkoxy group, a halogen group, etc. It is also possible to use a bridge between R5 and R6, for example a Pixyl group bridged via an oxygen atom.

[0081] [ka] A representative example of a protecting group having a silyl skeleton is TBS (R1=Me, R2=Me, R3=tBu), etc. In place of Me or tBu, other alkyl groups, aryl groups, etc. may be substituted.

[0082] [ka] A representative example of a protecting group having a Boc skeleton is Boc (all R=H), but other alkyl groups, aryl groups, etc. may be substituted.

[0083] In addition, the following protecting groups can also be used. [ka]

[0084] Among these protecting groups, THP and Trt are particularly preferred. When the amino acid residue is Ser, the side chain protecting group is particularly preferably THP or Trt, and when the amino acid residue is Thr, the side chain protecting group is particularly preferably THP.

[0085] When the side chain protecting group is a protecting group of an amino acid having a hydroxyl group substituted with an aryl group, such as Tyr, D-Tyr, or Tyr(3-F), preferred are protecting groups having a MOM skeleton, a Bn skeleton, a Dpm skeleton, a Trt skeleton, a silyl skeleton, a Boc skeleton, or a tBu skeleton, for example, represented by the following general formulas.

[0086] [ka] Representative examples of protecting groups with a MOM skeleton include MOM (R1=H, R2=H, X=Me), BOM (R1=H, R2=H, X=Bn), EE (R1=Me, R2=H, X=Et), THP (R2=H, with a ring structure of four carbon atoms between R1 and X), THF (R2=H, with a ring structure of three carbon atoms between R1 and X), and SEM (R1=H, R2=H, X=2-trimethylsilylethyl). The Me and Et substituents on the skeleton can also be replaced with other alkyl groups, benzyl groups, aryl groups, etc.

[0087] [ka] Representative examples of protecting groups having a Bn skeleton include Pis (R6=Me, R7=Me, other R=H), PMB (R3=OMe, other R=H), and DMB (R1=OMe, R3=OMe, other R=H). Other alkyl groups may be used in place of the Me substituent. In addition, the benzene ring may be substituted with an alkyl group, an aryl group, a halogen group, or the like.

[0088] [ka] A representative example of a protecting group having a Dpm skeleton is Dpm (all R=H). The aromatic ring may be substituted with an alkyl group, an aryl group, an alkoxy group, a halogen group, or the like. Also, a bridge may be used between R5 and R6, such as an Xan group bridged via an oxygen atom or a dibenzosuberyl group bridged via two carbon atoms.

[0089] [ka] Representative examples of protecting groups having a Trt skeleton include Trt (all R=H), Mmt (R3=Me, other R=H), Mtt (R3=OMe, other R=H), Clt (R1=Cl, other R=H), etc. The aromatic ring may be substituted with an alkyl group, an aryl group, an alkoxy group, a halogen group, etc. It is also possible to use a bridge between R5 and R6, for example a Pixyl group bridged via an oxygen atom.

[0090] [ka] A representative example of a protecting group having a silyl skeleton is TBS (R1=Me, R2=Me, R3=tBu), etc. In place of Me or tBu, other alkyl groups, aryl groups, etc. may be substituted.

[0091] [ka] A representative example of a protecting group having a Boc skeleton is Boc (all R=H), but other alkyl groups, aryl groups, etc. may be substituted.

[0092] [ka] A representative example of a protecting group having a tBu skeleton is tBu (all R=H). It may be substituted with alkyl groups, aryl groups, etc. other than H.

[0093] Among these protecting groups, tBu, Pis, Trt, Clt, THP, and THF are particularly preferred. When the amino acid residue is Tyr or D-Tyr, the side chain protecting group is particularly preferably tBu, Trt, Clt, or THP, and when the amino acid residue is Tyr(3-F), the side chain protecting group is particularly preferably tBu or Pis.

[0094] When the side chain protecting group is a protecting group for an amino acid having imidazole in the side chain, such as His or MeHis, it is preferable to use a protecting group having, for example, a MOM skeleton, a Bn skeleton, or a Trt skeleton represented by the following general formula:

[0095] [ka] Representative examples of protecting groups having a MOM skeleton include MBom (R1=H, R2=H, X=4-methoxybenzyl), 2,4-DMBom (R1=H, R2=H, X=2,4-dimethoxybenzyl), 3,4-DMBom (R1=H, R2=H, X=3,4-dimethoxybenzyl), EE (R1=Me, R2=H, X=Et), THP (R2=H, a ring structure with four carbon atoms between R1 and X), and THF (R2=H, a ring structure with three carbon atoms between R1 and X). The Me and Et substituents on the skeleton can also be replaced by other alkyl groups, benzyl groups, aryl groups, etc.

[0096] [ka] Representative examples of protecting groups having a Bn skeleton include Pis (R6=Me, R7=Me, other R=H), PMB (R3=OMe, other R=H), and DMB (R1=OMe, R3=OMe, other R=H). Other alkyl groups may be used in place of the Me substituent. In addition, the benzene ring may be substituted with an alkyl group, an aryl group, a halogen group, or the like.

[0097] [ka] Representative examples of protecting groups having a Trt skeleton include Trt (all R=H), Mmt (R3=Me, other R=H), Mtt (R3=OMe, other R=H), Clt (R1=Cl, other R=H), etc. The aromatic ring may be substituted with an alkyl group, an aryl group, an alkoxy group, a halogen group, etc.

[0098] Among these, Trt is particularly preferred. When the amino acid residue is His or MeHis, the side chain protecting group is particularly preferably Trt.

[0099] In addition, for example, when the carboxylic acid group of the main chain is used as a "free or active esterified carboxylic acid group", a protecting group having a MOM skeleton, a Bn skeleton, a Dpm skeleton, a Trt skeleton, a tBu skeleton, or a phenyl-EDOTn skeleton represented by the following general formula can be used as a protecting group for the carboxylic acid group of the side chain of Asp, Glu, and derivatives thereof, and when the carboxylic acid group of the side chain of Asp, Glu, and derivatives thereof is used as a "free or active esterified carboxylic acid group", a protecting group for the carboxylic acid group of the main chain can be used. In addition, a protecting group having an orthoester skeleton in which three alkoxy groups are bonded to a carbon atom derived from a carboxylic acid group can also be used as a protecting group for a carboxylic acid. The carbon atom forming these protecting groups may be substituted.

[0100] [ka] Representative examples of protecting groups having a MOM skeleton include BOM (R1=H, R2=H, X=Bn), THP (R2=H, with a ring structure of four carbon atoms between R1 and X), and THF (R2=H, with a ring structure of three carbon atoms between R1 and X). Substituents on the skeleton may also be other alkyl groups, benzyl groups, aryl groups, etc.

[0101] [ka] Representative examples of protecting groups having a Bn skeleton include Pis (R6=Me, R7=Me, other R=H), PMB (R3=OMe, other R=H), DMB (R1=OMe, R3=OMe, other R=H), piperonyl (R2 and R3 are substituted with oxygen atoms, and the oxygen atoms are bridged by one carbon atom, other R=H). Other alkyl groups may be used instead of the Me substituent. In addition, alkyl groups, aryl groups, halogen groups, etc. may be substituted on the benzene ring.

[0102] [ka] A representative example of a protecting group having a Dpm skeleton is Dpm (all R=H). The aromatic ring may be substituted with an alkyl group, an aryl group, an alkoxy group, a halogen group, or the like. Also, a bridge may be used between R5 and R6, for example a dibenzosuberyl group bridged via two carbon atoms.

[0103] [ka] Representative examples of protecting groups having a Trt skeleton include Trt (all R=H), Mmt (R3=Me, other R=H), Mtt (R3=OMe, other R=H), Clt (R1=Cl, other R=H), etc. The aromatic ring may be substituted with an alkyl group, an aryl group, an alkoxy group, a halogen group, etc. It is also possible to use a bridge between R5 and R6, for example a Pixyl group bridged via an oxygen atom.

[0104] [ka] Representative examples of protecting groups having a tBu skeleton include tBu (all R = H), Mpe (R1 = Me, R4 = Me, other R = H), etc. Other alkyl groups, aryl groups, etc. may be substituted.

[0105] [ka] Phenyl-EDOTn can have a combination of the following substituents: (i) R1=R2=R3=OMe, (ii) R1=R2=OMe, R3=H, (iii) R1=R2=H, R3=OMe, or (iv) R1=R2=R3=H.

[0106] [ka] The dicyclopropylmethyl group can also be used.

[0107] Among these, tBu, Pis and Trt are particularly preferred.

[0108] In the present invention, the term "Fmoc-protected peptide" refers to a peptide containing both or either one of the above-mentioned "Fmoc-protected amino acid" and the above-mentioned "Fmoc-protected amino acid analog". Examples of such peptides include dipeptides and oligopeptides containing two or more molecules of either or both of the above-mentioned Fmoc-protected amino acid and Fmoc-protected amino acid analog.

[0109] In the synthesis of peptides by the solid phase method of the present invention, Fmoc-protected amino acids, Fmoc-protected amino acid analogs, or Fmoc-protected peptides (sometimes referred to as Fmoc-protected amino acids, etc.) can be supported on a solid phase using a resin. The group (resin-binding group) used for binding the resin to the Fmoc-protected amino acids, etc. is not particularly limited as long as the peptide can be excised with an acid. The amount and rate of the Fmoc-protected amino acids, etc. supported are also not particularly limited. In the present invention, for example, trityl chloride resin (Trt resin), 2-chlorotrityl chloride resin (Clt resin), 4-methyltrityl chloride resin (Mtt resin), and 4-methoxytrityl chloride resin (Mmt) can be used. In particular, the resin preferably has a resin-binding group that is judged to be "H (<5% TFA in DCM)" as the acid sensitivity described in the Solid Phase Synthesis Handbook (published by Merck Ltd., published on May 1, 2002), and can be appropriately selected according to the functional group on the amino acid side used. For example, when a carboxylic acid (main chain carboxylic acid or side chain carboxylic acid such as Asp or Glu) or a hydroxy group on an aromatic ring (phenol group such as Tyr) is used as the functional group on the amino acid side, it is preferable to use trityl chloride resin (Trt resin) or 2-chlorotrityl chloride resin (Clt resin) as the resin. When an aliphatic hydroxy group (aliphatic alcohol group such as Ser or Thr) is used as the functional group on the amino acid side, it is preferable to use trityl chloride resin (Trt resin), 2-chlorotrityl chloride resin (Clt resin) or 4-methyltrityl chloride resin (Mtt resin) as the resin. The type of polymer constituting the resin is not particularly limited. In the case of a resin composed of polystyrene, either 100-200 mesh or 200-400 mesh may be used. In addition, the cross-linking rate is not particularly limited, but 1% DVB (divinylbenzene) cross-linking is preferable.

[0110] The Fmoc-protected amino acid, the Fmoc-protected amino acid analog, or the Fmoc-protected peptide is supported on the resin by a chemical reaction between the free carboxylic acid group or the active esterified carboxylic acid group of the amino acid located at the C-terminus of the Fmoc-protected amino acid, the Fmoc-protected amino acid analog, or the Fmoc-protected peptide and the resin binding group. In this case, the free carboxylic acid may be the main chain carboxylic acid of the amino acid or the amino acid analog, or may be a side chain carboxylic acid (Asp, etc.). Instead of the carboxylic acid group, the main chain or side chain free OH group or free SH group of the amino acid located at the C-terminus of the Fmoc-protected amino acid, the Fmoc-protected amino acid analog, or the Fmoc-protected peptide may be used for supporting the solid phase.

[0111] The protecting group having an Fmoc skeleton of the Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide supported on the solid phase is deprotected with a base to expose the amino group. The base used here is not particularly limited, but a deprotecting agent generally used in peptide synthesis can be used (for example, Amino Acid-Protecting Groups (Chem. Rev. 2009, 109, 2455-2504)). As such a deprotecting agent, for example, a secondary amine, a base having an amidine skeleton, or a base having a guanidine skeleton is preferable. Specific examples of secondary amines include piperidine, morpholine, pyrrolidine, and piperazine. Specific examples of bases having an amidine skeleton include 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 1,5-diazabicyclo[4.3.0]-5-nonene (DBN). A specific example of a base having a guanidine skeleton is 1,1,3,3-tetramethylguanidine.

[0112] The exposed amino group is condensed with a free or active esterified carboxylic acid group of a newly added Fmoc-protected amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide to form a peptide bond.

[0113] The condensing agent used for condensing an amino group and a carboxylic acid group is not particularly limited as long as it can form an amide bond, and is preferably a condensing agent generally used in peptide synthesis (for example, Peptide Coupling Reagents, More than a Letter Soup (Chem. Rev.2011,111, 6557-6602)). Specific examples of such condensing agents include condensing agents having a carbodiimide skeleton. For example, a condensing agent having a carbodiimide skeleton can be used in a condensation reaction in combination with a hydroxy compound capable of forming an active ester. Examples of condensing agents having a carbodiimide skeleton include N,N'-dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIC), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSCI·HCl) (for example, see WATANABE Chemical's catalog, Amino acids and chiral building blocks to new medicine). Examples of hydroxy compounds capable of forming active esters include 1-hydroxy-1H-benzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), ethyl 2-cyano-2-(hydroxyimino)acetate (oxyma), 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HOOBt or HODhbt), N-hydroxy-5-norbornene-2,3-dicarboximide (HONB), 2,3,4,5,Examples include 6-pentafluorophenol (HOPfp), N-hydroxysuccinimide (HOSu), and 6-chloro-1-hydroxy-1H-benzotriazole (Cl-HOBt) (see, for example, WATANABE Chemical's catalog, Amino acids and chiral building blocks to new medicine). In addition, salts having these skeletons, such as K-oxyma, the potassium salt of oxyma, can also be used. Among these, HOBt, HOAt, oxyma, and HOOBt are particularly preferred. Among them, it is preferable to use DIC and HOAt in combination, or DIC and oxyma in combination. Other examples of phosphonium and uronium condensation agents include O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), O-(7-aza-1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), and N-[1-(cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethyl]-2-methyl-1H-benzotriazol-1-yl ... O-[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium hexafluorophosphate (HOTU), O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-Tetramethyluronium tetrafluoroborate (TATU), 1H-benzotriazol-1-yloxy-tri(pyrrolidino)phosphonium hexafluorophosphate (PyBOP), 1H-benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), bromotri(pyrrolidino)phosphonium hexafluorophosphate (PyBroP), chlorotri(pyrrolidino)phosphonium (7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyCloP), (7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP), Bromotris(dimethylamino)phosphonium hexafluorophosphate (Brop), 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT), N,N,N',N'-Tetramethyl-O-(N-succinimidyl)uronium tetraphosphate (N-succinimidyl) Tetramethylthiuronium S-(1-oxido-2-pyridyl)-N,N,N',N'-tetrafluoroborate (TSTU), N,N,N',N'-tetramethyl-O-(N-succinimidyl)uronium hexafluorophosphate (HSTU), O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TDBTU), Tetramethylthiuronium S-(1-oxido-2-pyridyl)-N,N,N',N'-tetrafluoroborate The condensation reaction can be carried out by combining any one of the following bases: HATU and DIPEA, triethylamine (TEA), 2,4,6-trimethylpyridine (2,4,6-collidine), and 2,6-dimethylpyridine (2,6-lutidine). It is particularly preferable to use HATU in combination with DIPEA, or COMU in combination with DIPEA. Other examples include N,N'-carbonyldiimidazole (CDI), 1,1'-carbonyl-di-(1,2,4-triazole) (CDT), 4-(4,6-dimethoxy-1,3,Condensing agents such as 5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM) and propylphosphonic anhydride (T3P) can also be used.

[0114] The production method of the present invention includes a step of deprotecting a protecting group having an Fmoc skeleton of a newly added Fmoc-protected amino acid, an Fmoc-protected amino acid analog, or an Fmoc-protected peptide with a base to expose an amino group; The method of the present invention further includes a step of adding a new Fmoc-protected amino acid, an Fmoc-protected amino acid analog, or an Fmoc-protected peptide to form an amide bond. These steps may be repeated once or multiple times. The method of the present invention makes it possible to obtain a target peptide sequence by repeating the deprotection of the protecting group having the Fmoc skeleton and the condensation reaction with the next new Fmoc-protected amino acid, an Fmoc-protected amino acid analog, or an Fmoc-protected peptide.

[0115] When the present invention is carried out by the solid phase method, after the target peptide is obtained, it is excised from the solid phase (excision step). It is also possible to carry out structural transformation or cyclization of the peptide before carrying out the excision step. In the present invention, at the time of excision, the side chain functional groups protected by protecting groups may or may not be deprotected, and only some of the protecting groups may be deprotected. It is preferable that the excision step is carried out while the side chain functional groups remain protected.

[0116] Specifically, the reaction conditions for the excision step of the present invention are preferably those that produce a weak acid, and particularly those that produce a weaker acid than TFA. Specifically, such a weak acid is preferably an acid that has a pKa value higher than TFA in water. More specifically, an acid with a pKa value in the range of 0 to 15 is preferred, and an acid with a pKa value in the range of 6 to 15 in water is more preferred. Examples of acids that are weaker than TFA used in this step include TFE and HFIP. Two or more weak acids may be combined in any ratio, such as TFE / acetic acid. Also, any solvent, such as DCM, DCE, and water, may be mixed in any ratio. As a combination of such a weak acid and a solvent, a combination of TFE and DCM is particularly preferred. Other organic solvents or reagents (e.g., DIPEA, etc.), cation capture agents (e.g., triisopropylsilane, etc.), etc. may be added to the solution used for excision.

[0117] When a cleavage step is carried out before deprotecting the side chain protecting groups of the synthesized peptide, the weak acid used for cleavage is preferably weaker than the acid used in the deprotection reaction. In this case, two acids with different acidities that are weaker than TFA are prepared in advance, and the weaker acid is used for cleavage. When the cleavage step is carried out after deprotecting the protecting groups of the side chains of the synthesized peptide, the weak acid used for the cleavage is not particularly limited as long as it is an acid weaker than TFA.

[0118] In the deprotection step of the side chain protecting group of the present invention, it is possible to selectively carry out the desired deprotection reaction by reducing side reactions such as hydrolysis and N→O-acyl shift. The deprotection of the side chain protecting group is preferably carried out under conditions that result in a weaker acid than TFA. The reaction can be carried out at any temperature, and is preferably carried out at 0 to 40° C. When the deprotection is completed or the reaction is stopped during the deprotection, a base such as ammonia or a primary to tertiary amine can be used. A basic heterocyclic compound (for example, pyridine, imidazole, or their analogues) can also be used.

[0119] When further alterations or modifications are to be made to the peptide synthesized by the production method of the present invention, these steps can be carried out either before or after the excision step.

[0120] The peptide produced by the production method of the present invention can be a peptide that contains an amino acid residue or amino acid analog residue having one reactive site at the side chain on the C-terminus side, and an amino acid residue, amino acid analog residue, or carboxylic acid analog having another reactive site on the N-terminus side. Such a peptide can be produced, for example, by selecting starting Fmoc-protected amino acid, Fmoc-protected amino acid analog, and Fmoc-protected peptide so that an amino acid residue or amino acid analog residue having one reactive site is contained in the side chain on the C-terminus side, and an amino acid residue, amino acid analog residue, or carboxylic acid analog having another reactive site is contained on the N-terminus side.

[0121] This peptide can be cyclized by binding one reactive site to another reactive site. The production method of the present invention can include such a cyclization step. Specifically, the cyclization step can be carried out based on the description in WO2013 / 100132.

[0122] When the cyclization step is carried out after the cleavage step, the residue obtained by concentrating the reaction solution (cleavage solution) obtained in the cleavage step under reduced pressure may be used in the cyclization step, or the cleavage solution may be used as it is in the cyclization step.

[0123] In the present invention, the "carboxylic acid analog" includes compounds having both an amino group and a carboxyl group and having three or more atoms between them, various carboxylic acid derivatives having no amino group, peptides formed from 2 to 4 residues, and amino acids in which the main chain amino group is chemically modified by an amide bond with a carboxylic acid. The "carboxylic acid analog" may have a boric acid or boric acid ester moiety that can be used for cyclization. The "carboxylic acid analog" may be a carboxylic acid having a double bond moiety or a triple bond moiety, or a carboxylic acid having a ketone or a halide. In addition, the moiety other than the functional group specified in these compounds may be substituted, and may be selected (free substituent) from, for example, an alkyl group, an aralkyl group, an aryl group, a cycloalkyl group, a heteroaryl group, an alkenyl group, an alkynyl group, and the like.

[0124] The cyclization step includes, but is not limited to, cyclizing the two reactive points by, for example, an amide bond, a disulfide bond, an ether bond, a thioether bond, an ester bond, a thioester bond, or a carbon-carbon bond.

[0125] Cyclization by amide bond formation is, for example, cyclization by forming an amide bond between a reactive site (main chain amino group or amino group present in the side chain) of an N-terminal amino acid residue, an N-terminal amino acid analog residue, or an N-terminal carboxylic acid analog, and a reactive site of an amino acid residue or amino acid analog having one carboxylic acid in the side chain. In these reactions, the same condensing agent as that used in the above-mentioned peptide bond can be used. Specifically, for example, a combination of HATU and DIPEA, a combination of COMU and DIPEA, or the like can be used to condense a side chain carboxylic acid with an N-terminal main chain amino group, or a side chain amino group with a C-terminal main chain carboxylic acid. In this case, it is preferable to select the protecting group of the carboxylic acid on the C-terminal side and the protecting group of the carboxylic acid on the side chain to be used for cyclization, or the protecting group of the amino group on the main chain on the N-terminal side and the protecting group of the amino group on the side chain to be used for cyclization, taking into consideration their orthogonality. The protecting groups preferred in this series of peptide synthesis are as described above.

[0126] Cyclization by carbon-carbon bond formation is, for example, cyclization by forming a carbon-carbon bond between the reactive site of the N-terminal amino acid residue, the N-terminal amino acid analog residue, or the N-terminal carboxylic acid analog, and the reactive site of the amino acid residue or amino acid analog having one reactive site in the side chain. Specifically, for example, an alkenyl group is selected as the reactive site of the N-terminal amino acid residue, the N-terminal amino acid analog residue, or the N-terminal carboxylic acid analog, and an alkenyl group is selected as the reactive site of the amino acid residue or amino acid analog residue having one reactive site in the side chain, and a cyclization reaction can be carried out by a carbon-carbon bond reaction using a transition metal as a catalyst. At this time, examples of the transition metal used as a catalyst include ruthenium, molybdenum, titanium, and tungsten. For example, when ruthenium is used, the cyclization reaction can be carried out by a metathesis reaction. Also, for example, a combination of an aryl halide and a boronic acid or a boronic acid analog can be used as the reaction points of the N-terminal amino acid residue, the N-terminal amino acid analog residue or the N-terminal carboxylic acid analog, and the amino acid residue or amino acid analog residue having one reaction point in the side chain, and a cyclization reaction can be carried out by a carbon-carbon bond reaction using a transition metal as a catalyst. Examples of transition metals used as catalysts at this time include palladium, nickel, and iron. For example, when palladium is used, the cyclization reaction can be carried out by the Suzuki reaction. Also, for example, a combination of an alkenyl group and an aryl halide or an alkenyl halide can be used as the reaction points of the N-terminal amino acid residue, the N-terminal amino acid analog residue or the N-terminal carboxylic acid analog, and the amino acid residue or amino acid analog residue having one reaction point in the side chain, and a cyclization reaction can be carried out by a carbon-carbon bond reaction using a transition metal as a catalyst. Examples of transition metals used as catalysts at this time include palladium and nickel. For example, when palladium is used, the cyclization reaction can be carried out by a Heck-type chemical reaction.Also, for example, a combination of an acetylene group and an aryl halide or an alkenyl halide can be selected as the reaction site of the N-terminal amino acid residue, the N-terminal amino acid analog residue, or the N-terminal carboxylic acid analog, and the reaction site of the amino acid residue or amino acid analog residue having one reaction site in the side chain, and a cyclization reaction can be carried out by a carbon-carbon bond reaction using a transition metal as a catalyst. Examples of transition metals used as catalysts include palladium, copper, gold, and iron. For example, when a combination of palladium and copper is used, the cyclization reaction can be carried out by the Sonogashira reaction.

[0127] In the present invention, the obtained product can be purified as necessary. For example, a general peptide purification method such as a reverse phase column or a molecular sieve column can be used. In addition, purification can be performed by crystallization or solidification using an appropriate solvent. Concentration under reduced pressure is also possible before purification. All prior art documents cited in this specification are hereby incorporated by reference. EXAMPLES

[0128] The present invention is further illustrated by, but not limited to, the following examples.

[0129] In the examples, the following abbreviations are used: DCM Dichloromethane DCE 1,2-dichloroethane DMF N,N-Dimethylformamide DIC N,N'-Diisopropylcarbodiimide DIPEA N,N-Diisopropylethylamine DBU 1,8-diazabicyclo[5.4.0]-7-undecane hmm NMP N-Methyl-2-pyrrolidone FA Formic Acid TFA Trifluoroacetic acid TFE 2,2,2-trifluoroethanol HFIP 1,1,1,3,3,3-Hexafluoroisopropyl alcohol HOAt 1-Hydroxy-7-azabenzotriazole HOBt 1-Hydroxybenzotriazole WSCI·HCl 1-Ethyl-3-(3-dimethylaminopropyl) Carbodiimide hydrochloride TBME t-Butyl methyl ether TIPS Triisopropylsilane HATU O-(7-aza-1H-benzotriazol-1-yl )-N,N,N',N'-Tetramethyluronium Hexa Fluorophosphate

[0130] The reaction solvents used in peptide synthesis and solid-phase synthesis were those for peptide synthesis (purchased from Watanabe Chemical and Wako Pure Chemical). For example, DCM, DMF, NMP, 2% DBU in DMF, 20% piperidine in DMF, etc. For reactions in which water was not added as a solvent, dehydrated solvents, ultra-dehydrated solvents, and anhydrous solvents (purchased from Kanto Chemical and Wako Pure Chemical, etc.) were used.

[0131] The LCMS analysis conditions are as shown in Table 1. [Table 1]

[0132] Example 1. Basic synthesis route for cyclic peptides containing N-methyl amino acids in the sequence The synthesis of a cyclic peptide containing an N-methyl amino acid in its sequence was carried out by solid-phase synthesis using the Fmoc method, following the synthetic route shown in FIG. 1, which consists of the following five steps. A) A step of extending a peptide from the N-terminus of Asp, the carboxylic acid of which is supported on 2-chlorotrityl resin, using a peptide synthesizer by the Fmoc method. B) Cleavage of peptides from 2-chlorotrityl resin C) A step of condensing the carboxylic acid (white circle unit) on the side chain of Asp of the excised peptide with the amino group on the N-terminus of the peptide chain (triangle unit) to form a cyclization by an amide bond. D) A step of deprotecting the protecting groups of the side chain functional groups contained in the peptide chain. E) Purifying the compound by preparative HPLC.

[0133] In the present examples, unless otherwise specified, cyclic peptides were synthesized based on this basic synthesis route.

[0134] Fmoc-amino acids for peptide synthesis using a peptide synthesizer In the peptide synthesis described in this Example, the following Fmoc-amino acids were used in the synthesis by a peptide synthesizer (step A above).

[0135] Fmoc-Pro-OH, Fmoc-Thr(Trt)-OH, Fmoc-Ile-OH, Fmoc-Trp-OH, Fmoc-D-Tyr(tBu)-OH, Fmoc-D-Tyr(C lt)-OH, Fmoc-Ser(Trt)-OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-His(Trt)-OH, Fmoc-MeP he-OH, Fmoc-MeAla-OH, Fmoc-MeGly-OH, Fmoc-MeLeu-OH, Fmoc-Phe(4-CF3)-OH, Fmoc-b-Ala-OH, Fmo c-b-MeAla-OH, Fmoc-Nle-OH, Fmoc-Met(O2)-OH, Fmoc-Phe(3-Cl)-OH, Fmoc-MeVal, and Fmoc-Val-OH. These were purchased from Watanabe Chemical, Chempep, Chem-Impex, or the like.

[0136] Fmoc-MeSer(DMT)-OH, Fmoc-MePhe(3-Cl)-OH, Fmoc-MeAla(4-Thz)-OH, Fmoc-Hyp(Et)-OH, and Fmoc-γEtAbu-OH, Fmoc-nPrGly-OH. These were synthesized according to the method described in the literature (literature: International Publication No. WO2013 / 100132 A1).

[0137] Fmoc-Ser(THP)-OH (compound 1), Fmoc-Thr(THP)-OH (compound 2), Fmoc-MeSer(THP)-OH (compound 6), Fmoc-MeHis(Trt)-OH (compound 7), Fmoc-D-Tyr(THP)-OH(compound Compound 8), Fmoc-D-Tyr(Pis)-OH (Compound 11), Fmoc-Tyr(3-F,tBu)-OH (Compound 13), Fmoc-MePhe(4-Cl)-OH (Compound 16), and Fmoc-Tyr(3-F,Pis)-OH (Compound 22). These were synthesized as follows: These synthesized Fmoc-amino acids were used not only for peptide synthesis but also for investigating the deprotection of the protecting groups of the side chain functional groups or the protecting group of the C-terminal carboxylic acid group.

[0138] Example 1-1: Synthesis of (2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((tetrahydro-2H-pyran-2-yl)oxy)propanoic acid (compound 1, Fmoc-Ser(THP)-OH) [ka] Toluene (10 mL) was added to a mixture of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-hydroxypropanoic acid (Fmoc-Ser-OH, purchased from Watanabe Chemical, 1.0 g, 3.06 mmol) and pyridinium p-toluenesulfonate (PPTS, 0.038 g, 0.153 mmol), and the water content was removed by azeotropy by distilling off the toluene under reduced pressure. Ultra-dehydrated tetrahydrofuran (THF, 6.1 mL) and 3,4-dihydro-2H-pyran (1.9 mL, 21.3 mmol) were added to the resulting residue, and the mixture was stirred at 50°C for 4 hours under a nitrogen atmosphere. After confirming the disappearance of the raw materials by LCMS (SQDFA05), the mixture was cooled to 25°C and ethyl acetate (6 mL) was added. Saturated aqueous sodium chloride solution (6 mL) was then added to wash the organic layer, and the aqueous layer was extracted with ethyl acetate (6 mL). All the obtained organic layers were mixed and washed twice with saturated aqueous sodium chloride solution (6 mL). The organic layer was dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was dissolved in tetrahydrofuran (THF, 12.2 mL), and then 1.0 M phosphate buffer (12.2 mL) adjusted to pH 8.0 was added. This mixture was stirred at 50°C for 3 hours. After cooling to 25°C, ethyl acetate (12.2 mL) was added, and the organic layer and the aqueous layer were separated. After extraction with ethyl acetate (12.2 mL) added to the aqueous layer, all the obtained organic layers were mixed and washed twice with saturated aqueous sodium chloride solution (12.2 mL). The organic layer was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and the mixture was further dried at 25°C for 30 minutes under reduced pressure with a pump. The resulting residue was dissolved in dichloromethane (7 mL), and then heptane (16.6 mL) was added. Under controlled reduced pressure (~100 hPa), only dichloromethane was distilled off, and the resulting mixture was filtered to obtain a solid. This heptane washing procedure was repeated twice. The obtained solid was dried at 25°C under reduced pressure on the pump for 2 hours, yielding 1.40 g of residue. To the residue obtained, t-butyl methyl ether (TBME, 25 mL) and 0.05 M aqueous phosphoric acid solution (70 mL) with pH 2.1 were added, and the mixture was stirred at 25 degrees for 5 minutes, after which the organic layer and the aqueous layer were separated. After the aqueous layer was extracted with t-butyl methyl ether (TBME, 25 mL), all the organic layers obtained were mixed and washed twice with saturated aqueous sodium chloride solution (25 mL). The organic layer was dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was dried under reduced pressure at 25 degrees for 2 hours with a pump to obtain (2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((tetrahydro-2H-pyran-2-yl)oxy)propanoic acid (compound 1, Fmoc-Ser(THP)-OH, 1.22 g, 30 mol% of t-butyl methyl ether (TBME) remained). The resulting Fmoc-Ser(THP)-OH was stored in a freezer at -25°C. LCMS(ESI)m / z=410.2(MH) - Retention time: 0.81 minutes (Analysis conditions SQDFA05)

[0139] Example 1-2: Synthesis of (2S,3R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((tetrahydro-2H-pyran-2-yl)oxy)butanoic acid (compound 2, Fmoc-Thr(THP)-OH) [ka] Toluene (50 mL) was added to a mixture of (2S,3R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-hydroxybutanoic acid monohydrate (monohydrate of Fmoc-Thr-OH, purchased from Tokyo Kasei, 5.0 g, 13.9 mmol) and pyridinium p-toluenesulfonate (PPTS, 0.175 g, 0.70 mmol), and the water contained therein was removed by azeotropy by distilling off the toluene under reduced pressure. Super-dehydrated tetrahydrofuran (THF, 28 mL) and 3,4-dihydro-2H-pyran (8.8 mL, 97 mmol) were added to the resulting residue, and the mixture was stirred at 50°C for 4 hours under a nitrogen atmosphere. After confirming the disappearance of the raw materials by LCMS (SQDFA05), the mixture was cooled to 25°C and ethyl acetate (30 mL) was added. Saturated aqueous sodium chloride solution (30 mL) was then added to wash the organic layer, and the aqueous layer was extracted with ethyl acetate (30 mL). All the organic layers obtained were mixed and further washed twice with saturated aqueous sodium chloride solution (30 mL). The organic layer was dried over sodium sulfate, and the solvent was distilled off under reduced pressure to obtain 9.3 g of a crude product. Of the obtained crude product, 4.65 g was dissolved in tetrahydrofuran (THF, 30 mL), and then 1.0 M phosphate buffer (30 mL) adjusted to pH 8.0 was added. This mixture was stirred at 50°C for 4 hours. After cooling to 25°C, ethyl acetate (30 mL) was added and the organic layer and aqueous layer were separated. After adding ethyl acetate (30 mL) to the aqueous layer and performing extraction, all the obtained organic layers were mixed and washed twice with saturated aqueous sodium chloride solution (30 mL). The organic layer was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and further dried at 25°C for 30 minutes under reduced pressure with a pump. The resulting residue was dissolved in diethyl ether (50 mL), and then heptane (50 mL) was added. Under controlled reduced pressure (~100 hPa), only diethyl ether was distilled off, and the resulting mixture was filtered to obtain a solid. This heptane washing procedure was repeated twice. The obtained solid was dried at 25°C under reduced pressure on the pump for 2 hours to obtain the sodium salt of Fmoc-Thr(THP)-OH (2.80 g, 6.26 mmol). Ethyl acetate (50 mL) and 0.05 M aqueous phosphoric acid solution (140 mL) at pH 2.1 were added to the total amount of sodium salt of Fmoc-Thr(THP)-OH obtained, and the mixture was stirred at 25 degrees for 5 minutes, and then the organic layer and the aqueous layer were separated. Ethyl acetate (50 mL) was added to the aqueous layer for extraction, and then all the organic layers obtained were mixed and washed twice with saturated aqueous sodium chloride solution (50 mL). The organic layer was dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was dried under reduced pressure at 25 degrees for 2 hours with a pump, and the obtained solid was dissolved in t-butyl methyl ether (TBME, 50 mL), and the solvent was distilled off under reduced pressure. Further, by drying at 25 degrees under reduced pressure with a pump for 1 hour, (2S,3R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((tetrahydro-2H-pyran-2-yl)oxy)butanoic acid (compound 2, Fmoc-Thr(THP)-OH, 2.70 g, 30 mol% of t-butyl methyl ether (TBME) remaining) was obtained as a diastereomer derived from the asymmetric carbon on the THP protection. The obtained Fmoc-Thr(THP)-OH was stored in a freezer at -25 degrees. LCMS(ESI)m / z=424.2(MH) - Retention time: 0.84 minutes, 0.85 minutes (Analysis conditions SQDFA05)

[0140] Example 1-3: Synthesis of (2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-((tetrahydro-2H-pyran-2-yl)oxy)propanoic acid (compound 6, Fmoc-MeSer(THP)-OH) [ka] (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-hydroxypropanoic acid (Fmoc-MeSer-OH) was synthesized according to the method described in the literature (literature: International Publication No. WO 2013 / 100132 A1). Pyridinium p-toluenesulfonate (PPTS, 0.552 g, 2.197 mmol) and 3,4-dihydro-2H-pyran (23.85 mL) were added to a solution of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-hydroxypropanoic acid (Fmoc-MeSer-OH, 15 g, 43.9 mmol) in tetrahydrofuran (88 mL), and the mixture was stirred at 50°C for 4 hours. The mixture was cooled to 25°C, and ethyl acetate (90 mL) was added. The organic layer was then washed with saturated aqueous sodium chloride solution (90 mL), and the aqueous layer was extracted with ethyl acetate (90 mL). All the organic layers obtained were mixed and washed twice with saturated aqueous sodium chloride solution (90 mL). The organic layer was dried over sodium sulfate, and the solvent was removed under reduced pressure. Of the resulting residue, 15.0 g was dissolved in tetrahydrofuran (175 mL), and then 1.0 M phosphate buffer (175 mL) adjusted to pH 8.0 was added. This mixture was stirred at 50°C for 3 hours. After cooling to 25°C, ethyl acetate (175 mL) was added, and the organic layer and the aqueous layer were separated. After extraction by adding ethyl acetate (175 mL) to the aqueous layer, all the resulting organic layers were mixed and washed twice with saturated aqueous sodium chloride solution (175 mL). The organic layer was dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue obtained was dissolved in dichloromethane (100 mL), and then heptane (250 mL) was added. Under controlled reduced pressure (~100 hPa), only dichloromethane was distilled off, and the resulting mixture was filtered to obtain a solid. This washing procedure with heptane was repeated twice. The obtained solid was dried at 25°C under reduced pressure by pumping for 2 hours. To the residue obtained, t-butyl methyl ether (TBME, 250 mL) and 0.05 M aqueous phosphoric acid solution (700 mL) with pH 2.1 were added, and the mixture was stirred at 25 degrees for 5 minutes, after which the organic layer and the aqueous layer were separated. After the aqueous layer was extracted with t-butyl methyl ether (TBME, 250 mL), all the organic layers obtained were mixed and washed twice with saturated aqueous sodium chloride solution (250 mL). The organic layer was dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was dried under reduced pressure at 25 degrees for 2 hours with a pump to obtain (2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-((tetrahydro-2H-pyran-2-yl)oxy)propanoic acid (compound 6, Fmoc-MeSer(THP)-OH, 9.0 g, 30 mol% of t-butyl methyl ether (TBME) remained). The resulting Fmoc-MeSer(THP)-OH was stored in a freezer at -25°C. LCMS(ESI)m / z=426.4(M+H) + Retention time: 0.86 minutes (Analysis conditions SQDFA05)

[0141] Examples 1-4: Synthesis of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-(1-trityl-1H-imidazol-4-yl)propanoic acid (compound 7, Fmoc-MeHis(Trt)-OH) [ka] A 3000 mL flask was charged with a dichloromethane (1000 mL) solution of (S)-3-(1H-imidazol-4-yl)-2-(methylamino)propanoic acid hydrochloride (75 g, 364.71 mmol), dichlorodimethylsilane (51 g, 395.16 mmol), and triethylamine (40 g, 395.30 mmol). Then, a dichloromethane (500 mL) solution of (chloromethanetriyl)tribenzene (Trt-Cl, 111 g, 398.17 mmol) and triethylamine (40 g, 395.30 mmol) were added. The resulting reaction solution was stirred under heating and reflux for 4 hours, and further stirred at 20 degrees for 2 hours. Methanol was added to the reaction solution to stop the reaction, and the solvent was then distilled off under reduced pressure. The pH was adjusted to 8-8.5 with triethylamine, and 125 g of solid was obtained. 1,4-dioxane (1000 mL), potassium carbonate (84 g, 603.39 mmol), and water (1000 mL) were added to the obtained solid. Furthermore, (2,5-dioxopyrrolidin-1-yl) (9H-fluoren-9-yl)methyl carbonate (Fmoc-OSu, 102 g, 302.38 mmol) was added and stirred at 0 degrees for 2 hours. The obtained reaction solution was washed with diethyl ether (2000 mL), and the pH of the solution was adjusted to 6-7 using acetic acid. The obtained solid was filtered to obtain (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-(1-trityl-1H-imidazol-4-yl)propanoic acid (compound 7, Fmoc-MeHis(Trt)-OH, 155 g). LCMS(ESI)m / z=634.4(M+H) + Retention time: 1.07 minutes (Analysis conditions SQDAA05)

[0142] Examples 1-5: Synthesis of (2R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)propanoic acid (compound 8, Fmoc-D-Tyr(THP)-OH) [ka] (R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-hydroxyphenyl)propanoic acid (Fmoc-D-Tyr-OH, purchased from Watanabe Chemical, 500 mg, 1.24 mmol) and a catalytic amount of pyridinium paratoluenesulfonate (PPTS, 15.6 mg, 0.062 mmol) were added to toluene (5.0 mL), and the water content was removed by azeotropy by distilling off the toluene under reduced pressure. The resulting residue was dissolved in tetrahydrofuran (THF) (2.5 mL), and 3,4-dihydro-2H-pyran (785 μL, 8.68 mmol) was added, followed by stirring at 50°C for 4 hours under a nitrogen atmosphere. The reaction solution was cooled to 25°C, and ethyl acetate (3 mL) was added. Saturated saline (3 mL) was then added to wash the organic layer, and the aqueous layer was extracted with ethyl acetate (3 mL). All the organic layers obtained were mixed and washed twice with saturated saline (3 mL). The organic layer was dried over sodium sulfate, the solvent was removed under reduced pressure, and the mixture was dried under reduced pressure with a pump to obtain 596 mg of a residue. The resulting residue (300 mg) was dissolved in tetrahydrofuran (THF) (2.5 mL), and 1.0 M aqueous phosphoric acid solution (pH 8.0, 2.5 mL) was added and stirred at 50°C for 3 hours. Ethyl acetate (3 mL) was added to the reaction solution, and the organic layer and aqueous layer were separated, and the aqueous layer was extracted with ethyl acetate (3 mL). All the obtained organic layers were mixed and washed twice with saturated saline (3 mL). The organic layer was dried over sodium sulfate, and the solvent was distilled off under reduced pressure, and the mixture was further dried under reduced pressure with a pump for 30 minutes. The residue obtained was dissolved in dichloromethane (DCM) (2 mL) and heptane (5 mL) was added. Only dichloromethane (DCM) was removed by an evaporator, and the obtained white solid was collected by filtration. The same operation was repeated twice for the obtained white solid. The white solid thus obtained was dried under reduced pressure by pump for 2 hours. To the white solid, t-butyl methyl ether (TBME) (4.6 mL) and 0.05 M aqueous phosphoric acid solution (pH 2.1, 13 mL) were added, and the mixture was stirred at 25°C for 5 minutes. After separating the organic layer, the aqueous layer was extracted with t-butyl methyl ether (TBME) (4.6 mL). The organic layers were collected and washed twice with saturated saline (4.6 mL). The organic layer was dried over sodium sulfate, and the solvent was removed under reduced pressure. The residue was purified by reverse phase chromatography (Wakosil 25C18 10 g, water / acetonitrile) to obtain (2R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)propanoic acid (compound 8, Fmoc-D-Tyr(THP)-OH, 173 mg) as a diastereomer derived from the asymmetric carbon on the THP protection in a yield of 57%. LCMS(ESI)m / z=488.4(M+H) + Retention time: 0.92 minutes (Analysis conditions SQDFA05)

[0143] Examples 1-6: Synthesis of 2-phenylpropan-2-yl 2,2,2-trichloroacetimidate (compound 9) [ka] A 1.9 M NaHMDS tetrahydrofuran (THF) solution (850 μL, 1.62 mmol) was added dropwise to a diethyl ether (Et2O) solution (4.8 mL) of 2-phenylpropan-2-ol (purchased from Wako, 2.0 g, 14.7 mmol) at 22°C. The reaction solution was stirred at the same temperature for 20 minutes, then cooled to 0°C, and 2,2,2-trichloroacetonitrile (1.47 mL, 14.7 mmol) was added dropwise. The reaction solution was stirred at 0°C for 10 minutes, then heated to 15°C and stirred for an additional hour. The reaction solution was concentrated using an evaporator, and hexane (1.8 mL) and methanol (65 μL) were added to the resulting residue, followed by stirring at 15°C for 15 minutes. The resulting solid was filtered and washed with hexane (2.0 mL) three times to obtain 2-phenylpropan-2-yl 2,2,2-trichloroacetimidate (Compound 9) (4.19 g), which was used in the reaction without further purification. 1 H NMR(Varian 400-MR, 400 MHz, CDCl3)δ 1.89 (6H, s), 7.28 (1H, m), 7.36(2H, m), 7.43 (2H,m), 8.20 (1H, brs)

[0144] Examples 1-7: Synthesis of (R)-methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-hydroxyphenyl)propanoate (compound 10, Fmoc-D-Tyr-OMe) [ka] Under a nitrogen atmosphere, thionyl chloride (1.59 mL, 21.76 mmol) was added dropwise to a mixture of (R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)phenyl)propanoic acid (Fmoc-D-Tyr(tBu)-OH, purchased from Watanabe Chemical, 5.0 g, 10.88 mmol) and methanol (8.80 mL, 218 mmol) at 0°C. The resulting reaction solution was stirred at 25°C for 3 hours, and then the solvent was distilled off under reduced pressure. The resulting residue was dissolved in ethyl acetate, and the solution was washed twice with a saturated aqueous sodium chloride solution. The organic layer was dried over sodium sulfate, the solid was removed by filtration, and the solvent was distilled off under reduced pressure to obtain (R)-methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-hydroxyphenyl)propanoate (Compound 10, Fmoc-D-Tyr-OMe, 4.50 g). LCMS(ESI)m / z=418.3(M+H) + Retention time: 0.81 minutes (Analysis conditions SQDFA05)

[0145] Examples 1-8: Synthesis of (R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-((2-phenylpropan-2-yl)oxy)phenyl)propanoic acid (compound 11, Fmoc-D-Tyr(Pis)-OH) [ka] A cyclohexane solution (60μL) of 10M 2,2,2-trichloroacetimidate 2-phenylpropan-2-yl (compound 9) and a catalytic amount of boron trifluoride-ethyl ether complex (BF3-OEt, 4.55μL, 0.036 mmol) were added dropwise to a tetrahydrofuran (THF) solution (240μL) of 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-hydroxyphenyl)propanoate (compound 10, Fmoc-D-Tyr-OMe, 100 mg, 0.24 mmol) at 0°C. After stirring the reaction solution at 25°C for 1 hour, the same amount of 10M cyclohexane solution of 2-phenylpropan-2-yl 2,2,2-trichloroacetimidate (compound 9) (60μL) and boron trifluoride-ethyl ether complex (BF3-OEt, 4.55μL, 0.036mmol) were added again, and the reaction solution was stirred at 25°C for another 30 minutes. The reaction solution was diluted with dichloromethane (DCM) and saturated aqueous sodium bicarbonate was added. After extraction with dichloromethane, the organic layer was washed with saturated saline. The organic layer was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and the mixture was dried by pumping. A solution of dichloromethane (DCM) / hexane = 1 / 1 was added to the obtained residue, and the precipitate was removed by filtration. The filtrate was concentrated using an evaporator, and the resulting residue was purified by flash column chromatography (purif pack (registered trademark) SIZE 20, hexane / ethyl acetate) to give a mixture of 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-((2-phenylpropan-2-yl)oxy)phenyl)propanoic acid (R)-methyl (Fmoc-D-Tyr(Pis)-OMe). The mixture obtained above was dissolved in dichloroethane (DCE) (535 μL), trimethyltin(IV) hydroxide (Me3SnOH, 58.1 mg, 0.321 mmol) was added, and the mixture was stirred at 60°C for 7 hours. Trimethyltin(IV) hydroxide (Me3SnOH, 29.1 mg, 0.161 mmol) was further added to the reaction solution, and the mixture was stirred at 60°C for 15 hours. The reaction solution was concentrated using an evaporator, and t-butyl methyl ether (TBME, 1 mL) and 0.05 M aqueous phosphoric acid solution (pH 2.1, 2 mL) were added, and the mixture was stirred at 25°C for 5 minutes. After separating the organic layer, the aqueous layer was extracted twice with t-butyl methyl ether (TBME, 1 mL). The organic layer was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and the mixture was further dried by pumping. The resulting residue was purified by column chromatography (purif pack (registered trademark) SIZE 20, dichloromethane / methanol) to give (R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-((2-phenylpropan-2-yl)oxy)phenyl)propanoic acid (compound 11, Fmoc-D-Tyr(Pis)-OH, 33 mg) in a two-step yield of 39%. LCMS(ESI)m / z=522.4(M+H) + Retention time: 1.00 minutes (Analysis conditions SQDFA05)

[0146] Examples 1-9: Synthesis of (S)-methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-fluoro-4-hydroxyphenyl)propanoate (compound 12, Fmoc-Tyr(3-F)-OMe) [ka] (S)-2-amino-3-(3-fluoro-4-hydroxyphenyl)propanoic acid (H2N-Tyr(3-F)-OH, purchased from Astatech, 2.0 g, 10.0 mmol) was dissolved in 10% aqueous sodium carbonate solution, and then a solution of (2,5-dioxopyrrolidin-1-yl)(9H-fluoren-9-yl)methyl carbonate (Fmoc-OSu, 3.39 g, 10.0 mmol) in 1.4-dioxane (35 mL) was added at 0°C using a dropping funnel. The reaction solution was stirred at 25°C for 40 minutes, and then water (35 mL) and diethyl ether (70 mL) were added, followed by washing three times with diethyl ether. The pH of the aqueous layer was adjusted to 2-3 with a 5N aqueous hydrochloric acid solution, and then extracted three times with ethyl acetate (100 mL×3). The organic layer was dried over magnesium sulfate, the solvent was distilled off under reduced pressure, and the mixture was further dried by pumping. The obtained residue (4.08 g) was used directly in the next reaction without further purification. The above residue (1.04 g) was dissolved in methanol (10 mL), and thionyl chloride (SOCl2, 539 μL, 7.38 mmol) was added dropwise at 0°C. The reaction solution was stirred at 60°C for 1 hour, cooled to room temperature, and the solvent was removed using an evaporator. Ethyl acetate and water were added to the resulting residue, and the mixture was extracted twice with ethyl acetate. The organic layer was washed with saturated saline, dried over magnesium sulfate, and the solvent was removed under reduced pressure, and the mixture was further dried by pump. The resulting residue was purified by flash column chromatography (purif pack® SIZE 200, hexane / ethyl acetate), and 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-fluoro-4-hydroxyphenyl)propanoate (S)-methyl (compound 12, Fmoc-Tyr(3-F)-OMe, 900 mg, 2.07 mmol) was obtained in a two-step yield of 84%. LCMS(ESI)m / z=436.4(M+H) + Retention time: 0.82 minutes (Analysis conditions SQDFA05)

[0147] Examples 1-10: Synthesis of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)-3-fluorophenyl)propanoic acid (compound 13, Fmoc-Tyr(3-F,tBu)-OH) [ka] 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-fluoro-4-hydroxyphenyl)propanoic acid (S)-methyl (compound 12, Fmoc-Tyr(3-F)-OMe, 300 mg, 0.689 mmol) was added dropwise to a tetrahydrofuran (THF) solution (690 μL) of tert-butyl 2,2,2-trichloroacetimidate (308 μL, 1.72 mmol) and a catalytic amount of boron trifluoride-ethyl ether complex (BF3-OEt, 13.1 μL, 0.103 mmol) at 0°C. After stirring the reaction mixture at 25°C for 1 hour, the same amount of tert-butyl 2,2,2-trichloroacetimidate (308 μL, 1.72 mmol) and boron trifluoride-ethyl ether complex (BF3-OEt, 13.1 μL, 0.103 mmol) were added again, and the reaction mixture was stirred at 25°C for another 1 hour. The reaction mixture was diluted with dichloromethane (DCM), and saturated aqueous sodium bicarbonate was added. After extraction with dichloromethane, the organic layer was washed with saturated aqueous sodium bicarbonate and saturated saline. The organic layer was dried over sodium sulfate, the solvent was removed under reduced pressure, and the mixture was dried by pumping. The resulting residue was purified by flash column chromatography (purif pack (registered trademark) SIZE 60, hexane / ethyl acetate) to give (S)-methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)-3-fluorophenyl)propanoate (Fmoc-Tyr(3-F,tBu)-OMe) as a mixture. The mixture (40 mg) obtained above was dissolved in dichloroethane (DCE) (810 μL), trimethyltin(IV) hydroxide (Me3SnOH, 29.4 mg, 0.163 mmol) was added, and the mixture was stirred at 60°C for 1 hour. After adding formic acid (15.35 μL, 0.407 mmol) to the reaction solution, the mixture was purified by reverse phase chromatography (Wakosil25C18 10 g, 0.1% formic acid aqueous solution / 0.1% formic acid acetonitrile solution) to obtain (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)-3-fluorophenyl)propanoic acid (compound 13, Fmoc-Tyr(3-F,tBu)-OH, 27 mg, 56.5 μmol) in a two-step yield of 93%. LCMS(ESI)m / z=478.3(M+H) + Retention time: 0.94 minutes (Analysis conditions SQDFA05)

[0148] Examples 1-11: Synthesis of (S)-1-((9H-fluoren-9-yl)methyl)pyrrolidine-1,2-dicarboxylate 2-(2-phenylpropan-2-yl) (compound 14, Fmoc-Pro-OPis) [ka] To a mixture of 2-phenyl-2-propanol (14.2 g, 104 mmol) and dehydrated diethyl ether (35 mL) was added 1.9 M NaHMDS (tetrahydrofuran solution, 0.85 mL, 1.62 mmol) dropwise over 3 minutes at room temperature under a nitrogen atmosphere, and the mixture was then stirred at room temperature for 30 minutes. The reaction mixture was then ice-cooled to 0°C, and trichloroacetonitrile (11.5 mL, 115mmol) was added dropwise over 5 minutes. The mixture was stirred at 0°C for 10 minutes, then removed from the ice bath and at room temperature for an additional hour. The resulting mixture was ice-cooled to 0°C, and a mixture of (S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)pyrrolidine-2-carboxylic acid (Fmoc-Pro-OH, 42.3 g, 125 mmol) and dichloromethane (100 mL) was added over 15 minutes. After stirring at 0°C for 30 minutes, the mixture was filtered and washed with a hexane-dichloromethane (5 / 1) solution, and the solvent was then distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain pyrrolidine-1,2-dicarboxylate 2-(2-phenylpropan-2-yl) (S)-1-((9H-fluoren-9-yl)methyl) (compound 14, Fmoc-Pro-OPis, 26.3 g, 57.7 mmol). LCMS(ESI)m / z=456.4(M+H) + Retention time: 0.76 minutes (Analysis conditions SQDAA50)

[0149] Examples 1-12: Synthesis of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-(4-chlorophenyl)propanoic acid (compound 16, Fmoc-MePhe(4-Cl)-OH) [ka] Paraformaldehyde (48 g, 1.60 mol) and 10-camphorsulfonic acid (CSA, 4.6 g, 19.83 mmol) were added to a solution of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-chlorophenyl)propanoic acid (Fmoc-Phe(4-Cl)-OH, 170 g, 402.96 mmol) in toluene (2.5 L), and the mixture was stirred at 110°C for 16 hours. The reaction solution was then washed twice with saturated aqueous sodium bicarbonate (1 L) and twice with saturated aqueous sodium chloride (1 L). The organic layer was dried over sodium sulfate, the solid was removed by filtration, and the solvent was distilled off under reduced pressure to obtain 160 g of 4-(4-chlorobenzyl)-5-oxooxazolidine-3-carboxylate (S)-(9H-fluoren-9-yl)methyl. A solution of (S)-(9H-fluoren-9-yl)methyl 4-(4-chlorobenzyl)-5-oxooxazolidine-3-carboxylate (230 g, 530.10 mmol) in dichloromethane (2.5 L) was mixed with triethylsilane (881 g, 7.58 mol) and trifluoroacetic acid (TFA, 2518 g, 22.28 mol) and stirred at 30° C. for 12 hours. The solvent was then removed under reduced pressure, and the resulting residue was recrystallized from dichloromethane / hexane (1 / 10, v / v) to obtain (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-(4-chlorophenyl)propanoic acid (compound 16, Fmoc-MePhe(4-Cl)-OH, 205 g). LCMS(ESI)m / z=436.3(M+H) + Retention time: 0.99 minutes (Analysis conditions SQDAA05)

[0150] Examples 1-13: Synthesis of 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-fluoro-4-((2-phenylpropan-2-yl)oxy)phenyl)propanoic acid (S)-methyl (Compound 21, Fmoc-Tyr(3-F,Pis)-OMe) [ka] 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-fluoro-4-hydroxyphenyl)propanoic acid (S)-methyl (compound 12, Fmoc-Tyr(3-F)-OMe, 200 mg, 0.459 mmol) was dissolved in THF (460 μL), and then 2,2,2-trichloroacetimidic acid 2-phenylpropan-2-yl (compound 9, 322 mg, 1.15 mmol) and a catalytic amount of boron trifluoride-ethyl ether complex (BF3-OEt, 8.73 μL, 0.069 mmol) were added dropwise at 0°C. After stirring the reaction solution at room temperature for 30 minutes, the same amount of 2,2,2-trichloroacetimidate 2-phenylpropan-2-yl (322 mg, 1.15 mmol) and a catalytic amount of boron trifluoride-ethyl ether complex (BF3-OEt, 8.73 μL, 0.069 mmol) were added dropwise at 0°C. After stirring the reaction solution at room temperature for another 30 minutes, the reaction solution was diluted with dichloromethane and saturated aqueous sodium bicarbonate solution was added under ice cooling. After extraction with dichloromethane, the organic layer was washed with saturated saline. The organic layer was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and the mixture was dried by pumping. The obtained residue was washed twice with dichloromethane / hexane = 1 / 1 (20 mL, 10 mL), and the white solid was removed by filtration. The obtained filtrate was concentrated, and the residue was purified by flash column chromatography (purif pack (registered trademark) SIZE 20, hexane / ethyl acetate, 0.1% diisopropylethylamine (DIPEA)) to obtain (S)-methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-fluoro-4-((2-phenylpropan-2-yl)oxy)phenyl)propanoate (compound 21, Fmoc-Tyr(3-F,Pis)-OMe, 210 mg, 0.379 mmol) in a yield of 83%. LCMS(ESI)m / z=554.4(M+H) + Retention time: 1.09 minutes (Analysis conditions SQDFA05)

[0151] Examples 1-14: Synthesis of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-fluoro-4-((2-phenylpropan-2-yl)oxy)phenyl)propanoic acid (compound 22, Fmoc-Tyr(3-F,Pis)-OH) [ka] 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-fluoro-4-((2-phenylpropan-2-yl)oxy)phenyl)propanoate (S)-methyl (compound 21, Fmoc-Tyr(3-F, Pis)-OMe, 210 mg, 0.379 mmol) was dissolved in dichloroethane (DCE) (1.26 mL), trimethyltin(IV) hydroxide (Me3SnOH, 137 mg, 0.379 mmol) was added, and the mixture was stirred at 60°C for 3 hours. The reaction solution was concentrated using an evaporator, and t-butyl methyl ether (TBME, 2.0 mL) and 0.05 M aqueous phosphoric acid solution (pH 2.1, 4.0 mL) were added, followed by stirring at 25°C for 15 minutes. After separating the organic layer, the aqueous layer was extracted twice with t-butyl methyl ether (TBME, 1 mL). The organic layer was dried over sodium sulfate, the solvent was removed under reduced pressure, and the mixture was dried by pumping. The residue was dissolved in 0.1% formic acid acetonitrile solution and stirred for 15 minutes, after which the solution was purified by reverse phase chromatography (Wakosil 25C18 30 g, 0.1% formic acid aqueous solution / 0.1% formic acid acetonitrile) to obtain (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-fluoro-4-((2-phenylpropan-2-yl)oxy)phenyl)propanoic acid (compound 22, Fmoc-Tyr(3-F,Pis)-OH, 190 mg, 0.352 mmol) in a yield of 93%. LCMS(ESI)m / z=538.2(MH) - Retention time: 1.00 minutes (Analysis conditions SQDFA05)

[0152] Synthesis of resin-Fmoc amino acid conjugates for use in peptide synthesis by a peptide synthesizer The conjugate of resin and Fmoc-amino acid used for peptide synthesis by a peptide synthesizer was synthesized as follows.

[0153] Examples 1-15: Synthesis of (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-oxo-4-(piperidin-1-yl)butanoic acid-2-chlorotrityl resin (Compound 50, Fmoc-Asp(O-Trt(2-Cl)-resin)-pip) [ka] (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-oxo-4-(piperidin-1-yl)butanoic acid-2-chlorotrityl resin (compound 50, Fmoc-Asp(O-Trt(2-Cl)-resin)-pip) was synthesized according to the method described in the literature (literature: International Publication No. WO 2013 / 100132 A1).

[0154] In this specification, when a polymer or resin is bonded to a compound, the polymer or resin site may be represented by a circle. In addition, in order to clarify the reaction site of the resin site, the chemical structure of the reaction site may be represented by connecting it to a circle. For example, in the above structure (Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (compound 50)), the 2-chlorotrityl group of the resin is bonded to the side chain carboxylic acid of Asp via an ester bond. Note that pip means piperidine, and in the above structure, the carboxylic acid group at the C-terminus forms an amide bond with piperidine.

[0155] Examples 1-16 Synthesis of compound (compound 52) bound to resin via the side chain carboxylic acid of Fmoc-Asp-piptBu (compound 51)

[0156] Example 1-16-1: Synthesis of (S)-tert-butyl 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-(tert-butyl)piperidin-1-yl)-4-oxobutanoate (Compound 53, Fmoc-Asp(OtBu)-piptBu) (Note that piptBu means 4-(tert-butyl)piperidine, and indicates that the carboxylic acid group at the C-terminus forms an amide bond with 4-(tert-butyl)piperidine.) [ka] (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-butoxy)-4-oxobutanoic acid (10 g, 24.30 mmol), 4-(tert-butyl)piperidine hydrochloride (4.10 g, 23.09 mmol), and 1-hydroxybenzotriazole monohydrate (HOBt, 3.61 g) were dissolved in DMF (80 mL), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSCI·HCl, 5.59 g) was added at 0°C and stirred at 0°C for 30 minutes. Then, 4-methylmorpholine (2.54 mL) was added and stirred at room temperature for 1 hour. Hexane-ethyl acetate (1 / 1, v / v, 500 mL) was added to the reaction solution, and the organic layer was washed twice with saturated ammonium chloride aqueous solution, twice with saturated sodium bicarbonate aqueous solution, and once with saturated sodium chloride aqueous solution. The obtained organic layer was dried over sodium sulfate, the solid was removed by filtration, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (mobile phase: hexane-ethyl acetate) to obtain 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-(tert-butyl)piperidin-1-yl)-4-oxobutanoic acid (S)-tert-butyl (compound 53, Fmoc-Asp(OtBu)-piptBu, 11.5 g, 21.51 mmol). LCMS(ESI)m / z=535.4(M+H) + Retention time: 1.17 minutes (Analysis conditions SQDAA05)

[0157] Example 1-16-2: Synthesis of (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-(tert-butyl)piperidin-1-yl)-4-oxobutanoic acid (compound 51, Fmoc-Asp-piptBu) [ka] Toluene was added to 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-(tert-butyl)piperidin-1-yl)-4-oxobutanoate (S)-tert-butyl (compound 53, Fmoc-Asp(OtBu)-piptBu, 2.0 g, 3.74 mmol), and the solvent was distilled off under reduced pressure to remove the water contained by azeotropy. The resulting residue was dissolved in dichloromethane (1.66 mL), and the water content was confirmed to be 110 ppm by Karl Fischer measurement. The mixture was then stirred at 0°C for 5 minutes, and trifluoroacetic acid (TFA, 1.66 mL) was added dropwise at 0°C and stirred for 5 minutes. The reaction solution was returned to room temperature and stirred for 4 hours. The mixture was cooled to 0°C, and triethylamine (3.1 mL) was added dropwise. The mixture was diluted with dichloromethane (30 mL) and washed with 5% aqueous sodium dihydrogen phosphate solution (5% NaH2PO4aq, pH 4.4). The organic layer was dried over sodium sulfate, and the solid was removed by filtration. The solvent was then distilled off under reduced pressure at 20°C. The resulting residue was 19 FNMR measurement (DMSO-d6) confirmed the presence of TFA remaining, so the residue was diluted again with dichloromethane (30 mL) and washed with 5% aqueous sodium dihydrogen phosphate solution (5% NaH2PO4aq, pH 4.4). The organic layer was dried over sodium sulfate, and the solid was removed by filtration. The solvent was then distilled off under reduced pressure at 20 degrees to obtain (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-(tert-butyl)piperidin-1-yl)-4-oxobutanoic acid (compound 51, Fmoc-Asp-piptBu, 1.73 g). 19 FNMR confirmed that the residual TFA was below the detection limit. LCMS(ESI)m / z=479.4(M+H) + Retention time: 1.00 minutes (Analysis conditions SQDAA05)

[0158] Example 1-16-3: Synthesis of (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-(tert-butyl)piperidin-1-yl)-4-oxobutanoic acid-2-chlorotrityl resin (Compound 52, Fmoc-Asp(O-Trt(2-Cl)-resin)-piptBu) [ka] 2-Chlorotrityl chloride resin (1.60 mmol / g, 100-200mesh, 1%DVB, purchased from Watanabe Chemical, 4.52g, 7.23 mmol) and dehydrated dichloromethane (72 mL) were placed in a reaction vessel equipped with a filter and shaken at 25°C for 10 minutes. After removing the dichloromethane under nitrogen pressure, a mixture of (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-(tert-butyl)piperidin-1-yl)-4-oxobutanoic acid (compound 51, Fmoc-Asp-piptBu, 1.73 g), dehydrated dichloromethane (72 mL), dehydrated methanol (1.17 mL, ) and diisopropylethylamine (DIPEA, 3.02 mL) was added to the reaction vessel and shaken for 15 minutes. After removing the reaction solution by applying nitrogen pressure, a mixture of dehydrated dichloromethane (72 mL), dehydrated methanol (9.0 mL), and diisopropylethylamine (DIPEA, 3.02 mL) was added to the reaction vessel and shaken for 90 minutes. After removing the reaction solution by applying nitrogen pressure, dichloromethane was added and shaken for 5 minutes. The reaction solution was removed by applying nitrogen pressure. This washing of the resin with dichloromethane was repeated five times, and the obtained resin was dried overnight under reduced pressure to obtain (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-(tert-butyl)piperidin-1-yl)-4-oxobutanoic acid-2-chlorotrityl resin (compound 52, Fmoc-Asp(O-Trt(2-Cl)-resin)-piptBu, 5.23 g). The obtained Fmoc-Asp(O-Trt(2-Cl)-resin)-piptBu (compound 52, 16.5 mg) was placed in a reaction vessel, 20% piperidine / DMF solution (1 mL) was added, and the mixture was shaken at 25°C for 30 minutes. 30 μL was taken from the reaction mixture, which was diluted with DMF (2.97 mL), and its absorbance (301.2 nm) was measured (Shimadzu, UV-1600PC (cell length 1.0 cm)). The loading amount of Fmoc-Asp(O-Trt(2-Cl)-resin)-piptBu (compound 52) was calculated to be 0.356 mmol / g. In addition, other lots synthesized in the same manner but with different loading amounts were also used for peptide synthesis.

[0159] Example 1-17: Synthesis of compound (compound 55) bound to resin via the side chain carboxylic acid of Fmoc-Asp-MeOctyl (compound 54)

[0160] Example 1-17-1: Synthesis of (S)-tert-butyl 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(methyl(octyl)amino)-4-oxobutanoate (Compound 56, Fmoc-Asp(OtBu)-MeOctyl) (Note that MeOctyl means N-methyloctan-1-amine, and in this case, it indicates that the carboxylic acid group at the C-terminus forms an amide bond with N-methyloctan-1-amine.) [ka] (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-butoxy)-4-oxobutanoic acid (Fmoc-Asp(OtBu)-OH, 8.00 g, 19.44 mmol) and DMF (65 mL) were added to a 300 mL flask and stirred at room temperature for 5 minutes. Then, 4-methylmorpholine (2.57 mL) and O-(7-aza-1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU, 8.87 g, 23.33 mmol) were added and stirred at 0°C for 5 minutes. Furthermore, N-methyloctan-1-amine (3.35 mL, 18.47 mmol) was added dropwise over 2 minutes, and the resulting reaction solution was stirred at 0°C for 30 minutes. To this reaction solution, hexane-ethyl acetate (1 / 1, v / v, 400 mL) was added, and the mixture was washed with water (400 mL), saturated aqueous ammonium chloride solution (400 mL), 50% aqueous sodium hydrogen carbonate solution (400 mL), water (400 mL×2), and saturated aqueous sodium chloride solution (400 mL). The obtained organic layer was dried over sodium sulfate, the solid was removed, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain (S)-tert-butyl 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(methyl(octyl)amino)-4-oxobutanoate (compound 56, Fmoc-Asp(OtBu)-MeOctyl, 10.2 g, 19.00 mmol). LCMS(ESI)m / z=537.5(M+H) + Retention time: 0.84 minutes (Analysis conditions SQDFA50)

[0161] Example 1-17-2: Synthesis of (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(methyl(octyl)amino)-4-oxobutanoic acid (compound 54, Fmoc-Asp-MeOctyl) [ka] Toluene was added to 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(methyl(octyl)amino)-4-oxobutanoic acid (S)-tert-butyl (compound 56, Fmoc-Asp(OtBu)-MeOctyl, 8.1 g, 15.09 mmol), and the solvent was distilled off under reduced pressure to remove the water contained by azeotropy. The resulting residue was dissolved in dichloromethane (dehydrated, 6.7 mL), and the water content was confirmed to be 380 ppm by Karl Fischer measurement. The mixture was then stirred at 0°C for 5 minutes, trifluoroacetic acid (TFA, 6.7 mL) was added dropwise at 0°C over 5 minutes, and then stirred for 5 minutes. The reaction solution was returned to room temperature and stirred for 4 hours. The mixture was cooled to 0°C, and triethylamine (12.62 mL) was added dropwise. The mixture was diluted with dichloromethane (100 mL) and washed with 5% aqueous sodium dihydrogen phosphate solution (5% NaH2PO4aq). The organic layer was dried over sodium sulfate, and the solid was removed by filtration. The solvent was then distilled off under reduced pressure at 20°C. The resulting residue was 19 FNMR measurement (DMSO-d6) confirmed the presence of TFA, so the residue was dissolved in dichloromethane again and washed with 5% aqueous sodium dihydrogen phosphate (5% NaH2PO4aq). The organic layer was dried over sodium sulfate, and the solid was removed by filtration. The solvent was then distilled off under reduced pressure at 20 degrees to obtain (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(methyl(octyl)amino)-4-oxobutanoic acid (compound 54, Fmoc-Asp-MeOctyl, 6.61 g, 13.75 mmol). 19 FNMR confirmed that the residual TFA was below the detection limit. LCMS(ESI)m / z=481.4(M+H) + Retention time: 0.65 minutes (Analysis conditions SQDAA50)

[0162] Example 1-17-3: Synthesis of (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(methyl(octyl)amino)-4-oxobutanoic acid-2-chlorotrityl resin (Compound 55, Fmoc-Asp(O-Trt(2-Cl)-resin)-MeOctyl) [ka] 2-Chlorotrityl chloride resin (1.60 mmol / g, 100-200mesh, 1%DVB, purchased from Watanabe Chemical, 16.3g, 26.1 mmol) and dehydrated dichloromethane (261 mL) were placed in a reaction vessel equipped with a filter and shaken at 25°C for 10 minutes. After removing the dichloromethane under nitrogen pressure, a mixture of (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(methyl(octyl)amino)-4-oxobutanoic acid (compound 54, Fmoc-Asp-MeOctyl, 6.28 g, 13.07 mmol), dehydrated dichloromethane (261 mL), dehydrated methanol (4.23 mL, ) and diisopropylethylamine (DIPEA, 10.9 mL) was added to the reaction vessel and shaken for 15 minutes. After removing the reaction solution by applying nitrogen pressure, a mixture of dehydrated dichloromethane (261 mL), dehydrated methanol (32.4 mL), and diisopropylethylamine (DIPEA, 10.9 mL) was added to the reaction vessel and shaken for 90 minutes. After removing the reaction solution by applying nitrogen pressure, dichloromethane (261 mL) was added and shaken for 5 minutes. The reaction solution was removed by applying nitrogen pressure. This washing of the resin with dichloromethane was repeated twice, and the obtained resin was dried overnight under reduced pressure to obtain (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(methyl(octyl)amino)-4-oxobutanoic acid-2-chlorotrityl resin (compound 55, Fmoc-Asp(O-Trt(2-Cl)-resin)-MeOctyl, 18.2 g). Loading: 0.366 mmol / g In addition, other lots synthesized in the same manner but with different loading amounts were also used for peptide synthesis.

[0163] Examples 1-18: Synthesis of compound (compound 58) bound to resin via the side chain carboxylic acid of Fmoc-Asp-Pro-OPis (compound 57)

[0164] Example 1-18-1: Synthesis of 1-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(allyloxy)-4-oxobutanoyl)pyrrolidine-2-carboxylate (S)-2-phenylpropan-2-yl (Compound 59, Fmoc-Asp(OAll)-Pro-OPis) [ka] A solution of pyrrolidine-1,2-dicarboxylate 2-(2-phenylpropan-2-yl)(S)-1-((9H-fluoren-9-yl)methyl) (compound 14, Fmoc-Pro-OPis, 20.0 g, 43.9 mmol) in dehydrated DMF (40 mL) was cooled to 20°C in a water bath. 1,8-diazabicyclo[5.4.0]-7-undecene (DBU, 6.57 mL, 43.9 mmol) was added dropwise over 7 minutes, and the mixture was stirred at room temperature for 5 minutes. The reaction solution was then cooled to 0°C, pyridine hydrochloride (5.07 g, 43.9 mmol) was added, and the mixture was stirred at 0°C for 10 minutes. Then, a mixture of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(allyloxy)-4-oxobutanoic acid (Fmoc-Asp(OAll)-OH, 17.35 g, 43.9 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSCI·HCl, 11.8 g, 61.4 mmol), and 1-hydroxy-7-azabenzotriazole (HOAt, 7.17 g, 52.7 mmol) was added, and diisopropylethylamine (DIPEA, 7.6 mL, 43.9 mmol) was added dropwise over 7 minutes at 0°C. The reaction solution was stirred at room temperature for 20 minutes. To the resulting reaction solution, hexane (50 mL), diethyl ether (50 mL), saturated aqueous sodium bicarbonate solution (10 mL), and saturated aqueous sodium chloride solution (50 mL) were added, and the aqueous layer was extracted twice with diethyl ether. The resulting organic layers were all combined, washed three times with saturated aqueous sodium chloride solution (50 mL), and then dried over sodium sulfate. The solvent was removed under reduced pressure, and the resulting residue was purified by silica gel column chromatography (mobile phase: hexane-ethyl acetate) to obtain 1-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(allyloxy)-4-oxobutanoyl)pyrrolidine-2-carboxylate (S)-2-phenylpropan-2-yl (compound 59, Fmoc-Asp(OAll)-Pro-OPis, 24.5 g, 40.1 mmol). LCMS(ESI)m / z=611.4(M+H) + Retention time: 1.03 minutes (Analysis conditions SQDFA05)

[0165] Example 1-18-2: Synthesis of (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-oxo-4-((S)-2-(((2-phenylpropan-2-yl)oxy)carbonyl)pyrrolidin-1-yl)butanoic acid (compound 57, Fmoc-Asp-Pro-OPis) [ka] 1-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(allyloxy)-4-oxobutanoyl)pyrrolidine-2-carboxylate (S)-2-phenylpropan-2-yl (compound 59, Fmoc-Asp(OAll)-Pro-OPis, 24.16 g, 39.6 mmol) and tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4, 0.114 g, 0.099 mmol) were placed in a 300 mL two-neck flask, and the flask was purged with nitrogen. Then, dichloromethane (40 mL) was added, stirred at room temperature, and cooled to 14 degrees in a water bath. Phenylsilane (3.30 mL, 26.7 mmol) was added dropwise over 5 minutes, and the reaction solution was stirred at 14 to 17 degrees under a nitrogen atmosphere for 35 minutes. Next, SH silica (manufactured by Fuji Silysia, 5 g) and methanol (32.1 mL) were added, followed by Kieselgel 60 (15 g). Further, methanol (30 mL), SH silica (manufactured by Fuji Silysia, 5 g), and Kieselgel 60 (25 g) were added, and the mixture was stirred at 17 to 24 degrees until the liquid phase became colorless. The resulting mixture was filtered through Celite, washed with dichloromethane-methanol (10 / 1, v / v), and the solvent was distilled off under reduced pressure to obtain a crude product (25.38 g) of (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-oxo-4-((S)-2-(((2-phenylpropan-2-yl)oxy)carbonyl)pyrrolidin-1-yl)butanoic acid (compound 57, Fmoc-Asp-Pro-OPis). The resulting crude product was used for subsequent resin loading without purification. LCMS(ESI) m / z = 571.3 (M+H) + Retention time: 0.88 minutes (analysis condition SQDFA05)

[0166] Example 1-18-3: Synthesis of (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-oxo-4-((S)-2-(((2-phenylpropan-2-yl)oxy)carbonyl)pyrrolidin-1-yl)butanoic acid-2-chlorotrityl resin (Compound 58, Fmoc-Asp(O-Trt(2-Cl)-resin)-Pro-OPis)

Chemical formula

[0167] Example 2. Chemical synthesis of peptides using a peptide synthesizer (Steps A to C) Unless otherwise specified, peptide synthesis using the above basic synthetic route was carried out as follows.

[0168] Example 2-1: Solid-phase peptide synthesis using an automated synthesizer (Process A) Peptide synthesis was carried out by the Fmoc method using a peptide synthesizer (Multipep RS; manufactured by Intavis). Detailed operation procedures were described in the manual that came with the synthesizer.

[0169] The synthesizer was loaded with 2-chlorotrityl resin (100 mg per column) bound to the carboxylic acid moiety of the side chain of aspartic acid whose N-terminus was protected with Fmoc, various Fmoc-amino acids (0.6 mol / L, 0.5 mol / L for Fmoc-MeHis(Trt)-OH), 1-hydroxy-7-azabenzotriazole (HOAt) or oxyma (0.375 mol / L) in NMP, and a solution of diisopropylcarbodiimide (DIC) in N,N-dimethylformamide (DMF) (10% v / v). When the Fmoc-amino acid was Fmoc-Ser(THP)-OH (compound 1), Fmoc-Thr(THP)-OH (compound 2), or Fmoc-MeSer(THP)-OH (compound 6), these Fmoc-amino acids were allowed to coexist with oxyma in an NMP solution, and molecular sieves 4A 1 / 8 (Wako Pure Chemical Industries) or molecular sieves 4A 1 / 16 (Wako Pure Chemical Industries) was added and the solution was set in the synthesizer.

[0170] A DMF solution (2% v / v) of diazabicycloundecene (DBU) was used as the Fmoc deprotection solution. After washing the resin with DMF, the Fmoc group was deprotected, and then a condensation reaction with a new Fmoc amino acid was carried out. This constitutes one cycle, and the peptide was extended on the resin surface by repeating this cycle multiple times.

[0171] Example 2-2: Cleavage of extended peptide from resin (Process B) The N-terminal Fmoc group of the peptide elongated by the above method was removed on a peptide synthesizer, and the resin was washed with DMF. The resin was then re-swollen with DCM, and TFE / DCM (1 / 1, v / v, 2 mL) was added to the resin and shaken at room temperature for 2 hours. The solution in the tube was then filtered through a synthesis column to remove the resin, and the remaining resin was further washed twice with TFE / DCM (1 / 1, v / v, 1 mL). All the obtained cleavage solutions were mixed and concentrated under reduced pressure.

[0172] Example 2-3: Cyclization of excised peptides (Process C) The residue concentrated under reduced pressure after cleavage was dissolved in DMF / DCM (1 / 1, v / v, 8 mL). 0.5 M O-(7-aza-1H-benzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) / DMF solution (volume equivalent to 1.5 equivalents relative to the number of moles on the resin used (loading amount (mmol / g) multiplied by the amount of resin used (usually 0.10 g))) and DIPEA (1.8 equivalents relative to the number of moles on the resin used) were added and shaken at room temperature for 2 hours. The solvent was then distilled off under reduced pressure. The production of the desired cyclic peptide was confirmed by LCMS measurement.

[0173] Using the above method, peptides Pep1-Pep7 were synthesized to be used in the deprotection reaction described below. The sequences of Pep1 to Pep7 are shown in Table 2-1, their structures in Table 2-2, and LCMS data in Table 2-3. The deprotection conditions to be examined later (degree of hydrolysis or N→O-acyl shift failure observed during deprotection, or peptides to be coexisted in the solution to be examined) were evaluated using the residue containing the cyclic peptide obtained in this process.

[0174] [Table 2-1]

[0175] [Table 2-2] TIFF2024163219000060.tif189149 TIFF2024163219000061.tif189149 TIFF2024163219000062.tif96149

[0176] [Table 2-3]

[0177] Example 3. Weak acid (pKa in water is 0-9) and solvent (Y OTs Deprotection of the protecting groups of the side chain functional groups of peptides using a weak acid solution with a positive value, weak acidity (pKa in water is 5 to 14), and low nucleophilicity. (Process D)

[0178] Example 3-1. Possibility of deprotecting the protecting group of the side chain functional group of Fmoc-amino acid by the above-mentioned weak acid solution The conditions under which the protecting group of the side chain functional group of the Fmoc-amino acid used in peptide synthesis is a weaker acid than TFA, i.e., a weak acid with a pKa of 0 to 9 in water is used as Y OTs We investigated whether deprotection was possible in a solution in a solvent that had a positive value, was weakly acidic (pKa in water: 5 to 14), and had low nucleophilicity.

[0179] Specifically, tetramethylammonium hydrogen sulfate (pKa 2.0) was used as the weak acid, and HFIP (Y OTs The value is 3.82 (literature value: Prog. Phys. Org. Chem. 1990, 17,121-158), pKa 9.30) was used. More specifically, either a 0.1M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) or a 0.05M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) was used.

[0180] Example 3-1-1: Preparation of 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) A 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) was prepared by dissolving 68.5 mg of tetrabutylammonium hydrogen sulfate in 4 mL of a mixture of HFIP (11.66 mL), TIPS (0.24 mL), and DCE (0.10 mL).

[0181] Example 3-1-2: Preparation of 0.05 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) A 0.05 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) was prepared by dissolving 34.3 mg of tetrabutylammonium hydrogen sulfate in 4 mL of a mixture of HFIP (11.66 mL), TIPS (0.24 mL), and DCE (0.10 mL).

[0182] Deprotection of Fmoc-amino acids having a protecting group at the side chain or peptides containing amino acid residues having a protecting group at the side chain was carried out by the following method A or method B.

[0183] Example 3-1-3: Method A A mixture of Fmoc-amino acids (4.0 umol) with protecting groups on the side chains and peptides (either of the previously synthesized cyclic peptides Pep 1 to Pep 6 (residue after cyclization); up to 3.66 umol) was added with 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) (0.20 mL) or 0.05 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) (0.40 mL), shaken for 3 minutes, then left to stand at 25 degrees, and measured by LCMS (FA05) after a certain period of time. The progress of deprotection was calculated from the UV area ratio of the deprotected and protected forms.

[0184] Example 3-1-4: Method B Peptides containing amino acid residues with protecting groups on the side chains (either of the previously synthesized cyclic peptides Pep 1 to Pep 6 (residue after cyclization); up to 3.66 umol) were added with 0.1 M tetramethylammonium hydrogen sulfate / HFIP (2% TIPS) (0.20 mL) or 0.05 M tetramethylammonium hydrogen sulfate / HFIP (2% TIPS) (0.40 mL) and shaken for 3 minutes, then left to stand at 25 degrees, and after a certain period of time, LCMS (FA05) was measured. The progress of deprotection was calculated from the UV area ratio of the deprotected and protected forms.

[0185] The peptides used in methods A and B were elongated and cleaved from the resin by the methods previously described, then cyclized by the methods previously described, and the residue was concentrated under reduced pressure. The residue was dissolved in dichloromethane and divided into 10 equal portions in test tubes, and the solvent was again concentrated under reduced pressure.

[0186] The evaluation results are shown in Table 3 below. [Table 3]

[0187] The LCMS measurement results of the Fmoc-amino acids after deprotection are as follows: Fmoc-Tyr(3-F)-OH (deprotection products of run 3, run 4, and run 15) LCMS(ESI)m / z=422.3(M+H) + Retention time: 0.73 minutes (Analysis conditions SQDFA05) Fmoc-MeHis-OH (deprotected product of run 5) LCMS(ESI)m / z=392.3(M+H) + Retention time: 0.47 minutes (Analysis conditions SQDFA05) Fmoc-MeSer-OH (deprotected product of run 8) LCMS(ESI)m / z=342.3(M+H) + Retention time: 0.67 minutes (Analysis conditions SQDFA05) Fmoc-Ser-OH (deprotected product of run 10) LCMS(ESI)m / z=328.2(M+H) + Retention time: 0.64 minutes (Analysis conditions SQDFA05) Fmoc-Pro-OH (deprotected product of run 11) LCMS(ESI)m / z=338.3(M+H) + Retention time: 0.75 minutes (Analysis conditions SQDFA05) Fmoc-D-Tyr-OH (deprotected product of runs 12-14) LCMS(ESI)m / z=404.3(M+H) + Retention time: 0.72 minutes (Analysis conditions SQDFA05)

[0188] [ka] Deprotection product of Pep 1 (compound 101) (deprotection product of run 1 and run 2, compound 131) LCMS(ESI)m / z=1424.0(M+H) + Retention time: 0.79 minutes (Analysis conditions SQDFA05)

[0189] [ka] Deprotection product of Pep 2 (compound 102) (deprotection product of run 6, compound 132) LCMS(ESI)m / z=1526.3(M+H) + Retention time: 0.89 minutes (Analysis conditions SQDFA05)

[0190] [ka] Deprotection product of Pep 3 (compound 103) (deprotection product of run 7, compound 133) LCMS(ESI)m / z=1474.1(M+H) + Retention time: 0.78 minutes (Analysis conditions SQDFA05)

[0191] [ka] Deprotection product of Pep 5 (compound 105) (deprotection product of run 9, compound 135) LCMS(ESI)m / z=1331.7(M+H) + Retention time: 0.74 minutes (Analysis conditions SQDFA05)

[0192] From these results, it was confirmed that the deprotection of these protecting groups proceeded under the conditions of 0.1 M tetramethylammonium hydrogen sulfate / HFIP (2% TIPS) or 0.05 M tetramethylammonium hydrogen sulfate / HFIP (2% TIPS).

[0193] The side chain protecting groups are not affected by peptide cleavage conditions using a TFE-DCM (1 / 1, v / v) solution or a TFE-DCM (1 / 1, v / v) / DIPEA (1.8 equiv. added per theoretical mole calculated by multiplying the amount of resin used by the amount of resin loaded) solution. Therefore, the amino acid side chain functional groups remain protected during the intramolecular cyclization at the N-terminus of the peptide backbone and the carboxylic acid site of the Asp side chain following the cleavage step. This prevents undesired cyclization reactions in which the amino acid side chain functional groups act as nucleophiles.

[0194] 3-2.Possibility of suppressing hydrolysis and the generation of N→O-acyl shift products when the protecting groups of the side chain functional groups of Fmoc-amino acids are deprotected with the above weak acid solutions

[0195] Example 3-2-1: Deprotection of the cyclic compound (compound 101, Pep1) in which an amide bond is formed between the N-terminal amino group of H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pip and the side chain carboxylic acid of Asp, using 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) as the deprotection condition. Using Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (compound 50, resin loading: 0.342 mmol / g, 100 mg) as a resin, a cyclic compound (compound 101) was synthesized by forming an amide bond between the N-terminal amino group of H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pip and the side chain carboxylic acid of Asp using the method described previously. After cyclization, the residue was concentrated under reduced pressure, dissolved in dichloromethane and divided into 10 test tubes, and the solvent was concentrated again under reduced pressure. To one of the 10 equal parts, 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) (HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mL mixed solution was removed 4 mL, and 68.5 mg of tetramethylammonium hydrogen sulfate was dissolved in this) was added 0.20 mL. The test tube was sealed with a rubber septum, shaken for 3 minutes, and then left to stand at 25 degrees for 24 hours. The reaction was confirmed by LCMS (FA05), and the deprotection of the side chain (deprotection of the tBu group of D-Tyr(tBu)) was confirmed to be complete. In addition, the ratio of the target deprotected peptide (compound 131), the solvolyzate (a compound showing a mass spectrum of a peptide in which any amide bond is solvolyzed with HFIP as a solvent), and the hydrolyzate (a compound showing a mass spectrum of a peptide in which any amide bond is solvolyzed with water) was 72:10:18 (FIG. 2). Note that "TM+H2O" in this example refers to a compound in which any amide bond of the target has been hydrolyzed, and "TM+HFIP" refers to a compound in which any amide bond of the target has been solvolyzed with HFIP.

[0196] The data in Figure 2 are shown below. Target peptide (compound 131) LCMS(ESI)m / z=1424.0(M+H) + Retention time: 0.79 minutes (Analysis conditions SQDFA05) Hydrolysis (TM+H2O) LCMS(ESI)m / z=1442.0(M+H) + Retention time: 0.61 minutes (Analysis conditions SQDFA05) Solvolyzed by HFIP (TM+HFIP) LCMS(ESI)m / z=1592.0(M+H) + Retention time: 0.69 minutes, 0.71 minutes (Analysis conditions SQDFA05)

[0197] Example 3-2-2: Deprotection of the cyclic compound (compound 101, Pep1) in which an amide bond is formed between the N-terminal amino group of H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pip and the side chain carboxylic acid of Asp, using 0.05 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) as the deprotection condition. After synthesizing compound 101 (Pep1), 0.05 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) (HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mL mixed solution was extracted 4 mL, and 34.3 mg of tetramethylammonium hydrogen sulfate was dissolved in this) was added to another one of the 10 equal parts by the above operation. The test tube was sealed with a rubber septum, shaken for 3 minutes, and then left to stand at 25 degrees for 24 hours, and the reaction was confirmed by LCMS (FA05). As a result, the deprotection of the side chain (deprotection of the tBu group of D-Tyr(tBu)) proceeded to 81%, and at this time, the ratio of the target deprotected peptide (compound 131), the solvolyzed product (a compound showing the mass of one of the amide bonds of the peptide solvolyzed with the solvent HFIP), and the hydrolyzed product (a compound showing the mass of one of the amide bonds of the peptide hydrolyzed with water) was 93:3:4 (Figure 3). Note that "TM+H2O" represents a compound in which one of the amide bonds of the target has been hydrolyzed. Similarly, "TM+HFIP" represents a compound in which one of the amide bonds of the target has been solvolyzed with HFIP.

[0198] The data in Figure 3 are shown below. Target peptide (compound 131) LCMS(ESI)m / z=1424.1(M+H) + Retention time: 0.79 minutes (Analysis conditions SQDFA05) hydrolysis LCMS(ESI)m / z=1442.0(M+H) + Retention time: 0.61 minutes (Analysis conditions SQDFA05) Solvolyzed by HFIP LCMS(ESI)m / z=1592.0(M+H) + Retention time: 0.69 minutes, 0.71 minutes (Analysis conditions SQDFA05)

[0199] As shown in the comparative example described later, when a cyclic compound (compound 101, Pep1) in which an amide bond was formed between the N-terminal amino group of H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pip and the side chain carboxylic acid of Asp were deprotected using 5% TFA / DCE, hydrolysis had progressed to 87% after 2.5 hours at 25°C. In contrast, for the same peptide sequence, the use of 0.1 M or 0.05 M tetramethylammonium hydrogen sulfate / HFIP (2% TIPS) instead of 5% TFA significantly reduced the formation of hydrolysates (and solvolysates). This result also suggests that the concentration of the weak acid may be adjusted as desired, provided that the condition is met to make the weak acid weaker than TFA.

[0200] Example 3-2-3: Deprotection of the cyclic compound (compound 103, Pep3) in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp, using 0.05 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) as the deprotection condition. Using Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (compound 50, loading: 0.316 mmol / g, 100 mg) as a resin, a cyclic compound (compound 103, Pep3) was synthesized by forming an amide bond between the N-terminal amino group of Hg-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp using the method described previously. After cyclization, the residue was concentrated under reduced pressure, dissolved in dichloromethane and divided into 10 test tubes, and the solvent was concentrated again under reduced pressure. To one of the 10 equal parts, 0.05 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) (HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mL mixed solution was removed 4 mL, and 34.3 mg of tetramethylammonium hydrogen sulfate was dissolved in this) was added 0.40 mL. The test tube was sealed with a rubber septum, shaken for 3 minutes, and then left to stand at 25 degrees. The reaction was confirmed by LCMS (SQDFA05) at the 4-hour stage. As a result, it was confirmed that the side chain deprotection (deprotection of the DMT group of MeSer(DMT) and deprotection of the Trt group of Ser(Trt)) was completed. In addition, the UV area ratio in LC between the deprotected target peptide (compound 133, a cyclic compound in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp) and the N→O-acyl shift product (depsipeptide) of the target peptide was 96:4. After 22 hours from the start of the reaction and leaving the mixture at 25°C, LCMS (SQDFA05) measurements were performed. The UV area ratio in LC of the deprotected target peptide (compound 133, a cyclic compound in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp) and the N→O-acyl shifted product of the target peptide (depsipeptide) was 83:17 (Figure 4).

[0201] The data in Figure 4 is shown below. The target peptide (compound 133, a cyclic compound in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp) LCMS(ESI)m / z=1474.1(M+H) + Retention time: 0.78 minutes (Analysis conditions SQDFA05) N→O-acyl shift compound LCMS(ESI)m / z=1474.1(M+H) + Retention time: 0.64 minutes (Analysis conditions SQDFA05)

[0202] As described later, when the cyclic compound (compound 103, Pep3) in which an amide bond was formed between the N-terminal amino group of Hg-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp were deprotected under 5% TFA / DCE conditions, the N→O-acyl shift had progressed by 70% after 2 hours at 25°C. In contrast, for the same peptide sequence, the use of 0.05 M tetramethylammonium hydrogen sulfate / HFIP (2% TIPS) instead of 5% TFA significantly reduced the production of N→O-acyl shift products.

[0203] Example 3-2-4: Deprotection of the cyclic compound (compound 101, Pep1) in which an amide bond is formed between the N-terminal amino group of H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pip and the side chain carboxylic acid of Asp, using 0.05 M oxalic acid / HFIP solution (2% TIPS) as the deprotection condition. After synthesizing compound 101 (Pep1), 0.05 M oxalic acid / HFIP solution (2% TIPS) (HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mL mixed solution was extracted 4 mL, and 18.0 mg of oxalic acid was dissolved in this) was added to another one of the 10 equal parts by the above operation. The test tube was sealed with a rubber septum, shaken for 3 minutes, and then left to stand at 25 degrees for 4 hours, and the reaction was confirmed by LCMS (FA05). As a result, the deprotection of the side chain (deprotection of the tBu group of D-Tyr(tBu)) was completed, and at this time, the ratio of the target deprotected peptide (compound 131), the solvolyzed product (a compound showing the mass of one of the amide bonds of the peptide solvolyzed with HFIP as a solvent), and the hydrolyzed product (a compound showing the mass of one of the amide bonds of the peptide hydrolyzed with water) was 79:17:4 (Figure 5). Note that "TM+H2O" represents a compound in which one of the amide bonds of the target has been hydrolyzed. Similarly, "TM+HFIP" represents a compound in which one of the amide bonds of the target has been solvolyzed with HFIP.

[0204] The data in Figure 5 is shown below. Target peptide (compound 131) LCMS(ESI)m / z=1423.5(M+H) + Retention time: 0.79 minutes (Analysis conditions SQDFA05) hydrolysis LCMS(ESI)m / z=1441.5(M+H) + Retention time: 0.61 minutes (Analysis conditions SQDFA05) Solvolyzed by HFIP LCMS(ESI)m / z=1591.5(M+H) + Retention time: 0.68 minutes, 0.71 minutes (Analysis conditions SQDFA05)

[0205] Example 3-2-5: Deprotection of the cyclic compound (compound 101, Pep1) in which an amide bond is formed between the N-terminal amino group of H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pip and the side chain carboxylic acid of Asp, using 0.05 M maleic acid / HFIP solution (2% TIPS) as the deprotection condition. After synthesizing compound 101 (Pep1), 0.05 M maleic acid / HFIP solution (2% TIPS) (HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mL mixed solution was extracted 4 mL, and 23.2 mg of oxalic acid was dissolved in this) was added to another one of the 10 equal parts by the above operation. The test tube was sealed with a rubber septum, shaken for 3 minutes, and then left to stand at 25 degrees for 4 hours, and the reaction was confirmed by LCMS (FA05). As a result, the deprotection of the side chain (deprotection of the tBu group of D-Tyr(tBu)) was completed, and at this time, the ratio of the target deprotected peptide (compound 131), the solvolyzed product (a compound showing the mass of one of the amide bonds of the peptide solvolyzed with HFIP as a solvent), and the hydrolyzed product (a compound showing the mass of one of the amide bonds of the peptide hydrolyzed with water) was 81:12:7 (Figure 6). Note that "TM+H2O" represents a compound in which one of the amide bonds of the target has been hydrolyzed. Similarly, "TM+HFIP" represents a compound in which one of the amide bonds of the target has been solvolyzed with HFIP.

[0206] The data in Figure 6 is presented below. Target peptide (compound 131) LCMS(ESI)m / z=1423.5(M+H) + Retention time: 0.79 minutes (Analysis conditions SQDFA05) hydrolysis LCMS(ESI)m / z=1441.5(M+H) + Retention time: 0.61 minutes (Analysis conditions SQDFA05) Solvolyzed by HFIP LCMS(ESI)m / z=1591.4(M+H) + Retention time: 0.68 minutes, 0.71 minutes (Analysis conditions SQDFA05)

[0207] Example 3-2-6: Deprotection of the cyclic compound (compound 103, Pep3) in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp, using 0.05 M oxalic acid / HFIP solution (2% TIPS) as the deprotection condition. After synthesizing compound 103 (Pep3), 0.40 mL of 0.05 M oxalic acid / HFIP solution (2% TIPS) (HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mL mixed solution was extracted 4 mL, and 18.0 mg of oxalic acid was dissolved in this) was added to another one of the 10 equal parts in the above operation. The test tube was sealed with a rubber septum, shaken for 3 minutes, and then left to stand at 25 degrees for 4 hours, and the reaction was confirmed by LCMS (SQDFA05). As a result, it was confirmed that the deprotection of the side chain (deprotection of the DMT group of MeSer (DMT) and deprotection of the Trt group of Ser (Trt)) was completed. In addition, the UV area ratio in LC of the deprotected target peptide (compound 133, a cyclic compound in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp) and the N→O-acyl shift product (depsipeptide) of the target peptide was 86:14 (Figure 7).

[0208] The data in Figure 7 is shown below. The target peptide (compound 133, a cyclic compound in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp) LCMS(ESI)m / z=1473.5(M+H) + Retention time: 0.78 minutes (Analysis conditions SQDFA05) N→O-acyl shift compound LCMS(ESI)m / z=1473.5(M+H) + Retention time: 0.64 minutes (Analysis conditions SQDFA05)

[0209] Example 3-2-7: Deprotection of the cyclic compound (compound 103, Pep3) in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp, using 0.05 M maleic acid / HFIP solution (2% TIPS) as the deprotection condition. After synthesizing compound 103 (Pep3), 0.40 mL of 0.05 M maleic acid / HFIP solution (2% TIPS) (HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mL mixed solution was extracted 4 mL, and 23.2 mg of oxalic acid was dissolved in this) was added to another one of the 10 equal parts in the above operation. The test tube was sealed with a rubber septum, shaken for 3 minutes, and then left to stand at 25 degrees for 4 hours, and the reaction was confirmed by LCMS (SQDFA05). As a result, it was confirmed that the deprotection of the side chain (deprotection of the DMT group of MeSer (DMT) and deprotection of the Trt group of Ser (Trt)) was completed. In addition, the UV area ratio in LC of the deprotected target peptide (compound 133, a cyclic compound in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp) and the N→O-acyl shift product (depsipeptide) of the target peptide was 86:14 (Figure 8).

[0210] The data in Figure 8 is shown below. The target peptide (compound 133, a cyclic compound in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp) LCMS(ESI)m / z=1473.5(M+H) + Retention time: 0.79 minutes (Analysis conditions SQDFA05) N→O-acyl shift compound LCMS(ESI)m / z=1473.5(M+H) + Retention time: 0.64 minutes (Analysis conditions SQDFA05)

[0211] These results show that even when oxalic acid (pKa 1.23) or maleic acid (pKa 1.92) was used as the weak acid instead of tetramethylammonium hydrogen sulfate (pKa 2.0), deprotection could be carried out while suppressing hydrolysis, solvolysis, and N→O-acyl shift.

[0212] Example 3-2-8: Comparison of deprotection using 0.05 M tetramethylammonium hydrogen sulfate / HFIP (2% TIPS) as the deprotection condition and 0.05 M tetramethylammonium hydrogen sulfate / TFE (2% TIPS) as the deprotection condition for the cyclic compound (compound 107, Pep7) in which an amide bond is formed between the N-terminal amino group of H-Ala-Phe(4-CF3)-Trp-Trp-MeLeu-MeGly-MeGly-Pro-Hyp(Et)-Ser(Trt)-Asp-pip(tBu) and the side chain carboxylic acid of Asp. Using Fmoc-Asp(O-Trt(2-Cl)-resin)-piptBu (compound 52, loading: 0.356 mmol / g, 100 mg) as a resin, a cyclic compound (compound 107) was synthesized by forming an amide bond between the N-terminal amino group of H-Ala-Phe(4-CF3)-Trp-Trp-MeLeu-MeGly-MeGly-Pro-Hyp(Et)-Ser(Trt)-Asp-pip(tBu) and the side chain carboxylic acid of Asp, using the method described previously. After cyclization, the residue was concentrated under reduced pressure, dissolved in dichloromethane and divided into 10 test tubes, and the solvent was again distilled off under reduced pressure. To one of the 10 equal parts, 0.40 mL of 0.05 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) (205.8 mg of tetramethylammonium hydrogen sulfate dissolved in a solution of HFIP: 23.32 mL, TIPS: 0.48 mL, DCE: 0.20 mL) was added. The test tube was sealed with a rubber septum, left to stand at 25 degrees for 4 hours, and the reaction was confirmed by LCMS (FA05). As a result, the deprotection of the side chain (deprotection of the Trt group of Ser (Trt)) was completed, and at this time, the UV area ratio of the deprotected target peptide (compound 137) and the solvolyzed product (a compound showing the mass of one of the amide bonds of the peptide solvolyzed with HFIP as a solvent) was 53:47 (Figure 9). Note that "TM+HFIP" represents a compound in which one of the amide bonds of the target product was solvolyzed with HFIP.

[0213] [ka]

[0214] The data in Figure 9 is shown below. The peptide of interest (compound 137) LCMS(ESI)m / z=1492.1(M+H) + Retention time: 0.90 minutes (Analysis conditions SQDFA05) HFIP solvolysis product (one of the amide bonds is solvolyzed by HFIP) LCMS(ESI)m / z=1660.1(M+H) + Retention time: 0.78 minutes (Analysis conditions SQDFA05)

[0215] To the other test tube, which was divided into 10 equal parts, 0.40 mL of 0.05 M tetramethylammonium hydrogen sulfate / TFE solution (2% TIPS) (205.8 mg of tetramethylammonium hydrogen sulfate dissolved in a solution of TFE: 23.32 mL, TIPS: 0.48 mL, DCE: 0.20 mL) was added. The test tube was sealed with a rubber septum, left to stand at 25 degrees, and the reaction was confirmed by LCMS (FA05). As a result, after 4 hours, the deprotection of the side chain (deprotection of the Trt group of Ser(Trt)) had progressed by 96%, and at this time, the solvolysis product (a compound showing the mass of one of the amide bonds of the peptide solvolyzed in the solvent TFE) was below the detection limit by LCMS. The reaction was checked after 20 hours, and the deprotection of the side chain (deprotection of the Trt group of Ser(Trt)) was completed. At this time, the UV area ratio of the deprotected target peptide (compound 137) to the solvolyzed product (a compound showing the mass of a peptide in which any amide bond is solvolyzed with TFE as a solvent) was 97:3 (FIG. 10). Note that "TM+TFE" described in this example refers to a compound in which the target product (TM) is solvated with TFE (a compound in which any one of the amide bonds is solvolyzed with TFE).

[0216] The data in Figure 10 is shown below. The peptide of interest (compound 137) LCMS(ESI)m / z=1492.2(M+H) + Retention time: 0.90 minutes (Analysis conditions SQDFA05) Solvolyzed by TFE (one of the amide bonds is solvolyzed by TFE) LCMS(ESI)m / z=1592.0(M+H) + Retention time: 0.75 minutes (Analysis conditions SQDFA05)

[0217] The above results show that it is possible to use TFE instead of HFIP as a solvent to dissolve weak acids. OTs This suggests that any solvent may be usable as long as the value is positive, the solvent itself is weakly acidic (pKa in water is 5 to 14), and has low nucleophilicity.

[0218] Example 3-2-9: Deprotection using 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) as the deprotection condition, and quenching the reaction by adding a base (DIPEA) to the solution. Using Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (compound 50, loading: 0.342 mmol / g, 100 mg) as a resin, a cyclic compound (compound 105, Pep5) was synthesized by forming an amide bond between the N-terminal amino group of H-Ala-Trp-Nle-Trp-Ser(Trt)-Gly-MeAla-MePhe(3-Cl)-MeGly-Pro-Asp-pip and the side chain carboxylic acid of Asp using the method described previously. After cyclization, the residue was concentrated under reduced pressure, dissolved in dichloromethane and divided into 10 test tubes, and the solvent was concentrated again under reduced pressure. To each of the two test tubes, 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) (HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mL mixed solution was extracted 4 mL, and 68.5 mg of tetrabutylammonium hydrogen sulfate was dissolved in this) was added 0.40 mL. The tube was sealed with a rubber septum, shaken for 3 minutes, and then left to stand at 25 degrees for 4 hours, and the reaction was confirmed by LCMS (SQDFA05). As a result, the deprotection of the side chain (deprotection of the Trt group of Ser (Trt)) was completed, and at this time, no peaks were detected indicating the mass of the catalyzed decomposition product (a compound showing the mass of one of the amide bonds of the peptide solvolyzed with HFIP as a solvent) or the hydrolyzate (a compound showing the mass of one of the amide bonds of the peptide solvolyzed with water) other than the target deprotected peptide (compound 135) (Figure 11). Diisopropylethylamine (DIPEA, 14 μL, 2 equivalents to tetramethylammonium hydrogen sulfate) was added to each reaction mixture, and one test tube was left at 25°C for 18 hours, while the other test tube was concentrated under reduced pressure. When these were measured by LCMS (SQDFA05), no peaks indicating the masses of solvolysates or hydrolysates other than the deprotected peptide of interest were detected even at this point (Figure 11).

[0219] [ka]

[0220] The data in Figure 11 is shown below. The peptide of interest (compound 135) LCMS(ESI)m / z=1331.9(M+H) + Retention time: 0.74 minutes (Analysis conditions SQDFA05)

[0221] Example 3-2-10: Deprotection using 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) as the deprotection condition, and quenching the reaction by adding a base (DIPEA) to the solution. Using Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (compound 50, loading: 0.316 mmol / g, 100 mg) as a resin, a cyclic compound (compound 103, Pep3) was synthesized by forming an amide bond between the N-terminal amino group of Hg-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pip and the side chain carboxylic acid of Asp using the method described previously. After cyclization, the residue was concentrated under reduced pressure, dissolved in dichloromethane and divided into 10 test tubes, and the solvent was concentrated again under reduced pressure. The mixture was divided into 10 equal parts, and 0.40 mL of 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) (HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mL mixed solution was removed and 68.5 mg of tetramethylammonium hydrogen sulfate was dissolved in this solution) was added to each of the two test tubes. The test tube was sealed with a rubber septum, shaken for 3 minutes, and then left to stand at 25 degrees for 4 hours, and the reaction was confirmed by LCMS (FA05). As a result, the deprotection of the side chain (deprotection of the DMT group of MeSer(DMT) and deprotection of the Trt group of Ser(Trt)) was completed, and the UV area ratio in LC between the deprotected target peptide (compound 133) and the N→O-acyl shift product of the target peptide (depsipeptide) was 93:7. Diisopropylethylamine (DIPEA, 14 μL, 2 equivalents to tetramethylammonium hydrogen sulfate) was added to each reaction mixture, and one test tube was left at 25°C for 18 hours, while the other test tube was concentrated under reduced pressure immediately after adding DIPEA. When these were measured by LCMS (FA05), the UV area ratio of the target peptide and its N→O-acyl shifted derivative did not change in the one left at rest for 18 hours, while the UV area ratio of the target peptide and its N→O-acyl shifted derivative in the one concentrated under reduced pressure became 98:2 (Figure 12).

[0222] The data presented in Figure 12 is shown below. The peptide of interest (compound 133) LCMS(ESI)m / z=1474.1(M+H) + Retention time: 0.78 minutes (Analysis conditions SQDFA05) N→O-acyl shift compound LCMS(ESI)m / z=1474.1(M+H) + Retention time: 0.64 minutes (Analysis conditions SQDFA05)

[0223] The above results show that by adding DIPEA after the deprotection reaction is completed (or when you want to stop the reaction), it is possible to carry out post-treatment while suppressing problems such as hydrolysis (solvolysis) and N→O-acyl shift.

[0224] Example 4. Reactivity of Thr and MeSer when THP group is used as a protecting group for the side chain hydroxyl group The following experiment was carried out to examine the reactivity of Thr and MeSer when the THP group was used as a protecting group for the side chain hydroxyl group of these two amino acids, which are likely to have low reactivity during the elongation reaction.

[0225] Example 4-1: Comparative evaluation of the elongation reactivity of Fmoc-Thr(Trt)-OH and Fmoc-Thr(THP)-OH (compound 2) for a compound with an N-methylamino group at the N-terminus (H-MePhe(3-Cl)-D-Tyr(tBu)-Trp-MePhe-Trp-MePhe-Ile-Asp(O-2-Cl-Trt-resin)-pip) elongated on resin. Comparative evaluation of elongation reactivity was performed using a sequence having MePhe(3-Cl) at the N-terminus, which has low reactivity of the amino group due to steric hindrance. Fmoc-MePhe(3-Cl)-D-Tyr(tBu)-Trp-MePhe-Trp-MePhe-Ile-Asp(O-Trt(2-Cl)-resin)-pip (compound 108) was synthesized by the method described previously using Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (compound 50, loading: 0.329 mmol / g, 100 mg) as the resin. Dichloromethane (600uL) was added to the obtained Fmoc-MePhe(3-Cl)-D-Tyr(tBu)-Trp-MePhe-Trp-MePhe-Ile-Asp(O-Trt(2-Cl)-resin)-pip (compound 108), and the mixture was left to stand for 30 minutes to swell the resin. After removing the liquid phase, the resin was washed three times with DMF (600uL). 2% DBU / DMF (v / v, 600uL) was added to the obtained resin, and the mixture was shaken for 20 minutes to remove the liquid phase. The resin was washed three times with DMF (600uL). To this resin, a solution of 0.60 M Fmoc-Thr(Trt)-OH / 0.375 Moxyma in NMP (300 uL) and 10% (v / v) DIC / DMF (300 uL) or a solution of 0.60 M Fmoc-Thr(THP)-OH (compound 2) / 0.375 Moxyma in NMP (300 uL) and 10% (v / v) DIC / DMF (300 uL) was added and shaken. During shaking, ~10 mg of the reacting resin was taken out at 1 hour, 2 hours, and 4 hours, and the taken out resin was washed three times with DMF (600 uL), and 2% DBU / DMF (v / v, 600 uL) was added and shaken for 20 minutes, and the liquid phase was removed. The resin was washed three times with DMF (600 uL) and then three times with dichloromethane (600 uL). The resin was added with TFE / DCM (1 / 1, v / v, 1 mL) and shaken for 10 minutes. The resin was removed by filtration, and the liquid phase was concentrated under reduced pressure. The residue was analyzed by LCMS (analysis condition SQDFA05). The results are shown in Table 4.

[0226] [Table 4]

[0227] The ratio of unreacted / elongated in the table indicates the UV area ratio of LC. The unreacted in the table means H-MePhe(3-Cl)-D-Tyr(tBu)-Trp-MePhe-Trp-MePhe-Ile-Asp-pip (compound 109), and the elongated means H-Thr(Trt)-MePhe(3-Cl)-D-Tyr(tBu)-Trp-MePhe-Trp-MePhe-Ile-Asp-pip (compound 110: when Fmoc-Thr(Trt)-OH was added) or H-Thr(THP)-MePhe(3-Cl)-D-Tyr(tBu)-Trp-MePhe-Trp-MePhe-Ile-Asp-pip (compound 111: when Fmoc-Thr(THP)-OH was added).

[0228] [ka] Unreacted compound (compound 109) LCMS(ESI)m / z=1422.9(M+H) + Retention time: 0.77 minutes (Analysis conditions SQDFA05)

[0229] [ka] Elongated form (Thr(Trt)) (Compound 110) LCMS(ESI)m / z=1766.2(M+H) + Retention time: 0.92 minutes (Analysis conditions SQDFA05)

[0230] [ka] Elongated form (Thr(THP)) (compound 111) LCMS(ESI)m / z=1608.1(M+H) + Retention time: 0.80 minutes (Analysis conditions SQDFA05)

[0231] Example 4-2: Elongation reactivity of Fmoc-Thr(Trt)-OH or Fmoc-Thr(THP)-OH (compound 2) when Hb-MeAla-Ile-MeLeu-MeAla-MeLeu-Thr(PG)-MePhe-MeAla-MeLeu-MePhe-Asp(O-Trt(2-Cl)-resin)-pip was synthesized on a synthesizer. The elongation reactivity was examined by elongating Thr to a sequence having MePhe at the N-terminus, which has low reactivity due to steric hindrance, and a sequence having MeLeu at the N-terminus, which is sterically bulky relative to the amino group of Thr. Hb-MeAla-Ile-MeLeu-MeAla-MeLeu-Thr(PG)-MePhe-MeAla-MeLeu-MePhe-Asp(O-Trt(2-Cl)-resin)-pip (PG of Thr side chain represents a protecting group, and in this experiment represents Trt protection or THP protection) was prepared by the method described above using Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (compound 50, 100 mg) as a resin, and peptide elongation was performed according to the peptide synthesis method by the Fmoc method already described in the Examples. At that time, Fmoc-Thr(Trt)-OH or Fmoc-Thr(THP)-OH (compound 2) was used for the elongation of Thr. After peptide elongation, the N-terminal Fmoc group was removed on the peptide synthesizer, and the resin was washed with DMF and DCM. After reswelling the resin with DCM, TFE / DCM (1 / 1, v / v, 2 mL) was added to the resin and shaken at room temperature for 2 hours to cleave the peptide from the resin. The solution in the tube was then filtered through a synthesis column to remove the resin, and the remaining resin was washed twice with TFE / DCM (1 / 1, v / v, 1 mL). After cleavage, when Fmoc-Thr(Trt)-OH was used, the Trt group of Thr(Trt) was deprotected by shaking for 5 minutes at 25°C using a mixture of 4N HCl / 1,4-dioxane (19.5 uL), TIPS (0.25 mL), and DCM (0.73 mL). DIPEA (24 uL) was then added to neutralize the acid, and the elongation reactivity was examined by LCMS.

[0232] The LCMS results of this product are shown in Figure 13. The peptide of interest (compound 112, Hb-MeAla-Ile-MeLeu-MeAla-MeLeu-Thr-MePhe-MeAla-MeLeu-MePhe-Asp-pip) and the peptide of interest with Thr missing (compound 113, Hb-MeAla-Ile-MeLeu-MeAla-MeLeu-MePhe-MeAla-MeLeu-MePhe-Asp-pip) were observed at the same retention time of 0.69 minutes. MS (negative mode) also showed that the peptide with Thr missing was approximately 30%.

[0233] [ka]

[0234] The data in Figure 13 is shown below. Target compound (compound 112, Hb-MeAla-Ile-MeLeu-MeAla-MeLeu-Thr-MePhe-MeAla-MeLeu-MePhe-Asp-pip) LCMS(ESI)m / z=1373.6(M+H) + Retention time: 0.69 minutes (Analysis conditions SQDAA50)

[0235] [ka] Target - Thr (Compound 113, Hb-MeAla-Ile-MeLeu-MeAla-MeLeu-MePhe-MeAla-MeLeu-MePhe-Asp-pip) LCMS(ESI)m / z=1272.6(M+H) + Retention time: 0.69 minutes (Analysis conditions SQDAA50)

[0236] The LCMS results of this product are shown in Figure 14. In contrast to the case where Fmoc-Thr(Trt)-OH was added, when Fmoc-Thr(THP)-OH was added, the peptide of interest (compound 114, Hb-MeAla-Ile-MeLeu-MeAla-MeLeu-Thr(THP)-MePhe-MeAla-MeLeu-MePhe-Asp-pip) from which Thr had been removed (compound 113, Hb-MeAla-Ile-MeLeu-MeAla-MeLeu-MePhe-MeAla-MeLeu-MePhe-Asp-pip) was not detected. When Fmoc-Thr(THP)-OH (compound 2) was used, the cleavage solution was directly measured by LCMS without deprotection after cleavage from the resin, so the THP protection of the Thr side chain remained.

[0237] [ka]

[0238] The data in Figure 14 is shown below. Target compound (compound 114) LCMS(ESI)m / z=1458.1(M+H) + Retention time: 0.73 minutes (Analysis conditions SQDFA05)

[0239] The above results indicate that Fmoc-Thr(THP)-OH (compound 2) has higher reactivity than Fmoc-Thr(Trt)-OH, which is used to extend Thr in general peptide synthesis. In particular, it was shown that high condensation efficiency can be achieved when extending a bulky amino group with an N-alkylated N-terminus. It was also confirmed that the extension of a bulky Fmoc-amino acid (in this case, Fmoc-MeLeu-OH) to the N-terminal amino group of Thr(THP) in the subsequent extension reaction proceeded without any problems.

[0240] Example 4-2: Confirmation of the MeSer extension reactivity when Fmoc-MeSer(DMT)-OH or Fmoc-MeSer(THP)-OH (compound 6) is used when H-MeSer(PG)-MeVal-MeHis(Trt)-Tyr(3-F,tBu)-Pro-MeHis(Trt)-Pro-Trp-MePhe(4-Cl)-Asp(O-Trt(2-Cl)-resin)-Pro-OPis is synthesized on a synthesizer. H-MeSer(PG)-MeVal-MeHis(Trt)-Tyr(3-F,tBu)-Pro-MeHis(Trt)-Pro-Trp-MePhe(4-Cl)-Asp(O-Trt(2-Cl)-resin)-Pro-OPis (PG in the MeSer side chain represents a protecting group, and in this experiment represents DMT protection or THP protection) was prepared by the method described previously, and Fmoc-Asp(O-Trt(2-Cl)-resin)-Pro-OPis (compound 58, loading amount 0.3736 mmol / g, 100 mg) was used as a resin, and peptide elongation was performed according to the peptide synthesis method by the Fmoc method already described in the Examples. At that time, Fmoc-MeSer(DMT)-OH or Fmoc-MeSer(THP)-OH (compound 6) was used for MeSer elongation. After peptide elongation, the N-terminal Fmoc group was removed on the peptide synthesizer, and the resin was washed with DMF and DCM. The resulting resins were dried under reduced pressure, and then 30 mg of each resin was taken out. After reswelling 30 mg of each resin in DCM, TFE / DCM (1 / 1, v / v, 2 mL) was added to the resin and shaken at room temperature for 2 hours to cleave the peptide from the resin. The solution in the tube was then filtered through a synthesis column to remove the resin, and the remaining resin was further washed twice with TFE / DCM (1 / 1, v / v, 1 mL). All the cleavage solutions obtained were mixed and concentrated under reduced pressure. To the resulting residue, 1.3 mL of 0.05 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) prepared by the method described above was added to dissolve the residue, and then the residue was allowed to stand at room temperature for 1 hour. The side chain protecting groups other than the side chain tBu protection of Tyr(3-F) (DMT protection or THP protection of the MeSer side chain, and Trt protection of the MeHis side chain) and the Pis protection of the main chain C-terminus were deprotected, and the reaction was confirmed by measuring LCMS.

[0241] The LCMS results for the synthesis using Fmoc-MeSer(DMT)-OH·0.75 DIPEA are shown in Figure 15. The target peptide (compound 115, H-MeSer-MeVal-MeHis-Tyr(3-F,tBu)-Pro-MeHis-Pro-Trp-MePhe(4-Cl)-Asp-Pro-OH) and the compound with MeSer removed from the target peptide (compound 116, H-MeVal-MeHis-Tyr(3-F,tBu)-Pro-MeHis-Pro-Trp-MePhe(4-Cl)-Asp-Pro-OH) were observed at the same retention time of 0.50 min. In addition, MS (negative mode) revealed that the compound contained 50% of a peptide lacking MeSer (compound 116, H-MeVal-MeHis-Tyr(3-F,tBu)-Pro-MeHis-Pro-Trp-MePhe(4-Cl)-Asp-Pro-OH).

[0242] [ka]

[0243] The data in Figure 15 is shown below. Target compound (compound 115) LCMS(ESI)m / z=1559.7(M+H) + Retention time: 0.50 minutes (Analysis conditions SQDFA50) Target product - MeSer (compound 116) LCMS(ESI)m / z=1458.8(M+H) + Retention time: 0.50 minutes (Analysis conditions SQDFA50)

[0244] [ka]

[0245] In contrast, the LCMS results for the synthesis using Fmoc-MeSer(THP)-OH (compound 6) are shown in Figure 16. The target peptide (compound 115, H-MeSer-MeVal-MeHis-Tyr(3-F,tBu)-Pro-MeHis-Pro-Trp-MePhe(4-Cl)-Asp-Pro-OH) and the compound with MeSer removed from the target peptide (compound 116) were observed at the same retention time of 0.50 minutes, but MS (negative mode) confirmed that the amount of the peptide with MeSer removed (compound 116, H-MeVal-MeHis-Tyr(3-F,tBu)-Pro-MeHis-Pro-Trp-MePhe(4-Cl)-Asp-Pro-OH) was less than 10%.

[0246] The data in Figure 16 is shown below. Target compound (compound 115) LCMS(ESI)m / z=1559.7(M+H) + Retention time: 0.50 minutes (Analysis conditions SQDFA50) Target product - MeSer (compound 116) LCMS(ESI)m / z=1458.7(M+H) + Retention time: 0.50 minutes (Analysis conditions SQDFA50)

[0247] These results indicate that Fmoc-MeSer(THP)-OH (compound 6) is more reactive than Fmoc-MeSer(DMT)-OH, and that high condensation efficiency can be achieved when elongating the N-terminal N-methylated amino group.

[0248] Deprotection of cyclized peptide in 5.5% TFA (Comparative Example)

[0249] Comparative Example 1: Deprotection of the side chain protecting group of the compound (compound 101, Pep-1) in which an amide bond is formed between the N-terminal amino group of H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pip and the Asp side chain carboxylic acid (deprotection of tBu protection of D-Tyr(tBu)) (when 5% TFA / DCE (5% TIPS) was used) Using Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (compound 50, resin loading 0.373 mmol / g, 100 mg) synthesized by the method described above, peptide elongation was carried out on a synthesizer to obtain H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp(O-Trt(2-Cl)-resin)-pip. The resin was then reswelled with DCM, and TFE / DCM (1 / 1, v / v, 2 mL) was added to the resin and shaken at room temperature for 2 hours to cleave the peptide from the resin. The solution in the tube was then filtered through a synthesis column to remove the resin, and the remaining resin was washed twice with TFE / DCM (1 / 1, v / v, 1 mL). All of the cleavage solutions obtained were mixed and concentrated under reduced pressure. The resulting residue was dissolved in DMF / DCM (1 / 1, v / v, 8 mL), and O-(7-aza-1H-benzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU, 21 mg) / DMF solution (0.5 M) and DIPEA (12 μL) / DMF (88 μL) solution were added and stirred at room temperature for 2 hours. The reaction was confirmed by LCMS measurement (analysis condition SQDFA05), and the production of a compound (compound 101, Pep-1) in which an amide bond was formed between the N-terminal amino group of H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pip and the Asp side chain carboxylic acid was confirmed. LCMS(ESI)m / z=1480.0(M+H) + Retention time: 0.93 minutes (Analysis conditions SQDFA05) Thereafter, the solvent was distilled off under reduced pressure, and 5% TFA / DCE (5% TIPS) (8 mL, the water content was confirmed to be <200 ppm by Karl Fischer measurement) was added to the obtained residue and stirred for 2 hours and 30 minutes. The solvent was distilled off under reduced pressure, and the residue was subjected to LCMS (FA05) measurement. As a result, the MS of the target compound H-Ala-Trp-Nle-Trp-D-Tyr-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pip, which formed an amide bond with the N-terminal amino group and the Asp side chain carboxylic acid (compound 131), and its hydrolyzate (one of the amide bonds was hydrolyzed) was confirmed, and the ratio of the corresponding UV areas was 13:87 (FIG. 17). The LC measurement results are shown in FIG. 17. In addition, "TM+H2O" described in this example represents a compound in which one of the amide bonds of the target compound was hydrolyzed.

[0250] [ka]

[0251] The data in Figure 17 is shown below. Target product (compound 131, a compound in which an amide bond is formed between the N-terminal amino group of H-Ala-Trp-Nle-Trp-D-Tyr-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pip and the Asp side chain carboxylic acid) LCMS(ESI)m / z=1424.0(M+H) + Retention time: 0.79 minutes (Analysis conditions SQDFA05) Hydrolyzate (H-Ala-Trp-Nle-Trp-D-Tyr-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pip, in which one of the amide bonds is hydrolyzed between the N-terminal amino group and the Asp side chain carboxylic acid) LCMS(ESI)m / z=1442.0(M+H) + Retention time: 0.61 minutes (Analysis conditions SQDFA05)

[0252] These results confirmed that when deprotection was performed using 5% TFA / DCE (5% TIPS), approximately 90% of the target compound was hydrolyzed, making it difficult to obtain the target compound, especially in the case of cyclic peptides that were highly N-methylated and had a sequence of consecutive N-methyl amino acids.

[0253] Comparative Example 2: Deprotection of the side chain protecting groups (DMT protection of MeSer side chain and Trt protection of Ser side chain) of the compound (compound 103, Pep3) in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pip and the Asp side chain carboxylic acid (when using 5% TFA / DCE (5% TIPS)) Using Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (compound 50, resin loading 0.316 mmol / g, 100 mg) synthesized by the method described above, peptide elongation was carried out on a synthesizer to obtain Hg-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp(O-Trt(2-Cl)-resin)-pip. The resin was then reswelled with DCM, and TFE / DCM (1 / 1, v / v, 2 mL) was added to the resin and shaken at room temperature for 2 hours to cleave the peptide from the resin. The solution in the tube was then filtered through a synthesis column to remove the resin, and the remaining resin was washed twice with TFE / DCM (1 / 1, v / v, 1 mL). The peptide cleavage procedure from the resin was repeated twice, and all the resulting cleavage solutions were mixed and concentrated under reduced pressure. The resulting residue was dissolved in DMF / DCM (1 / 1, v / v, 8 mL), and a solution of O-(7-aza-1H-benzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU, 18 mg) / DMF (0.5 M) and a solution of DIPEA (9.9 μL) / DMF (39.6 μL) were added thereto, followed by stirring at room temperature for 2 hours. The reaction was confirmed by LCMS measurement (SQDFA05). It was found that 70% of the compound (compound 103, Pep3) in which an amide bond was formed between the N-terminal amino group of Hg-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pip and the Asp side chain carboxylic acid, had the DMT protection of the MeSer side chain removed (LCMS(ESI) m / z=1716.2 (M+H)). + , retention time: 1.06 min), and 30% of the compound was free of both the DMT protection of the MeSer side chain and the Trt protection of the Ser side chain (LCMS (ESI) m / z=1474.1 (M+H) + , retention time: 0.78 min) was confirmed. The ratio was calculated from the UV area ratio of LC. Thereafter, the solvent was distilled off under reduced pressure, and the residue was dissolved in dichloromethane and divided into 10 equal parts in test tubes. These were concentrated under reduced pressure to remove the dichloromethane. Note that the "residue after cyclization" used in the above examples refers to the residue obtained by concentrating under reduced pressure after dividing into 10 equal parts. 5% TFA / DCE (5% TIPS) (0.8 mL, water content 32.5 ppm, measured by Karl Fischer) was added to one of the test tubes, and the mixture was shaken for 3 minutes, and then allowed to stand at 25 degrees for 2 hours. The solvent was removed under reduced pressure, and the residue was measured by LCMS (FA05). The UV area ratio of the target compound (compound 133) formed by the N-terminal amino group of Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip and the Asp side chain carboxylic acid, the N→O-acyl shift product of the target compound, the product in which one hydroxyl group of the target compound was TFA esterified, and the product in which two hydroxyl groups of the target compound were TFA esterified was confirmed to be 17:46:32:5. The LC measurement results are shown in Figure 18.

[0254] [ka]

[0255] The data in Figure 18 is shown below. The target peptide (compound 133, a compound in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip and the Asp side chain carboxylic acid) LCMS(ESI)m / z=1473.8(M+H) + Retention time: 0.79 minutes (Analysis conditions SQDFA05) N→O-acyl shift product of the target compound (a compound in which an N→O-acyl shift has occurred at one or both of the two hydroxyl groups of the target compound) LCMS(ESI)m / z=1473.8(M+H) + Retention time: 0.62 minutes (Analysis conditions SQDFA05) Compounds in which one hydroxyl group of the target substance is esterified with TFA LCMS(ESI)m / z=1569.8(M+H) + Retention time: 0.89 minutes (Analysis conditions SQDFA05) Compound in which the two hydroxyl groups of the target substance are esterified with TFA LCMS(ESI)m / z=1665.9(M+H) + Retention time: 0.99 minutes (Analysis conditions SQDFA05)

[0256] From these results, it was confirmed that when the sequence contains an amino acid with a β-hydroxyl group, such as MeSer or Ser, the N→O-acyl shift occurs during deprotection using 5% TFA / DCE (5%TIPS). It was also confirmed that during deprotection under these conditions, one or both of the two side chain hydroxyl groups are esterified with TFA. It was confirmed that these undesired reactions make it difficult to obtain the target product.

[0257] In order to suppress the production of N→O-acyl shift products and the TFA esterification of hydroxyl groups, tests were conducted in which the reaction temperature was lowered to 0°C and the TFA concentration was lowered.

[0258] Comparative Example 3: Deprotection of the side chain protecting groups (DMT protection of MeSer side chain and Trt protection of Ser side chain) of the compound (compound 103, Pep3) in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pip and the Asp side chain carboxylic acid (when performed at 0 degrees using 5% TFA / DCE (5% TIPS)) After the cyclization, 5% TFA / DCE (5%TIPS) (0.8 mL, water content 36.6 ppm, measured by Karl Fischer) was added to one of the 10 equal parts of the test tube at 0 degrees, shaken for 1 minute, and then left to stand at 0 degrees for 4 hours. LCMS (FA05) measurement of the reaction solution confirmed that the UV area ratio of the target compound (compound 133) formed by the N-terminal amino group of the target compound Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip and the Asp side chain carboxylic acid, the target N→O-acyl shift product, one hydroxyl group of the target compound esterified with TFA, and one hydroxyl group of the target N→O-acyl shift product esterified with TFA was 56:12:21:11. The LC measurement results are shown in Figure 19.

[0259] The data in Figure 19 is shown below. The target peptide (compound 133, a compound in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip and the Asp side chain carboxylic acid) LCMS(ESI)m / z=1473.7(M+H) + Retention time: 0.78 minutes (Analysis conditions SQDFA05) N→O-acyl shift product of the target compound (a compound in which an N→O-acyl shift has occurred at one or both of the two hydroxyl groups of the target compound) LCMS(ESI)m / z=1473.7(M+H) + Retention time: 0.65 minutes (Analysis conditions SQDFA05) Compounds in which one hydroxyl group of the target substance is esterified with TFA LCMS(ESI)m / z=1569.7(M+H) + Retention time: 0.89 minutes (Analysis conditions SQDFA05) A compound in which one hydroxyl group of the N→O-acyl shift product of the target compound is esterified with TFA LCMS(ESI)m / z=1569.7(M+H) + Retention time: 0.73 minutes (Analysis conditions SQDFA05)

[0260] Comparative Example 4: Deprotection of the side chain protecting groups (DMT protection of MeSer side chain and Trt protection of Ser side chain) of the compound (compound 103, Pep3) in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pip and the Asp side chain carboxylic acid (when performed at 25 degrees using 2% TFA / DCE (5% TIPS)) After the cyclization, 2% TFA / DCE (5% TIPS) (0.8 mL, water content 30.1 ppm, measured by Karl Fischer) was added to one of the 10 equal portions at 25°C, shaken for 1 minute, and then allowed to stand at room temperature for 4 hours. The reaction solution was subjected to LCMS (FA05) measurement, and it was confirmed that the UV area ratio of the target compound Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip, which is a compound in which an amide bond is formed between the N-terminal amino group and the Asp side chain carboxylic acid (compound 133), the target N→O-acyl shifted product, the target product with one hydroxyl group esterified with TFA, the target product with two hydroxyl groups esterified with TFA, and the target product with one hydroxyl group esterified with TFA of the N→O-acyl shifted product was 30:34:24:3:9. The LC measurement results are shown in Figure 20.

[0261] The data in Figure 20 is shown below. The target peptide (compound 133, a compound in which an amide bond is formed between the N-terminal amino group of Hg-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pip and the Asp side chain carboxylic acid) LCMS(ESI)m / z=1473.8(M+H) + Retention time: 0.78 minutes (Analysis conditions SQDFA05) N→O-acyl shift product of the target compound (a compound in which an N→O-acyl shift has occurred at one or both of the two hydroxyl groups of the target compound) LCMS(ESI)m / z=1473.8(M+H) + Retention time: 0.65 minutes (Analysis conditions SQDFA05) Compounds in which one hydroxyl group of the target substance is esterified with TFA LCMS(ESI)m / z=1569.8(M+H) + Retention time: 0.89 minutes (Analysis conditions SQDFA05) Compound in which the two hydroxyl groups of the target substance are esterified with TFA LCMS(ESI)m / z=1665.7(M+H) + Retention time: 0.99 minutes (Analysis conditions SQDFA05) A compound in which one hydroxyl group of the N→O-acyl shift product of the target compound is esterified with TFA LCMS(ESI)m / z=1569.8(M+H) + Retention time: 0.73 minutes (Analysis conditions SQDFA05)

[0262] From the above results, problems such as the N→O-acyl shift and the TFA esterification of the hydroxyl groups contained in the compounds could not be completely solved by simply lowering the reaction temperature or using a lower concentration TFA solution.

[0263] Example 6. Application of the present invention to parallel synthesis (solid phase method)

[0264] Example 6-1: Synthesis of peptides cyclized by amide cyclization between the N-terminal amino group and the side chain carboxyl group of aspartic acid We synthesized a group of peptides in which the C-terminus was amidated (with either piperidine, 4-(tert-butyl)piperidine, or N-methyloctan-1-amine) or in which the carboxylic acid group of the side chain of aspartic acid bound to proline at the C-terminus was cyclized through an amide bond with the main chain amino group at the N-terminus.

[0265] Compound 50 (2-chlorotrityl resin carrying compound 48 (Fmoc-Asp-pip)), Compound 52 (2-chlorotrityl resin carrying compound 51 (Fmoc-Asp-piptBu)), Compound 55 (2-chlorotrityl resin carrying compound 54 (Fmoc-Asp-MeOctyl)), or Compound 58 (2-chlorotrityl resin carrying compound 57 (Fmoc-Asp-Pro-OPis)) was used in an amount of 100 mg, and Fmoc-MeVal-OH, Fmoc-MePhe(3-Cl)-OH (Compound 15), Fmoc-MePhe(4-Cl)-OH (Compound 16), Fmoc-MeHis(Trt)-OH (Compound 7), Fmoc-MePhe-OH, Fmoc-Me Ser(DMT)-OH (compound 5), Fmoc-MeSer(THP)-OH (compound 6), Fmoc-MeAla-OH, Fmoc-nPrGly-OH (compound 20), Fmoc-M eGly-OH, Fmoc-Hyp(Et)-OH (compound 18), Fmoc-Pro-OH, Fmoc-Thr(THP)-OH (compound 2), Fmoc-Ile-OH, Fmoc-Va Peptide elongation was carried out using l-OH, Fmoc-Trp-OH, Fmoc-Tyr(3-F,tBu)-OH (compound 13), Fmoc-Phe(4-CF3)-OH, Fmoc-Phe(3-Cl)-OH, Fmoc-Ser(Trt)-OH, Fmoc-Met(O2)-OH, Fmoc-b-Ala-OH, Fmoc-Ala-OH, Fmoc-Gly-OH, etc. (For MeSer elongation, Fmoc-MeSer(DMT)-OH (compound 5) was used in PS-53 and PS-54 (Table 5-1), and Fmoc-MeSer(THP)-OH (compound 6) was used for the others.) Peptide elongation was carried out according to the peptide synthesis method by the Fmoc method already described in the Examples. After peptide elongation, the N-terminal Fmoc group was removed on a peptide synthesizer, and the resin was washed with DMF.

[0266] The resin was then reswelled with DCM, and TFE / DCM (1 / 1, v / v, 2 mL) and diisopropylethylamine (DIPEA, a volume equivalent to 1.8 moles per mole of resin used (loading amount (mmol / g) multiplied by the amount of resin used (usually 0.10 g)) were added to the resin, followed by shaking at room temperature for 2 hours to cleave the peptide from the resin. The solution in the tube was then filtered through a synthesis column to remove the resin, and the remaining resin was washed twice with TFE / DCM (1 / 1, v / v, 1 mL). All of the cleavage solutions obtained were mixed and concentrated under reduced pressure.

[0267] The resulting residue was dissolved in DMF / DCM (1 / 1, v / v, 8 mL), and 0.5 M O-(7-aza-1H-benzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) / DMF solution (volume equivalent to 1.5 equivalents relative to the molar amount of resin used (resin loading amount (mmol / g) multiplied by the amount of resin used (0.1 g))) and DIPEA (1.8 equivalents relative to the molar amount of resin used) were added, followed by stirring at room temperature for 2 hours. The solvent was then distilled off under reduced pressure.

[0268] The resulting residue was deprotected as follows. When the sequence contains Tyr(3-F,tBu), 2 mL of 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) prepared by the method already described was added, the residue was dissolved, and the mixture was left to stand at room temperature or 30 degrees for 24 hours. When the sequence does not contain Tyr(3-F), 4 mL of 0.05 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS) prepared by the method already described was added, the residue was dissolved, and the mixture was left to stand at room temperature for 4 hours. After leaving the mixture to stand for a certain period of time, diisopropylethylamine (DIPEA, 70 μL) was added, and the solvent was distilled off under reduced pressure.

[0269] After the solvent was removed under reduced pressure, the residue was dissolved in DMF. Insoluble matter was removed by filtration, and the residue was purified by preparative-HPLC to obtain the title amide-cyclized cyclic peptides (PS-1 to PS-54). The sequences of PS-1 to PS-54 are shown in Table 5-1, the structures in Table 5-2, and the mass spectrum values, liquid chromatography retention times, purity, and yield of the obtained peptides in Table 5-3.

[0270] [Table 5-1] TIFF2024163219000083.tif216149

[0271] [Table 5-2] TIFF2024163219000085.tif198149 TIFF2024163219000086.tif198149 TIFF2024163219000087.tif198149 TIFF2024163219000088.tif198149 TIFF2024163219000089.tif198149 TIFF2024163219000090.tif198149 TIFF2024163219000091.tif198149 TIFF2024163219000092.tif198149 TIFF2024163219000093.tif198149 TIFF2024163219000094.tif198149 TIFF2024163219000095.tif198149 TIFF2024163219000096.tif198149 TIFF2024163219000097.tif198149 TIFF2024163219000098.tif198149 TIFF2024163219000099.tif198149 TIFF2024163219000100.tif198149 TIFF2024163219000101.tif198149 TIFF2024163219000102.tif198149 TIFF2024163219000103.tif198149 TIFF2024163219000104.tif198149 TIFF2024163219000105.tif198149 TIFF2024163219000106.tif198149 TIFF2024163219000107.tif198149 TIFF2024163219000108.tif198149 TIFF2024163219000109.tif198149 TIFF2024163219000110.tif198149

[0272] [Table 5-3]

[0273] Example 7. Application of the present invention to a liquid phase method The synthesis including the extension reaction in a liquid phase method is shown below.

[0274] Application to partial liquid phase method Synthesis of a cyclic peptide (compound 154, a cyclic peptide in which an amide bond is formed between the amino group at the main chain N-terminus of H-Ala-Trp-Nle-Trp-Ser-nPrGly-MePhe(3-Cl)-MeHis-MeGly-Pro-Asp-Pro-OH and the side chain carboxylic acid group of Asp) involving coupling of Fmoc-Ala-OSu (compound 152) with H-Trp-Nle-Trp-Ser(THP)-nPrGly-MePhe(3-Cl)-MeHis(Trt)-MeGly-Pro-Asp-Pro-OPis (compound 151) in solution phase The peptide was synthesized according to the synthesis route shown in FIG. 21, which includes an elongation reaction by a liquid phase method.

[0275] Example 7-1: Synthesis of H-Trp-Nle-Trp-Ser(THP)-nPrGly-MePhe(3-Cl)-MeHis(Trt)-MeGly-Pro-Asp-Pro-OPis (Compound 151) [ka] Using Fmoc-Asp(O-Trt(2-Cl)-resin)-Pro-OPis (compound 58, loading amount 0.3736 mmol / g, 200 mg) synthesized by the method described above, peptide elongation was carried out according to the peptide synthesis method using the Fmoc method already described in the Examples. After peptide elongation, the N-terminal Fmoc group was removed on a peptide synthesizer, and the resin was washed with DMF. The resin was then reswelled with DCM, and TFE / DCM (1 / 1, v / v, 4 mL) and diisopropylethylamine (24 μL) were added to the resin and shaken at room temperature for 2 hours to cleave the peptide from the resin. The solution in the tube was then filtered through a synthesis column to remove the resin, and the remaining resin was washed twice with TFE / DCM (1 / 1, v / v, 2 mL). All the cleavage solutions obtained were mixed and concentrated under reduced pressure to obtain the title compound (compound 151, H-Trp-Nle-Trp-Ser(THP)-nPrGly-MePhe(3-Cl)-MeHis(Trt)-MeGly-Pro-Asp-Pro-OPis, 113.8 mg). This was used in the next step without purification. LCMS(ESI)m / z=1860.9(M+H) + Retention time: 0.72 minutes (Analysis conditions SQDFA05)

[0276] Example 7-2: Synthesis of (S)-2,5-dioxopyrrolidin-1-yl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanoate (Compound 152, Fmoc-Ala-OSu) [ka] (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanoic acid (Fmoc-Ala-OH, 1.00 g, 3.21 mmol), 1-hydroxypyrrolidine-2,5-dione (HOSu, 0.554 g, 4.82 mmol), and dichloromethane (6.4 mL) were mixed under a nitrogen atmosphere. The mixture was cooled to 0°C on ice, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSCI·HCl, 0.924 g, 4.82 mmol) was added. The resulting reaction solution was stirred at 0°C for 1 hour and at room temperature for 15 hours. Subsequently, the solvent was distilled off under reduced pressure, and the resulting residue was purified by reverse-phase silica gel chromatography (0.1% formic acid aqueous solution / 0.1% formic acid acetonitrile solution) to obtain (S)-2,5-dioxopyrrolidin-1-yl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanoate (compound 152, Fmoc-Ala-OSu, 1.05 g). LCMS(ESI)m / z=409.3(M+H) + Retention time: 0.80 minutes (Analysis conditions SQDFA05)

[0277] Example 7-3: Coupling of 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanoic acid (S)-2,5-dioxopyrrolidin-1-yl (compound 152, Fmoc-Ala-OSu) with H-Trp-Nle-Trp-Ser(THP)-nPrGly-MePhe(3-Cl)-MeHis(Trt)-MeGly-Pro-Asp-Pro-OPis (compound 151) followed by Fmoc removal. [ka] To the resulting H-Trp-Nle-Trp-Ser(THP)-nPrGly-MePhe(3-Cl)-MeHis(Trt)-MeGly-Pro-Asp-Pro-OPis (compound 151, 113.8 mg) in dichloromethane (245 μL), 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanoic acid (S)-2,5-dioxopyrrolidin-1-yl (compound 152, Fmoc-Ala-OSu, 26.2 mg) and diisopropylethylamine (DIPEA, 12.8 μL) were added and stirred at 25 degrees for 1 hour. Subsequently, methylamine (40% methanol solution, 11.9 μL) was added to the reaction solution and stirred for 30 minutes, and then DBU (11.1 μL) was added and stirred for another 30 minutes. The resulting reaction solution was purified by reversed-phase silica gel column chromatography (0.1% formic acid aqueous solution / 0.1% formic acid acetonitrile solution), and the obtained fraction was lyophilized. The resulting residue was dissolved in dichloromethane and washed with saturated sodium bicarbonate aqueous solution and saturated sodium chloride aqueous solution to obtain H-Ala-Trp-Nle-Trp-Ser(THP)-nPrGly-MePhe(3-Cl)-MeHis(Trt)-MeGly-Pro-Asp-Pro-OPis (compound 153, 79.3 mg, 0.041 mmol). LCMS(ESI)m / z=1931.8(M+H) + Retention time: 0.73 minutes (Analysis conditions SQDFA05)

[0278] Example 7-4: Synthesis of a compound (compound 154) in which the N-terminal amino group of H-Ala-Trp-Nle-Trp-Ser-nPrGly-MePhe(3-Cl)-MeHis-MeGly-Pro-Asp-Pro-OH and the carboxylic acid group of the Asp side chain are amide-cyclized (cyclization reaction of compound 153 and subsequent deprotection reaction) [ka] The obtained H-Ala-Trp-Nle-Trp-Ser(THP)-nPrGly-MePhe(3-Cl)-MeHis(Trt)-MeGly-Pro-Asp-Pro-OPis (compound 153, 79.3 mg, 0.041 mmol) was dissolved in DMF (20 mL) and dichloromethane (20 mL), HATU (17.2 mg, 0.045 mmol) and diisopropylethylamine (10.8 μL, 0.062 mmol) were added, and the mixture was stirred at 25 degrees for 2 hours. Subsequently, the solvent was distilled off under reduced pressure, and then 0.05 M tetramethylammonium hydrogen sulfate / HFIP (2% TIPS) solution (prepared by the method already described in this example, 8 mL) was added and the mixture was left to stand at 25 degrees for 1 hour. Diisopropylethylamine (140 μL) was added to the obtained reaction solution, and the solvent was distilled off under reduced pressure. The resulting residue was purified by reverse-phase silica gel column chromatography (0.1% formic acid aqueous solution / 0.1% formic acid acetonitrile solution), and the obtained fraction was lyophilized to obtain a compound in which the N-terminal amino group of H-Ala-Trp-Nle-Trp-Ser-nPrGly-MePhe(3-Cl)-MeHis-MeGly-Pro-Asp-Pro-OH and the carboxylic acid group of the Asp side chain were amide-cyclized (compound 154, 59 mg, 0.040 mmol, 98%). LCMS(ESI)m / z=1469.7(M+H) + Retention time: 0.61 minutes (Analysis conditions SQDFA05)

[0279] As with the above-mentioned peptide synthesis involving segment coupling in solution phase, the synthesis method of the present invention is also applicable to solution phase methods. [Industrial Applicability]

[0280] According to the present invention, peptides containing N-substituted amino acids that are expected to be useful as pharmaceuticals can be synthesized with high purity and high synthesis efficiency. The present invention is useful in fields such as industrial production of peptides containing N-substituted amino acids that can be used as raw materials for pharmaceuticals.

Claims

1. 1. A method for producing a peptide comprising at least one N-substituted amino acid or N-substituted amino acid analog, comprising: 1) A step of preparing a peptide, comprising the steps of: reacting a weak acid having a pKa value of 1 to 5 in water with a weak acid having at least one side chain of an amino acid or an amino acid analogue that is not deprotected under basic conditions and has an ionization ability Y OTs having a protecting group that is deprotected under conditions using a weak acid solution, including a solvent having a positive pKa in water of 5 to 14; 2) removing the protecting group under conditions using the weak acid solution.

2. The method according to claim 1, wherein the peptide prepared in step 1) contains an amino acid residue or an amino acid analog residue having one reactive site on the C-terminus side, and an amino acid residue, an amino acid analog residue, or a carboxylic acid analog having another reactive site on the N-terminus side.

3. The method of claim 2, further comprising the step of binding said one reactive site to said other reactive site to cyclize said peptide.

4. The method according to claim 3 , wherein the amino acid residue, amino acid analog residue or carboxylic acid analog having another reactive site is at the N-terminus and the bond is an amide bond.

5. The method according to claim 3, wherein the amino acid residue, amino acid analog residue or carboxylic acid analog having another reactive site is at the N-terminus, and the bond is a carbon-carbon bond.

6. 6. The method according to claim 1, wherein in step 1), the protecting group protects at least one functional group selected from a hydroxy group, a phenol group, an imidazole group, and a carboxylic acid group.

7. The method according to any one of claims 1 to 6, wherein the protecting group of the side chain is a protecting group that is deprotected in the range of pH 1 to pH 7, or a protecting group that is deprotected in 10% or less TFA.

8. The process according to any one of claims 1 to 7, wherein the side chain protecting group is selected from the following a) to d): a) when the side chain protecting group is a protecting group for a hydroxyl group in the side chain of Ser, Thr, Hyp, or a derivative thereof, any protecting group selected from a MOM skeleton group, a Bn skeleton, a Dpm skeleton, a Trt skeleton, a silyl skeleton, and a Boc skeleton represented by the following general formula: b) when the side chain protecting group is a protecting group for a hydroxyl group in the side chain of Tyr or a derivative thereof, any protecting group selected from a MOM skeleton, a Bn skeleton, a Dpm skeleton, a Trt skeleton, a silyl skeleton, a Boc skeleton, and a tBu skeleton represented by the following general formula: c) when the side chain protecting group is a protecting group for an imidazole ring in the side chain of His or a derivative thereof, it is any protecting group selected from a MOM skeleton, a Bn skeleton, and a Trt skeleton represented by the following general formula: d) when the side chain protecting group is a protecting group for a carboxylic acid group in the side chain of Asp, Glu, or a derivative thereof, any protecting group selected from a MOM skeleton, a Bn skeleton, a Dpm skeleton, a Trt skeleton, a tBu skeleton, a phenyl-EDOTn skeleton, and an orthoester skeleton in which the carbon atom of the protecting carboxylic acid group is converted into a skeleton substituted with three alkoxy groups, which are represented by the following general formulas; <Protective Group Having a MOM Skeleton> 【Chemistry 1】 (In the formula, R1 is H, R2 is H, and X is methyl, benzyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl, 3,4-dimethoxybenzyl, or 2-trimethylsilylethyl; R1 is methyl, R2 is H and X is ethyl; or R1, R2, and R3 are all methyl; or R1 and X together form -CH 2 -CH 2 -CH 2 - or -CH 2 -CH 2 -CH 2 -CH 2 - and R2 is H In this case, when any of R1, R2, and X is methyl or ethyl, these groups may be further substituted with alkyl, benzyl, or aryl. <Protective Group Having a Bn Skeleton> 【Chemistry 2】 (In the formula, R1-R5 are each independently H, alkyl, aryl, or halogen, and R6 and R7 are alkyl, or R1, R2, R4, and R5 are each independently H, alkyl, aryl, or halogen; R3 is methoxy; and R6 and R7 are H; R1 and R3 are methoxy, R2, R4, and R5 are each independently H, alkyl, aryl, or halogen, and R6 and R7 are H; or R1, R4, and R5 are each independently H, alkyl, aryl, or halogen, and R2 and R3 together represent -O-CH 2 -O- is formed. <Protective Group Having Dpm Skeleton> 【Chemistry 3】 (In the formula, R1-R10 are each independently H, alkyl, aryl, alkoxy, or halogen; or R1 to R4 and R7 to R10 are each independently H, alkyl, aryl, alkoxy, or halogen, and R5 and R6 together are -O- or -CH 2 -CH 2 - is formed.) <Protective Group Having a Trt Skeleton> 【Chemistry 4】 (In the formula, R1 to R15 are each independently H, alkyl, aryl, alkoxy, or halogen; R1, R2, and R4-R15 are each independently H, alkyl, aryl, alkoxy, or halogen, and R3 is methyl or methoxy; R1 is Cl and R2-R15 are each independently H, alkyl, aryl, alkoxy, or halogen; or R1 to R4 and R7 to R15 are each independently H, alkyl, aryl, alkoxy, or halogen, and R5 and R6 together form --O--. <Protective Group Having a Silyl Skeleton> 【Chemistry 5】 (In the formula, R1 to R3 are each independently an alkyl or aryl. <Protecting group having a Boc skeleton> 【Chemistry 6】 (In the formula, R1 to R9 are each independently H, alkyl, or aryl. <Protecting group having tBu skeleton> 【Chemistry 7】 (In the formula, R1 to R9 are each independently H, alkyl, or aryl. <Protective Group Having a Phenyl-EDOTn Skeleton> 【Chemistry 8】 (In the formula, R1 to R3 are each independently H or methoxy.

9. The process according to any one of claims 1 to 8, wherein the solvent is a fluoroalcohol.

10. The process according to any one of claims 1 to 9, wherein the fluoroalcohol is TFE or HFIP.

11. The method according to any one of claims 1 to 10, wherein the weak acid having a pKa value in water of 1 to 5 is selected from tetramethylammonium hydrogen sulfate, oxalic acid, and maleic acid.

12. The method according to any one of claims 1 to 11, wherein the produced peptide comprises 5 to 30 amino acid and / or amino acid analog residues.

13. The method according to any one of claims 1 to 12, wherein the peptide produced contains two or more N-substituted amino acids or N-substituted amino acid analogs.

14. The method according to any one of claims 1 to 13, wherein the N-substituted amino acid is an N-alkyl amino acid, and the N-substituted amino acid analog is an N-alkyl amino acid analog.

15. A method for deprotecting a protecting group on at least one side chain of an amino acid or amino acid analog constituting a peptide, comprising the steps of: the peptide comprises at least one N-substituted amino acid or N-substituted amino acid analog; The protecting group is not deprotected under basic conditions and has a pKa value of 1 to 5 in water and a weak acid with an ionization ability Y OTs is a protecting group that is deprotected under conditions using a weak acid solution, including a solvent having a positive value and a pKa in water of 5 to 14; The method includes a step of deprotecting the protecting group under conditions using the weak acid solution.

Citation Information

Patent Citations

  • Multiple N-methylated cyclic hexapeptides for treatment of neurogenic inflammation

    EP2177533A1

  • Cyclopentapeptide derivatives and uses thereof

    EP2380596A1

  • Modified cyclopentapeptides and uses thereof

    WO2015185162A1

  • Peptide-compound cyclization method

    WO2013100132A1